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Summary 
 
Irritable bowel syndrome is one of the most common problems reported to 
general practitioners and gastroenterologists. It has been shown that many of 
the gut and systemic symptoms are due to lactose sensitivity, the sugar found 
mainly in milk. Undigested carbohydrates and other foods absorbed by the 
small intestine reach the bacteria in the large intestine. There is little oxygen 
here, the bacteria metabolise these to produce gases such as hydrogen and 
methane, and a variety of small organic metabolites such as methylglyoxal. 
These metabolites are absorbed into the bloodstream and can affect tissues 
around the body. 
The overall aim of this thesis was to investigate the potential role of the 
bacterial metabolic toxin hypothesis in the development of diabetes. To 
specifically investigate the ability of these toxins to covalently modify proteins 
and to investigate the biological activity of these modified proteins on glucose 
uptake and cell differentiation. Albumin and insulin have been shown to exhibit 
mono-oxygenase activity demonstrated by coelenterazine 
chemiluminescence. It was heat denaturable, demonstrated saturable 
substrate characteristics, was inhibited or activated by cations (Fe2+, Fe3+, Zn2+ 
and Ca2+) known to bind to these proteins and was inhibited by drugs that are 
known to bind to Sudlow’s site I on albumin. The inhibition of albumin 
catalysed coelenterazine chemiluminescence observed in the presence of 
drugs that are known to bind to Sudlow’s site I on albumin proposes that this is 
also the coelenterazine binding site. Molecular 3D modelling confirmed that 
coelenterazine binds to this site. Methylglyoxal covalently modified these 
proteins resulting in reduced biological activity. Tetraethylammonium 
significantly inhibited 3T3-L1 cell differentiation in the presence of insulin. 
However, methylglyoxal and tetrandrine did not significantly inhibit 3T3-L1 cell 
differentiation. The results in this thesis support the hypothesis that bacterial 
metabolic toxins can covalently modify proteins and alter their biological 
activity.  
 
List of contents 
 
iv 
 
 
List of contents 
Declaration         i 
Summary         ii 
List of contents         iii 
Acknowledgements        x 
List of figures and tables       xi 
Abbreviations         xvi 
 
1. Introduction        1 
 1.1. Lactose, lactase and lactose sensitivity    3 
  1.1.1. Lactose and lactase     3 
  1.1.2. Hypolactasia and lactose sensitivity   4 
 1.2. Lactose sensitivity and irritable bowel syndrome   9 
 1.3. Gas and metabolite release as a result of carbohydrate  10
        metabolism 
  1.3.1. Methylglyoxal and its pathway    11 
 1.4. The structure of the pancreas     15 
  1.4.1. The exocrine pancreas     16 
  1.4.2. The endocrine pancreas     17 
 1.5. Insulin synthesis, storage and secretion    19 
  1.5.1. Insulin synthesis      20 
  1.5.2. Insulin storage      20 
  1.5.3. Insulin secretion      20 
 1.6. The insulin receptor and the mechanism of insulin action  22 
  1.6.1. The insulin receptor     22 
  1.6.2. The mechanism of insulin action    24 
 1.7. Diabetes, its complications and the involvement of methylglyoxal 26 
  1.7.1. Type 1 diabetes      29 
   1.7.1.1. The causes of type 1 diabetes   29 
List of contents 
 
v 
 
   1.7.1.2. The pathogenesis of type 1 diabetes  37 
   1.7.1.3. The treatment and prevention of type 1  39 
                diabetes 
  1.7.2. Type 2 diabetes      39 
   1.7.2.1. The causes of type 2 diabetes   40 
   1.7.2.2. The pathogenesis of type 2 diabetes  46 
   1.7.2.3. The treatment and prevention of type 2  50 
    diabetes 
  1.7.3. Type 1.5 diabetes     50 
  1.7.4. Advanced glycation end-products and the pathogenesis 51
            of diabetes 
 1.8. Hypothesis, aims and experimental strategy    54 
  1.8.1. The bacterial metabolic toxin hypothesis   54 
  1.8.2. Overall aim and specific aims    55 
   1.8.2.1. Overall aim     55 
   1.8.2.2. Specific aims     55 
  1.8.3. Experimental strategy     55 
 
2. Materials and methods       56 
 2.1. Materials        56 
 2.2. Protein catalysed coelenterazine chemiluminescence  56 
  2.2.1. The chemiluminometer     56 
   2.2.1.1. The sample housing    57 
   2.2.1.2. The photomultiplier tube   57 
   2.2.1.3. The detector     58 
   2.2.1.4. Signal processing    59 
  2.2.2. The optimisation of conditions    59 
  2.2.3. The preparation of reagents    61 
   2.2.3.1. The preparation of 50 mM HEPES buffer 61 
   2.2.3.2. The preparation of proteins   61 
   2.2.3.3. The preparation of coelenterazine  61 
List of contents 
 
vi 
 
  2.2.4. The determination of protein catalysed coelenterazine 62
            chemiluminescence 
 2.3. Cell culture        63 
  2.3.1. Cell culture medium     63 
   2.3.1.1. DMEM for 3T3-L1 cell culture and maintenance 63 
   2.3.1.2. MEM-α for 7F2 cell culture and maintenance 64 
  2.3.2. Cell husbandry      64 
 2.4. Cell counting       65 
  2.4.1. Haemocytometry      65 
 
3. Chemiluminescence activity of albumin and insulin   66 
 3.1. Introduction       66 
  3.1.1. Types of luminescence     66 
   3.1.1.1. Chemiluminescence and its discovery  67 
   3.1.1.2. Bioluminescence    68 
  3.1.2. Light emission due to these reactions   69 
   3.1.2.1. Light emission as a result of a chemical  69
    reaction (chemiluminescence) 
   3.1.2.2. Light emission as a result of a chemical  70
    reaction in a biological system    
    (bioluminescence) 
  3.1.3. The jellyfish, Aequorea victoria and the discovery of 72
            coelenterazine 
  3.1.4. Coelenterazine and its role in bioluminescence  73 
   3.1.4.1. Coelenterazine     73 
   3.1.4.2. The bioluminescence reaction of coelenterazine 74 
  3.1.5. Overall aim, specific aims and experimental strategy 76 
   3.1.5.1. Overall aim     76 
   3.1.5.2. Specific aims     76 
   3.1.5.3. Experimental strategy    76 
 3.2. Materials and methods      77 
  3.2.1. Materials       77 
List of contents 
 
vii 
 
  3.2.2. Preparation of reagents     77 
  3.2.3. The determination of protein enzymatic activity  77 
  3.2.4. The effect of thermal denaturation of protein  77 
            enzymatic activity 
  3.2.5. The effect of increasing substrate concentration  77
            on chemiluminescence 
  3.2.6. The effect of increasing pH on protein enzymatic activity 78 
  3.2.7. The effect of divalent cations on protein enzymatic activity 78 
  3.2.8. Statistical analysis     78 
 3.3. Results        78 
  3.3.1. The effect of HSA and other proteins on coelenterazine 78
            chemiluminescence 
  3.3.2. Investigating the enzymatic activity of HSA and insulin 81 
   3.3.2.1. The effect of denatured HSA and insulin on 81
    coelenterazine chemiluminescence 
3.3.2.2. The effect of increasing coelenterazine 83
 concentration on HSA catalysed  
  coelenterazine chemiluminescence 
3.3.2.3. The effect of increasing pH on protein 84
 catalysed coelenterazine 
 chemiluminescence 
3.3.2.4. The effect of divalent cations on HSA 86
 (and insulin) catalysed coelenterazine 
 chemiluminescence 
 3.4. Discussion and conclusions     94 
 
4. Testing the hypothesis that albumin and insulin   103 
chemiluminescence is enzymatic 
 4.1. Introduction       103 
  4.1.1. Human serum albumin     103 
  4.1.2. The structure of HSA     104 
  4.1.3. HSA binding regions     105 
   4.1.3.1. The fatty acid binding regions   105 
   4.1.3.2. The metal-binding regions   107 
   4.1.3.3. The two main drug binding regions  107 
List of contents 
 
viii 
 
  4.1.4. Ligand binding at Sudlow’s site I    108 
  4.1.5. Ligand binding at Sudlow’s site II    110 
  4.1.6. The competitive binding properties of ligands  112 
  4.1.7. The covalent modification of proteins by methylglyoxal 113 
  4.1.8. Hypothesis, aims and experimental strategy  114 
   4.1.8.1. Hypothesis     114 
   4.1.8.2. Aims      114 
   4.1.8.3. Experimental strategy    115 
 4.2. Materials and methods      115 
  4.2.1. Materials       115 
  4.2.2. Preparation of reagents     115 
  4.2.3. To investigate the effect of drugs on HSA catalysed 115
           coelenterazine chemiluminescence 
  4.2.4. The production of covalently modified proteins and 116
           their effect of protein catalysed coelenterazine  
          chemiluminescence 
  4.2.5. To determine if molecular 3D modelling can be used to 116
           predict the coelenterazine binding site 
  4.2.6. Statistical analysis     117 
 4.3. Results        117 
  4.3.1. The effect of drugs on HSA catalysed coelenterazine 117
           chemiluminescence 
   4.3.1.1. The effect of drugs that are known to bind to 118 
   Sudlow’s site I on HSA catalysed   
   coelenterazine chemiluminescence 
   4.3.1.2. The effect of drugs that are known to bind to  122
   Sudlow’s site II on HSA catalysed  
   coelenterazine chemiluminescence 
  4.3.2. The mixed enzyme kinetics of albumin   126 
  4.3.3. Molecular 3D modelling used to identify the  127
           coelenterazine binding site 
  4.3.4. The inhibition of albumin and insulin catalysed  128
           coelenterazine chemiluminescence by methylglyoxal 
  4.3.5. The increased albumin and insulin catalysed  129
           coelenterazine chemiluminescence by hydrogen   
           peroxide 
List of contents 
 
ix 
 
 4.4. Discussion and conclusions     130 
 
5. The effect of methylglyoxal on insulin action    140 
 5.1. Introduction       140 
  5.1.1. Glucose homeostasis     140 
  5.1.2. Decreased blood glucose levels and the role of glucagon 141 
  5.1.3. Increased blood glucose and the role of insulin  141 
   5.1.3.1. Glucose transporters and glucose uptake 142
   by insulin-sensitive tissues 
   5.1.3.2. Insulin stimulates glycogenesis   145 
   5.1.3.3. Insulin stimulates lipogenesis and inhibits 145
   lipolysis 
  5.1.4. The role of insulin in cell differentiation   146 
  5.1.5. Overall aim, specific aims and experimental strategy 146 
   5.1.5.1. Overall aim     146 
   5.1.5.2. Specific aims     147 
   5.1.5.3. Experimental strategy    147 
 5.2. Materials and methods      147 
  5.2.1. Materials       147 
  5.2.2. Cell culture      148 
   5.2.2.1. Adipogenesis assay cell culture medium  148 
  5.2.3. Adipogenesis assays and adipocyte formation  149 
   5.2.3.1. Adipogenesis assay    149 
   5.2.3.2. Oil red O staining for lipids   150 
   5.2.3.3. Quantification of lipid formation   150 
  5.2.4. Glucose uptake and GLUT4 expression   150 
   5.2.4.1. Glucose uptake by the rat hemi-diaphragm 151
   in the presence and absence of insulin 
   5.2.4.2. Glucose uptake by 7F2 cells in the presence 152
   and absence of insulin 
  5.2.5. Molecular biology      152 
   5.2.5.1. RNA extraction     153 
List of contents 
 
x 
 
   5.2.5.2. Polymerase Chain Reaction   153 
   5.2.5.3. Electrophoresis     154 
  5.2.6. Statistical analysis     154 
 5.3. Results        155 
  5.3.1. The differentiation of 3T3-L1 cells induced by insulin 155 
  5.3.2. The effect of insulin and other compounds on  157
           3T3-L1 cell differentiation 
  5.3.3. Glucose uptake by rat hemi-diaphragm and 7F2 cells 162 
 5.4. Discussion and conclusions     162 
 
6. General discussion and future work     170 
 6.1. General discussion and conclusions     170 
 6.2. Future work       176 
 
7. Appendix         179 
 7.1. Publications relevant to this thesis     179 
 7.2. Cell culture media formulae      180 
 
8. References        184 
 
 
 
 
 
  
 
 
 
 
 
Acknowledgements 
 
xi 
 
 
Acknowledgements 
 
It is a pleasure to acknowledge all of those who have provided me with the 
support and assistance throughout the course of this thesis. First, I would like 
to thank my supervisors Dr Ken Wann and Professor Anthony Campbell for 
their continuous support, guidance and patience. I would like to thank Dr 
Andrea Brancale who gave his time and expertise with regards to molecular 
3D modelling. I would also like to thank Dr Neil Henney, who taught me some 
of the techniques required to carry out this project. I must thank my fellow PhD 
students as the years would not have been quite the same without them. I 
would like to thank my parents and my brother, who have provided me with an 
endless amount of encouragement and support in everything I have done to 
date. Without them I would not be where I am today. Finally, I would like to 
thank both The Darwin Centre and The Waterloo Foundation, who with their 
financial support made this thesis possible. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
List of figures and tables 
 
xii 
 
List of figures  
 
Figure 1.1.  The global incidence of lactose sensitivity  6 
Figure 1.2. The pathways through which anaerobic   7                        
bacteria in the large intestine generate gases                      
and bacterial metabolic toxins 
Figure 1.3. The chemical structure of methylglyoxal (MeG)  11 
Figure 1.4. The metabolism of methylglyoxal in   12                         
mammalian systems 
Figure 1.5. The methylglyoxal pathway    13 
Figure 1.6. The structure of the pancreas    15 
Figure 1.7. The histology of a pancreatic acinus   16 
Figure 1.8. The amino acid sequence of human insulin  19 
Figure 1.9. A diagram showing the processes involved in  21               
glucose-stimulated insulin secretion (GSIS) 
Figure 1.10. The structure of the insulin receptor (IR)   23 
Figure 1.11. The mechanism of insulin action    24 
Figure 1.12. Virus-induced autoimmune disease   32 
Figure 1.13. A diagram showing the release of beta-   34                 
casomorphin-7 (BCM-7) from the beta-casein                
variant A1 but not from the A2 variant 
Figure 1.14. The pathophysiology of hyperglycaemia   49                                 
in type 2 diabetes 
Figure 2.1. The set up of the chemiluminometer used  56 
Figure 2.2. The optimisation of the photomultiplier tube  60 
Figure 2.3. The pathway showing the chemiluminescence  62             
reaction of coelenterazine 
Figure 3.1. The equation for a chemiluminescence reaction  69 
Figure 3.2. The equation for a bioluminescence reaction  70 
Figure 3.3. Aequorea victoria     73 
Figure 3.4. The structure of coelenterazine    73 
Figure 3.5. The pathway of the chemiluminescence reaction  75                    
of coelenterazine 
List of figures and tables 
 
xiii 
 
Figure 3.6. The stimulation of coelenterazine chemiluminescence 79 
catalysed by human (HSA) and bovine (BSA) albumin 
Figure 3.7. The stimulation of coelenterazine chemiluminescence 80           
by human insulin, compared with that of gelatin and 
haemoglobin 
Figure 3.8. The inhibition of human serum albumin (HSA)  82            
catalysed coelenterazine chemiluminescence by           
thermal denaturation 
Figure 3.9. The effect of thermal denaturation on human insulin 83   
catalysed coelenterazine chemiluminescence 
Figure 3.10. The effect of varying coelenterazine concentration 84                
on human serum albumin (HSA) catalysed 
chemiluminescence 
Figure 3.11. The effect of pH on human serum albumin (HSA) 85      
catalysed coelenterazine chemiluminescence 
Figure 3.12. The effect of pH on human insulin catalysed  86       
coelenterazine chemiluminescence 
Figure 3.13. The inhibition of human serum albumin (HSA)  87           
catalysed coelenterazine chemiluminescence                        
by Fe
3+
 
Figure 3.14. The inhibition of human serum albumin (HSA)  88              
catalysed coelenterazine chemiluminescence                       
by Fe
2+
 
Figure 3.15. The inhibition of human serum albumin (HSA)  89             
catalysed coelenterazine chemiluminescence                       
by Fe
2+
 and Fe
3+
 
Figure 3.16. The inhibition of human serum albumin (HSA)  90            
catalysed coelenterazine chemiluminescence                       
by Ca
2+
 
Figure 3.17. The inhibition of human serum albumin (HSA)  91            
catalysed coelenterazine chemiluminescence                        
by Zn
2+
 
Figure 3.18. The stimulation of human insulin catalysed  92        
coelenterazine chemiluminescence by Zn
2+
    
Figure 3.19. The effect of Zn
2+
 on human serum albumin (HSA) 93             
and human insulin catalysed coelenterazine 
chemiluminescence 
Figure 4.1. Ribbon diagram of human serum albumin (HSA)  104          
showing the three major domains (domains I, II and III)       
and the six subdomains 
List of figures and tables 
 
xiv 
 
Figure 4.2. Ribbon diagram of human serum albumin (HSA)  106          
showing the seven fatty acid binding sites distributed 
throughout the protein 
Figure 4.3. The ligand binding capacity of human serum albumin 108      
(HSA) 
Figure 4.4. The chemical structures of some of the drugs that 109               
bind to Sudlow’s site I 
Figure 4.5. The chemical structures of some of the drugs that 111               
bind to Sudlow’s site II 
Figure 4.6. The inhibition of human serum albumin (HSA)  119           
catalysed coelenterazine chemiluminescence                       
by warfarin 
Figure 4.7. The inhibition of human serum albumin (HSA)  120            
catalysed coelenterazine chemiluminescence                       
by furosemide 
Figure 4.8. The inhibition of human serum albumin (HSA)  121            
catalysed coelenterazine chemiluminescence                       
by indomethacin 
Figure 4.9. The inhibition of human serum albumin (HSA)  122            
catalysed coelenterazine chemiluminescence                        
by tolbutamide 
Figure 4.10. The inhibition of human serum albumin (HSA)  123             
catalysed coelenterazine chemiluminescence                        
by diazepam 
Figure 4.11. The inhibition of human serum albumin (HSA)  124            
catalysed coelenterazine chemiluminescence                        
by phenytoin  
Figure 4.12. The inhibition of human serum albumin (HSA)  125            
catalysed coelenterazine chemiluminescence                       
by ibuprofen 
Figure 4.13. The competitive binding properties of warfarin  126                        
on human serum albumin (HSA) catalysed         
coelenterazine chemiluminescence 
Figure 4.14. Molecular 3D modelling showing coelenterazine  128             
binding to both Sudlow’s site I and site II on human         
serum albumin (HSA) 
Figure 4.15. The inhibition of protein catalysed coelenterazine 129 
chemiluminescence by methylglyoxal (MeG) 
Figure 4.16. The inhibition of protein catalysed coelenterazine 130 
chemiluminescence by hydrogen peroxide (H2O2) 
List of figures and tables 
 
xv 
 
Figure 4.17. The binding of coelenterazine and warfarin to  134               
Sudlow’s site I on HSA demonstrated using               
molecular 3D modelling 
Figure 5.1. The structure of the facilitative glucose transporters 143     
(GLUTs) 
Figure 5.2. Scheme showing the 3T3-L1 cell differentiation  149             
process 
Figure 5.3. The determination of 3T3-L1 cell differentiation on 156            
days 4, 7 and 10 in the presence and absence of     
adipogenic media containing insulin, DEX and IBMX 
Figure 5.4. Images showing adipocyte formation quantified  157                
using oil red O stain over a period of 10 days 
Figure 5.5. The effect of insulin on 3T3-L1 cell differentiation 158                
over a period of 10 days 
Figure 5.6. The effect of tetrandrine on 3T3-L1 cell differentiation 159         
over a period of 10 days 
Figure 5.7. The effect of tetraethylammonium (TEA) on 3T3-L1 160              
cell differentiation over a period of 10 days 
Figure 5.8. The effect of methylglyoxal (MeG) on 3T3-L1 cell 161 
differentiation over a period of 10 days  
 
List of tables 
 
Table 1.1.  The symptoms recorded by Charles Darwin  2 
Table 1.2. The prevalence of primary lactose hypolactasia  6                              
in various ethnic groups 
Table 1.3. The gut and systemic symptoms of lactose  8                       
sensitivity 
Table 1.4. The gases and metabolites that are released  10                         
by the different bacteria in the gut following            
carbohydrate metabolism 
Table 1.5. The number of people potentially affected by  28               
diabetes in the future compared to those affected                  
by disease in the year 2000 
Table 1.6. Groups of peptides that have been isolated from  35                 
both bovine and human beta-casein 
Table 3.1. Types of luminescence and the basis of light  67               
emission 
List of figures and tables 
 
xvi 
 
Table 4.1. Drugs that bind to Sudlow’s sites I and II on human 112         
serum albumin (HSA) with high affinities 
Table 4.2. The association (Ka) and dissociation (Kd) constants 132              
of drugs that are known to bind with high affinity                     
to HSA 
Table 5.1. The volumes of reagents required to make 50 ml  148           
control, adipogenic and post-adipogenic cell culture      
medium for 3T3-L1 cells 
Table 5.2. Oligonucleotide primer details for the GLUT4  153            
transporter 
Table 5.3. The composition of 12.5 μl PCR reactions  154 
Table 5.4. PCR reaction conditions    154 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations 
 
xvii 
 
 
Abbreviations 
 
[Ca
2+
]i    intracellular calcium 
[S]    substrate concentration 
4E-BP1    eIF-4E binding protein 
ADAMTS9   ADAM metallopeptidase with thrombospondin type 1 
motif 9 
ADP    adenosine diphosphate 
AGEs    advanced glycation endproducts 
AKT    serine/threonine protein kinase (also known as PKB) 
Al    aluminium 
Ala    alanine 
AMP    adenosine monophosphate 
ANOVA    analysis of variance 
APS    SIRP family member 
ARAP1    ArfGAP with RhoGAP domain, ankyrin repeat and PH 
domain 1 
Arg    arginine 
Asn    asparagine 
ATP    adenosine triphosphate 
Au    gold 
B    basic 
BCL11A   B-cell CLL/lymphoma 11A (zinc finger protein) 
BCM    beta-casomorphin 
BFP    blue fluorescent protein 
BK    big potassium 
bp    base pairs  
BSA    bovine serum albumin 
C/EBP    CCAAT/enhancer binding protein 
C3G    Rho-family guanine nucleotide exchange factor 
Abbreviations 
 
xviii 
 
Ca    calcium 
CaCl2    calcium chloride 
cAMP    cyclic adenosine monophosphate 
CAP    CbI associated protein 
CAPN10   calpain 10 
Cav3.1    voltage dependent T-type calcium channel 
Cb1    SIRP family member 
CDC123-CAMK1D  cell division cycle 123 homolog-calcium/calmodulin-
dependent protein kinase 1D 
CDK    cyclin-dependent kinase 
CDKAL1   CDK5 regulatory subunit associated protein 1-like 1 
cDNA    complementary DNA 
CEL    carboxyethyl-lysine 
CH3    methane 
CHCHD9   coiled-coil-helix-coiled-coil-helix domain containing 9 
CHCl3    chloroform 
cm    centimetres 
CML    carboxymethyl-lysine 
CO2    carbon dioxide 
CoA    coenzyme A 
C-peptide   connecting peptide 
Crk    adapter protein 
CTLA4    cytotoxic T-lymphocyte-associated protein-4 
Cu    copper 
CVB    Coxsackie B virus 
Cys    cysteine 
Da    Dalton 
DAG    diacylglycerol 
DEX    dexamethasone 
DGI    Diabetes Genetics Initiative 
DHAP    dihydroxyacetone phosphate 
Abbreviations 
 
xix 
 
DIAGRAM   Diabetes Genetics, Replication and Meta-Analysis 
DMEM    Dulbecco’s Modified Eagle Medium 
DMF    dimethylformamide 
DMSO    dimethyl sulphoxide 
DNA    deoxyribonucleic acid 
dNTP    deoxyribonucleotide triphosphate 
DUSP9    dual specificity phosphatase 9 
D-PBS    Dulbecco’s phosphate buffered saline 
E    expanded 
EDTA    ethylenediaminetetraacetic acid 
eIF2B    guanine nucleotide exchange factor 
ELISA    enzyme-linked immunosorbant assay 
ER    endoplasmic reticulum 
ESRD    end-stage renal disease 
F    fast 
FA    fatty acid 
FAD    flavin adenine dinucleotide 
FBS    foetal bovine serum 
FCS    foetal calf serum 
Fe    iron 
FeCl3    iron III chloride 
FeSO4    iron II sulphate 
FFA    free fatty acid 
FUSION   Finland-United States Investigation of NIDDM 
g    grams 
G    gravity    
Gab1    SIRP family member 
GAD    glutamic acid decarboylase 
GAD-65   glutamic acid decarboxylase-65 
GADA    antibody to GAD 
Abbreviations 
 
xx 
 
GAP    glyceraldehyde-3-phosphate 
GAPDH   glyceraldehydes 3-phosphate dehydrogenase 
GDH    glycerophosphate dehydrogenase 
GFP    green fluorescent protein 
Gln    glutamine 
Glu    glutamic acid 
GLUT2    glucose transporter 2 
GLUT4    glucose transporter 4 
Gly    glycine 
Grb2    adapter protein containing SH3 domains 
GSH    glutathione 
GSIS    glucose stimulated insulin secretion 
GSK3    glycogen synthase kinase 3 
GTP    guanosine triphosphate 
GWA    genome wide association 
GWAS    genome wide association studies 
H2    hydrogen 
H2O    water 
H2O2    hydrogen peroxide 
H2SO4    sulphuric acid 
HCl    hydrochloric acid 
HEPES    4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HHEX    hematopoietically expressed homeobox 
His    histidine 
HLA    non-human leukocyte antigen 
HMGA2   high mobility group AT-hook 2 
HMIT    H
+
-coupled myo-inositol transporter 
HNF1A    HNF homeobox A 
HNF1B    HNF homeobox B 
HSA    human serum albumin 
Abbreviations 
 
xxi 
 
IA2    islet-cell antigen-2 
IAA    insulin autoantibody 
IBMX    isobutylmethylxanthine  
IBS    irritable bowel syndrome 
IC50    the half maximal inhibitory concentration 
ICA    islet cell autoantibody 
IDDM    insulin-dependent diabetes mellitus 
IFIH1    interferon induced with helicase C domain 1 
IGF    insulin-like growth factor 
IGF2BP2   insulin-like growth factor 2 mRNA binding protein 2 
IKKβ    TNF-induced insulin resistance mediator 
IL    interleukin 
IL2RA    interleukin 2 receptor, alpha 
Ile    isoleucine 
INF    interferon 
INS    insulin gene 
IP3    inositol-1,4,5-triphosphate 
IR    infra red 
IR    insulin receptor 
IRS    insulin receptor substrate 
JAZF1    JAZF zinc finger 1 
JNK1    JUN kinase-1 
K    potassium 
K+-ATP   ATP-dependent potassium channel 
Ka    association constant 
kcat    turnover number 
KCNJ11   potassium inwardly-rectifying channel, subfamily J, 
member 11 
KCNQ1    potassium voltage-gated channel, KQT-like 
subfamily, member 1 
Kd    dissociation constant 
Abbreviations 
 
xxii 
 
kDa    kilodalton 
kg    kilogram 
Ki    inhibition constant 
KLF14    Kruppel-like factor 14 
Km    Michaelis constant 
Leu    leucine 
LPH    lactase-phloritzin hydrolase 
Lys    lysine 
M    molar 
m/z    mass-to-charge ratio 
mA    milliamps 
MAPK    mitogen-activated protein kinase 
MeG    methylglyoxal 
MEM-α    Alpha Minimum Essential Medium 
Mg    magnesium 
mg    milligrams 
MG-H    MeG-derived hydroimidazolones 
MG-H1    Nδ-(5-hydro-5-methylimidazol-4-on-2-yl)ornithine 
MG-H2    2-amino-5-(2-amino-5-hydro-5-methyl-4-imidazolon-
1-yl)pentanoic acid 
MG-H3    2-amino-5-(2-amino-4-hydro-4-methyl-5-imidazolon-
1-yl)pentanoic acid 
MHC    major histocompatibility complex 
min    minutes 
ml    millilitres 
mm    millimetres 
mM    millimolar 
MOE    Molecular Operating Environment 
MOLD    MeG-lysine dimer 
mRNA    messenger ribonucleic acid 
mTOR    mammalian target of rapamycin 
Abbreviations 
 
xxiii 
 
mV    millivolts 
N    native 
Na    sodium 
Na2HPO4   sodium phosphate dibasic 
NAC    N-acetyl-cysteine 
NAD    nicotinamide adenine dinucleotide 
NaH2PO4   sodium dihydrogen phosphate 
NaOH    sodium hydroxide 
Nck    small adapter protein 
NEFA    non-esterified fatty acid 
NHS    national health service 
NIDDM    non-insulin-dependent diabetes mellitus 
NK    natural killer 
nm    nanometres 
nmol    nanomoles 
NOTCH2   notch 2 
O2    oxygen 
p110    catalytic subunit of PI 3-kinase    
p70s6k    p70 ribosomal S6 kinase 
PARP    poly(ADP-ribose) polymerase 
PBS    phosphate buffered saline 
PC1    prohormone convertase 1 
PC2    prohormone convertase 2 
PDB    Protein Data Bank 
PDK-1    protein kinase 3-phosphoinositide-dependent protein 
kinase-1 
PDX-1    pancreatic and duodenal homeobox 1 
Phe    phenylalanine 
PI 3-kinase   phosphatidylinositol 3-kinase 
PI3K    phosphoinositide 2-kinase 
PIP2    phosphatidylinositol-4,5-bisphosphate 
Abbreviations 
 
xxiv 
 
pKa    acid dissociation constant 
PKB    protein kinase B 
PKC    protein kinase C 
PMT    photomultiplier tube 
PP    pancreatic polypeptide 
PPAR    peroxisome proliferator activated receptor 
PPARG    peroxisome proliferator-activated receptor gamma 
ppm    parts per million 
PRC1    protein regulator of cytokinesis 1 
Pro    proline 
PTP    protein tyrosine phosphatase 
PTPN22   protein tyrosine phosphatase, non-receptor type 22 
PTPRD    protein tyrosine phosphatase, receptor type D 
rER    rough endoplasmic reticulum 
RNA    ribonucleic acid 
ROS    reactive oxygen species 
rpm    rotations per minute 
SE    standard error 
SEM    standard error of the mean 
Ser    serine 
SGLT    sodium-dependent glucose transporter 
SH2    src-homology 2 
shc    src homology 2 domain 
SHP2    tyrosine-specific protein phosphatase 
SLC30A8   solute carrier family 30 (zinc transporter), member 8 
SOCS    suppressor of cytokine signalling  
sos    son-of-sevenless 
SREBP-1c   steroid regulatory element binding protein 
SRR    serine racemase 
SUMO4   small ubiquitin-like modifier 4 
Abbreviations 
 
xxv 
 
TAE    Tris acetate-EDTA 
TC10    small signalling G-protein 
TCA    tricarboxylic acid 
TCF7L2   transcription factor 7-like 2 
TEA    tetraethylammonium 
THADA    thyroid adenoma associated 
Thr    threonine 
TP53INP1   tumour protein p53 inducible nuclear protein 1 
Trp    tryptophan 
TSPAN8-LGR5   tetraspanin 8-leucine-rich repeat-containing G protein 
coupled receptor 5 
Tyr    tyrosine 
UK    United Kingdom 
UV    ultraviolet 
v    reaction rate 
Val    valine 
Vmax    maximum rate 
VNTR    variable number of tandem nucleotide repeats 
WAT    white adipose tissue 
WFS1    Wolfram syndrome 1 (wolframin) 
WHO    World Health Organisation 
WTCCC   The Wellcome Trust Case Control Consortium 
ZBED3    zinc finger, BED-type containing 3 
ZFAND6   zinc finger, AN1 type domain 6 
Zn    zinc 
ZnCl2    zinc chloride 
α-cells    alpha cells 
α-GAL    α-galactosidease 
β-cells    beta cells 
β-galactose-1,4-glucose  lactose 
δ-cells    delta cells 
Abbreviations 
 
xxvi 
 
μl    microlitres 
μm    micrometres 
μM    micromolar 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
Chapter 1: 
 
Introduction 
 
Chapter 1: Introduction 
 
1 
 
1. Introduction 
The most common condition observed by gastroenterologists is irritable bowel 
syndrome (IBS). This condition accounts for approximately 50 % of all 
referrals (Campbell et al., 2010). IBS is characterised by a diverse range of 
gut and systemic symptoms such as gut pain, gas, diarrhoea or constipation 
as well as severe headaches, severe fatigue, muscle and joint pain and heart 
palpitations. The success rates at treating this condition are poor leading to a 
reduced quality of life for the affected individual as well as costing the NHS a 
significant amount for consultations with doctors and for the relevant drug 
therapy for the management of the symptoms. So that this condition can be 
controlled effectively, it is important to understand the mechanism involved in 
the production of the symptoms that characterise it. It has been shown that 
lactose and food intolerance are the major causes of IBS (Campbell and 
Matthews, 2005, Campbell et al., 2005, Waud et al., 2008). The symptoms of 
IBS occur due to the production of “toxic” metabolites by the bacteria found in 
the large intestine as a result of the anaerobic breakdown of food such as 
carbohydrates that were unable to be absorbed by the small intestine. The 
“toxic” metabolites produced by the bacteria can include alcohols, diols (e.g. 
butan-2,3-diol), ketones, acids and aldehydes (e.g. methylglyoxal). The 
production of these bacterial toxins can have a significant effect on the 
signalling mechanisms of cells around the body and this explains why 
individuals with IBS, lactose and food intolerance experience these symptoms 
(Campbell et al., 2005).  
Charles Darwin (1809 – 1882) was unwell for the majority of his life. In 
December 1831, he was in Plymouth waiting to board a ship called the 
“Beagle”, when he developed chest pain and palpitations. However, once on 
the ship these symptoms improved and he seemed to be healthy apart from 
the occasional fever and some sea-sickness (Campbell and Matthews, 2005). 
These symptoms were thought to be due to Darwin contracting typhoid 
(Campbell et al., 2005). After returning home and marrying in 1837 he 
developed the same symptoms and was ill again. At times, Darwin felt so 
unwell he had to stop working for a number of weeks at a time. He began a 
diary recording his symptoms (Table 1.1) and the worst symptoms he 
experienced were constant nausea and vomiting, stomach pain, flatulence as 
well as headaches and some dizziness.  
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Some other symptoms he also had included eczema (mainly on his face), 
boils and chronic fatigue. He saw a number of doctors – one of these included 
his father and tried a diverse range of medications and some home remedies, 
however these were all unsuccessful in treating his symptoms. The only time 
Darwin’s condition improved was when he reduced his milk and cream intake 
(Campbell and Matthews, 2005, Campbell et al., 2005). 
 
Symptoms recorded by Charles Darwin 
 Severe gastrointestinal problems, such as gut pain 
 Nausea and vomiting 
 Severe headaches and dizziness 
 Joint pain 
 Chronic fatigue 
 Trembling 
 Insomnia 
 Allergies, such as eczema 
 Mouth ulcers 
 Boils 
 Heart palpitations 
 Depression 
 Poor resistance to infections 
 
Table 1.1. The symptoms recorded by Charles Darwin (Campbell and Matthews, 
2005). 
 
The regular occurrence of these symptoms began to have a significant impact 
on Darwin’s life. His work began to slow down and he turned down invites to 
parties as well as preventing him from attending the Oxford debate in 1860 
(Campbell and Matthews, 2005). Many proposals have been put forward in an 
attempt to diagnose Darwin and these include: arsenic poisoning, Chagas’ 
disease and psychosomatic disorders, such as bereavement syndrome and 
more recently Crohn’s disease, but none of these conditions match with the 
symptoms he experienced (Orrego and Quintana, 2007, Sheehan et al., 2008, 
Hayman, 2009, Greene and Greene, 2009). However, the symptoms do match 
exactly those seen in patients with systemic lactose intolerance and there is a 
substantial amount of evidence to suggest that Darwin had this condition: 
 The symptoms Darwin had matched those seen in patients suffering 
with systemic lactose intolerance 
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 He began to develop gut pain and vomiting 2-3 hours after eating and 
this is consistent with the time that it takes for lactose to reach the 
large intestine 
 His diet consisted mainly of milk, cream and other dairy containing 
products  
 He had a family history of illness 
 He did not have his illness whilst on board the Beagle between 1831 
and 1836 as there was no fresh milk or dairy products on board the 
ship 
 He displayed significant improvement when he reduced his milk and 
cream intake 
It is therefore predicted that Charles Darwin suffered for most of his life with 
lactose intolerance and had this been known, simply reducing the amount of 
lactose intake in his diet would have considerably improved his way of life.  
1.1. Lactose, lactase and lactose sensitivity 
1.1.1. Lactose and lactase 
Lactose (β-galactose-1,4-glucose) is the disaccharide sugar found in the milk 
of all mammals. The only mammals that do not have lactose are Pinnepedia 
(sea lions and walruses). Lactose is made up of the two sugars galactose and 
glucose linked together by a 1,4-linkage. On average, human milk contains 7.0 
g of lactose in 100 ml whereas cow’s milk contains approximately 4.7 g of 
lactose in 100 ml (Arola and Tamm, 1994).  
When lactose is ingested, it must be broken down into galactose and glucose 
(Arola and Tamm, 1994). So that lactose can be absorbed it is hydrolysed in 
the small intestine by lactase-phloritzin hydrolase (LPH) also known as lactase 
in short (Matthews et al., 2005, Vesa et al., 2000, Escher et al., 1992). Lactase 
is found at high levels in the jejunum at the start of the small intestine and its 
only purpose is to hydrolyse lactose (Vesa et al., 2000). Lactase is a protein 
consisting of 1059 amino acids and has a molecular weight of 320 kDa. It is an 
unusual protein in that it contains two active sites in its polypeptide chain. One 
active site is responsible for hydrolysing lactose and the other is responsible 
for hydrolysing aryl and aliphatic glycosides e.g. phloritzin into glucose and 
phloretin. Phloretin can be found in apple tree leaves and is a potent diabetic 
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agent (Matthews et al., 2005). Once lactose has been broken down by lactase 
into its constituent monosaccharides, they are absorbed from the intestine.  
The sodium-dependent glucose transporter 1 (SGLT1) is found on the apical 
surfaces of the intestinal absorptive cells (enterocytes) of the small intestine. 
The presence of this type of transporter enables the uptake of these 
monosaccharides into the cells against the concentration gradient, using the 
Na+ gradient as the energy source. The presence of another glucose 
transporter, glucose transporter 2 (GLUT2), which is located on the opposite 
side of the cells, then allows the release of glucose and galactose into the 
bloodstream. Galactose is harmful to the eyes as well as other cells of the 
body and therefore once in the bloodstream it is rapidly metabolised by the 
liver to remove it from the body. Some compounds found in foods can lead to 
the inhibition of glucose and galactose uptake by the SGLT1 transporter. For 
example, raffinose and stachyose, a tri- and tetra-saccharide, respectively can 
inhibit the uptake of glucose and galactose by the SGLT1 transporter. 
Raffinose is a trisaccharide consisting of galactose, glucose and fructose, 
whereas stachyose is a tetrasaccharide composed of two galactose units, 
glucose and fructose (or stachyose = raffinose + galactose). These sugars are 
found in beans, chick peas, pulses and root vegetables, such as parsnips. 
They can be hydrolysed by the enzyme α-galactosidease (α-GAL). However, 
the human digestive tract does not contain the enzyme α-GAL, that is required 
to breakdown these sugars. Therefore, these sugars pass undigested through 
the small intestine and stomach. When they reach the large intestine, the 
bacteria here which do contain the α-GAL enzyme can breakdown these 
sugars resulting in the production of gases such as CO2, methane and 
hydrogen, leading to the flatulence that is commonly associated with the 
consumption of beans and some vegetables (Matthews et al., 2005, Campbell 
et al., 2005).  
1.1.2. Hypolactasia and lactose sensitivity 
Depending on the ethnic background of an individual, normal lactase activity 
(normolactasia) can continue into adulthood and it is this that allows humans 
to be able to consume large quantities of milk without developing any 
symptoms (Arola and Tamm, 1994). However, after weaning, the lactase 
levels can significantly decrease. Hypolactasia is a medical term for the loss of 
lactase in the small intestine therefore leaving the unhydrolysed lactose in the 
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jejunum where it can then be metabolised by the intestinal bacteria (Arola and 
Tamm, 1994). If there is little or no lactase in the small intestine, lactose is 
either partially digested or undigested and remains in the small intestine where 
it can cause the wide range of symptoms seen in lactose intolerance. 
It is due to these low levels of lactase that has resulted in a significant 
proportion of the world’s population becoming hypolactasic. There are three 
mechanisms that can cause this: 
Primary adult hypolactasia – this is the most common type and is the 
loss of the enzyme on weaning (Campbell et al., 2005). The activity of the 
enzyme, lactase, will have decreased to approximately 10 % of normal 
levels found in children. At which age the amount of lactase declines 
varies from less than two years to 10 - 20 years (Arola and Tamm, 1994). 
Secondary hypolactasia – this type is also known as acquired 
hypolactasia and usually occurs following any gastrointestinal illness that 
results in brush border damage or can be due to significant increases in 
transit time in the jejunum border. This type has the potential to be 
reversed and is therefore able to be treated (Campbell et al., 2005). 
Congenital alactasia – this type is rare and therefore only a small 
number of people suffer with congenital alactasia however, it is common 
amongst the Finnish population. This is the absence of lactase, even from 
birth. Babies that are born with this type cannot digest lactose that is 
present in breast milk and standard infant milk formulas. This absence of 
lactase is due to mutations in the lactase gene (Campbell et al., 2005). 
Most adults have a normal lactase level at birth however; this level 
significantly decreases following weaning (Swagerty et al., 2002). Humans 
lose between 90 and 95 % of birth lactase levels by the time they reach early 
childhood and the level of lactase continues to decrease throughout life. The 
prevalence of hypolactasia can vary between different ethnic groups (fig. 1.1 
and Table 1.2). Asians are predicted to have a very low tolerance to lactose 
due to losing between 95 and 100 % of lactase.  
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Ethnic group Prevalence (%) 
 
 Northern Europeans 
 White Americans 
 Central Europeans 
 Northern Indians 
 Southern Indians 
 Hispanics 
 Ashkenazi Jews 
 Blacks 
 American Indians 
 Asians 
 
 
2 – 15 
6 – 22 
9 – 23 
20 – 30 
60 – 70 
50 – 80 
60 – 80 
60 – 80 
80 – 100 
95 – 100 
 
 
Table 1.2. The prevalence of primary lactose hypolactasia in various ethnic 
groups (Swagerty et al., 2002). 
 
 
 
Figure 1.1. The global incidence of lactose sensitivity 
 
Lactose malabsorption is caused when lactose is metabolised into its two 
sugar constituents, glucose and galactose, by lactase, but these are not fully 
absorbed by the small intestine. As a result of these not being fully absorbed, 
patients experience symptoms similar to those seen in patients who suffer with 
lactose intolerance e.g. abdominal pain, flatulence and diarrhoea. Patients 
with lactose malabsorption are able to consume a moderate amount of milk 
without experiencing significant symptoms (Johnson et al., 1993). Lactose 
malabsorption does not always lead to lactose intolerance (Ferguson, 1981). 
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Lactose sensitivity is due to the lack of the enzyme, lactase, on the brush 
border (microvilli) of the small intestine (Matthews and Campbell, 2000, 
Campbell et al., 2004). 
 
 
 
Figure 1.2. The pathways through which anaerobic bacteria in the large intestine 
generate gases and bacterial metabolic toxins. The structures of the fermentation 
products and putative bacterial metabolic toxins are shown in the box (Campbell et al., 
2005, Campbell et al., 2010). 
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So that it can be absorbed, the milk sugar lactose must be hydrolysed at the 
intestinal brush border by the enzyme lactase. Following weaning, there is a 
decrease in lactase activity and this reduction in lactase activity leads to the 
development of lactose intolerance (Suarez et al., 1995). When undigested 
lactose remains and is not absorbed in the small intestine, it is passed to the 
large intestine. In the large intestine there are 1014 individual bacteria 
representing over 1000 different species and weighing approximately 1 kg. 
There is very little oxygen in the large intestine, approximately < 1 μM. The 
bacteria here anaerobically metabolise lactose resulting in the production of 
gases and metabolic toxins (fig. 1.2) (Campbell et al., 2010). The gases 
(hydrogen and methane) produced cause gut distension, resulting in pain and 
flatulence, whereas, the metabolic toxins can be reabsorbed into the 
bloodstream and can travel around the body and can be harmful to a range of 
tissues throughout the body, such as neurones, cardiac cells, other muscles, 
endocrine cells and cells making up the immune system (Campbell et al., 
2005). It is predicted that these putative metabolic toxins can lead to the 
development of diabetes. Lactose sensitivity produces gastrointestinal 
symptoms such as abdominal pain and distension but there are also systemic 
symptoms (Table 1.3). Some of the systemic symptoms are missed by 
clinicians due to their intermittent appearance. 
 
Symptoms 
Gut related: 
 Abdominal pain 
 Gut distension 
 Borborygmi 
 Flatulence 
 Diarrhoea 
 Constipation 
 Nausea and 
vomiting 
Systemic related: 
 Headache and light headedness 
 Loss of concentration 
 Poor short term memory 
 Severe fatigue 
 Muscle pain 
 Joint pain (+/- swelling and stiffness) 
 Allergy (eczema, asthma, rhinitis, sinusitis, pruritis 
 Mouth ulcers 
 Heart palpitations and arrhythmias 
 Sore throat 
 Increased micturition 
 
Table 1.3. The gut and systemic symptoms of lactose sensitivity (Matthews et al., 
2005). 
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These symptoms can vary between individuals and depends on the amount of 
lactase a person has in the small intestine and how much lactose has been 
consumed. For example, if there is a significant amount of lactose compared 
to the amount of lactase present the symptoms of lactose intolerance can be 
quite severe.  
To determine if a patient is lactose sensitive the patient is required to consume 
50 g of lactose orally. The consumption of 50 g of lactose is the equivalent to 
the same patient drinking 1 litre of cow’s milk. Once the lactose has been 
consumed breath hydrogen is measured every half an hour over a time course 
of 3 hours. The development of symptoms after the consumption of this 50 g 
lactose does not necessarily mean that individuals cannot tolerate a small 
amount of milk, as some people who did not have a history of any gut 
problems prior to ingestion did however, display some symptoms after taking 
the 50 g lactose. A person is considered to be lactose sensitive if they have a 
breath hydrogen measurement above 20 parts per million (ppm). The 
consumption of 50 g lactose is significantly high and will over whelm the 
remaining lactase available in those individuals that have already lost the 
enzyme after weaning, resulting in the symptoms shown in Table 1.3 
(Matthews et al., 2005, Waud et al., 2008). 
Lactose sensitivity can often be misdiagnosed and after years of discomfort 
and a poor quality of life, the right diagnosis and by simply removing lactose 
from the diet can considerably improve the quality of life of someone with this 
condition (Matthews et al., 2005). 
1.2. Lactose sensitivity and irritable bowel syndrome 
Irritable bowel syndrome (IBS) is a chronic gastrointestinal problem that is 
characterised by abdominal discomfort, bloating and diarrhoea. It is a common 
condition and is the most common reason for visiting a gastroenterologist, 
where there are approximately 2.4 – 3.5 million visits each year (Waud et al., 
2008, Cash and Chey, 2004). The symptoms of IBS are the same as those 
seen in individuals with lactose sensitivity (Gupta et al., 2007) and the 
prevalence of lactose sensitive patients with IBS ranges from 17 to 86 % 
(Frissora and Koch, 2005). Therefore, patients who have been diagnosed with 
IBS are often advised to undergo a lactose sensitivity test or breath hydrogen 
test to see if they are also lactose sensitive (Waud et al., 2008). Sometimes, if 
the lactose sensitivity test does not suggest that the patient is lactose 
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sensitive, the patients are advised to remove lactose containing products from 
their diet and this has helped to considerably reduce their symptoms and 
improved their overall quality of life.  
1.3. Gas and metabolite release as a result of carbohydrate metabolism 
It is known that when undigested carbohydrates remain in the small intestine 
rather than being broken down into monosaccharides so that they can be 
absorbed they get passed into the large intestine where the bacteria can 
anaerobically metabolise them. As a result of carbohydrate metabolism by the 
bacteria, gases and a range of metabolites are produced. The metabolites 
produced will depend on the species of bacteria (Campbell et al., 2007). Table 
1.4 shows the gases and metabolites that can be released by the different 
bacteria in the large intestine. 
 
Substances that are released: Examples: 
 
Gases 
 
 
Metabolites 
 
 
Carbon dioxide, hydrogen, methane, hydrogen 
sulphide, oxygen, nitrogen and ammonia 
 
Alcohols (e.g. ethanol), diols (e.g. butan-2,3-diol), 
aldehydes (acetaldehyde), short chain fatty acids, 
dimethyl hydrazine, amino acid degradation 
products and cyclic AMP 
 
 
Table 1.4. The gases and metabolites that are released by the different bacteria 
in the gut following carbohydrate metabolism (Campbell et al., 2005). 
 
Of these substances that are released, the metabolites are of particular 
interest. These metabolites include compounds such as methylglyoxal, 
diacetyl, propan-1,3-diol, butan-2,3-diol, acetaldehyde, formic acid, D-lactic 
acid and ethanol (Campbell et al., 2005, Campbell et al., 2010). It is proposed 
that these bacterial metabolic toxins are responsible for the development of 
diseases such as diabetes. This thesis will focus on the putative toxin, 
methylglyoxal.  
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1.3.1. Methylglyoxal and its pathway 
Methylglyoxal (MeG) (fig. 1.3) is also known as pyruvaldehyde or 2-
oxopropanal (CH3-CO-CH=O or C3H4O2). It is a dicarbonyl compound as it 
consists of two carbonyl groups. Of these two carbonyl groups, one is 
aldehydic and the other is ketonic and this therefore makes MeG a ketal. 
 
Figure 1.3. The chemical structure of methylglyoxal (MeG). 
 
MeG is present at low concentrations in the body (Jan et al., 2005) but it can 
also be produced by bacteria in the gut and by mammalian cells. Many 
bacteria in the gut contain the enzyme MeG synthase (E.C. 4.2.99.11) and it is 
this enzyme that is responsible for the conversion of dihydroxyacetone 
phosphate (DHAP) into MeG via the removal of a phosphate group. From this, 
it has been predicted that the bacteria found in the intestine may be one of the 
most important sources of MeG production (Baskaran et al., 1989, Ferguson 
et al., 1998).  
MeG can also be produced intracellularly via enzymatic or non-enzymatic 
pathways in nearly all mammalian cells (Cook et al., 1998, Turk, 2010). The 
primary source of MeG in mammalian cells is by the fragmentation and 
removal of a phosphate group from the enediol intermediate, triose 1,2-
enediol-3-phosphate in the interconversion of DHAP and glyceraldehyde-3-
phosphate (GAP) (fig. 1.4). The removal of this phosphate group may occur 
enzymatically. The enzymatic removal of the phosphate group from DHAP is 
carried out by the enzyme, MeG synthase (Thornalley, 1996, Best and 
Thornalley, 1999, Mukohda et al., 2009, Chaplen, 1998).  
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The generation of MeG is controlled by the amount of DHAP and phosphate 
that is present. During times where there are increased concentrations of 
DHAP, MeG synthase is stimulated and is responsible for the production of 
MeG (Booth et al., 2003). High phosphate concentrations inhibit the enzyme, 
MeG synthase thus preventing further production of MeG. The enzyme, 
triosephosphate isomerase, can affect the levels of DHAP present as the 
enzyme is responsible for the interconversion of GAP to DHAP when there are 
low concentrations of phosphate (Booth et al., 2003). The increased 
production of DHAP leads to the stimulation of MeG synthase and results in 
MeG production. MeG can also be produced as a result of lipid and/or L-
threonine and L-lysine catabolism (Chaplen, 1998).  
 
 
 
Figure 1.4. The metabolism of methylglyoxal (MeG) in mammalian systems 
(Chaplen, 1998). 
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Therefore, from this it can be seen that both bacterial cells and mammalian 
cells produce MeG via the removal of a phosphate group from DHAP by the 
enzyme MeG synthase.  
 
 
 
Figure 1.5. The methylglyoxal pathway (Ackerman et al., 1974). 
 
The excessive intake of carbon containing compounds (e.g. glucose) by a cell 
stimulates the MeG pathway (fig. 1.5) and therefore causes increased MeG 
production. MeG is toxic to cells, therefore there are number of mechanisms in 
place to convert it into non-toxic metabolites. Once MeG has been produced, 
the enzyme MeG reductase is responsible for the conversion of MeG to 
lactaldehyde and then the enzyme aldehyde dehydrogenase converts 
lactaldehyde into L-lactate. MeG is also the physiological substrate for the 
glyoxalase system. The glyoxalase system can be found in the cytosol of all 
mammalian cells and is comprised of the two enzymes, glyoxalase I (E.C. 
4.4.1.5) and glyoxalase II (E.C. 3.1.2.6) (Chaplen, 1998).  
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The enzymes of this system are responsible for maintaining low levels of MeG 
by converting it into non-toxic metabolites (Best and Thornalley, 1999, Jan et 
al., 2005). Glyoxalase I is the enzyme that converts MeG into 
lactoylglutathione and glyoxalase II is the enzyme that converts 
lactoylglutathione into D-lactate. Both L- and D-lactate are then converted into 
pyruvate which can then go on to enter the TCA cycle.  
MeG has a concentration of 1.4 μM in healthy subjects. Elevated 
concentrations have been noticed in diabetic patients. Patients with type 1 
diabetes have a 5- to 6-fold increase whereas patients with type 2 diabetes 
have a 2- to 3-fold increase in MeG concentration. Therefore a strong 
association has been formed between increased MeG concentration and 
hyperglycaemia. Increased MeG concentrations at times of hyperglycaemia 
can affect cellular function due to the toxin reacting with the amino groups of 
proteins thus resulting in impaired cell function and diabetic complications. For 
example, the modification of the insulin receptor substrate by MeG has been 
proposed to be involved in impaired insulin signalling (Queisser et al., 2010, 
Rabbani and Thornalley, 2011, Lee et al., 2009).  
Not only is MeG produced as a result of carbohydrate metabolism by the 
bacteria in the large intestine, but it can also be obtained from the diet and is 
found at high levels in some products. High levels of MeG can be found in 
processed food and coffee. Individuals that do not consume a diet rich in 
carbohydrates but in fact have a diet rich in vegetables, beans and pulses can 
still have elevated concentrations of these bacterial metabolic toxins. The 
production of MeG can alter the balance of gut microflora and will eventually 
get absorbed into the blood where it can have damaging effects on tissues in 
the body. Diet is an easy factor to modify and a simple change in diet may 
help to rebalance the gut microflora and reduce MeG production.  
The glyoxlase system is found in the cytosol of all mammalian cells and is 
responsible for the detoxification of MeG. Any alterations in the expression of 
the genes involved in this process can affect MeG production. For example, 
the inhibition of the gene glyoxalase I can prevent the detoxification of MeG 
thus allowing it to damage target tissues.  
Variations in the production of bacterial toxins like MeG may help to explain 
why only a small minority of individuals develop diabetes. It can be concluded 
that diet has an important role in the production of MeG as the toxin can be 
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produced as a result of metabolism or can be found at high levels in some 
food products. This may help to explain why non-obese individuals are just as 
likely as obese individuals to develop diabetes as a consequence of elevated 
MeG production.  
1.4. The structure of the pancreas 
The pancreas (fig. 1.6) is a gland organ in the digestive and endocrine 
systems of invertebrates that has an unusual structure. It can be found slightly 
below and behind the stomach. It is soft, pinkish-grey in colour, measuring 15-
25 cm in length and has a mass of approximately 70 – 150 g (Carola et al., 
1990, Slack, 1995). 
 
 
Figure 1.6. The structure of the pancreas (Slack, 1995). 
 
The pancreas consists of three regions: 
 The head 
 The body 
 The tail 
The pancreas has an exocrine and endocrine function. Therefore, the 
pancreas is made of both exocrine and endocrine cells (Pocock and Richards, 
2004, Slack, 1995). 
Chapter 1: Introduction 
 
16 
 
1.4.1. The exocrine pancreas 
The exocrine cells are grouped in acini. They are shaped like a pyramid and 
contain basal nuclei, rough endoplasmic reticulum (rER), golgi complex and a 
number of secretory granules containing the digestive enzymes. There are at 
least 22 digestive enzymes and these include proteases, amylases, lipases 
and nucleases. The majority of these enzymes are secreted as inactive 
precursors, however, when the reach the duodenum they become activated. 
At the junction where the acini and ducts meet, there are centroacinar cells 
which are rich in mitochondria. These centroacinar cells are responsible for 
the secretion of non-enzymatic components of the pancreatic juice, such as 
bicarbonate.  
The ducts are lined with columnar epithelial cells. A small number of goblet 
and brush cells similar to those found in the intestine are also found in larger 
ducts. The release of pancreatic juice is controlled by hormonal stimulation by 
secretin, cholecystokinin and gastrin as well as by neural stimuli (Slack, 1995). 
 
 
 
Figure 1.7. The histology of a pancreatic acinus (Slack, 1995). 
 
The exocrine acinar cells (fig 1.7) secrete digestive enzymes such as: 
 Pancreatic amylase – starch is a major dietary carbohydrate. This 
enzyme is responsible for converting polysaccharides into smaller 
molecules such as monosaccharides and disaccharides. It is a 
powerful enzyme that will act on cooked and uncooked starches 
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 Pancreatic lipase – triglyceride molecules are too large to be readily 
absorbed across the intestinal mucosa so they are broken down into a 
2-monosaccharide and two free fatty acids by the enzyme pancreatic 
lipase. For the triglyceride to be digested and for the products of this 
digestion to be absorbed, there must be a sufficient amount of bile 
salts present in the intestinal lumen, therefore suggesting that normal 
absorption and digestion of fat relies on secretions from the pancreas 
and the liver 
 Pancreatic proteolytic enzymes (proteases) – this category consists 
of trypsinogen, chymotrypsinogen and procarboxypeptidase. This 
enzyme is responsible for the breakdown of proteins. Proteases are 
harmful enzymes to have in cells, however, the synthesis and storage 
of the inactive precursors, trypsinogen, chymotrypsinogen and 
procarboxypeptidase in secretory vesicles is the way in which the cells 
can deal with these enzymes safely. The secretory vesicles also 
contain a trypsin antagonist just in case some of the trypsinogen 
becomes activated resulting in the formation of trypsin. Following 
exocytosis, the trypsin antagonist is diluted out and is ineffective. 
When trypsinogen is secreted into the lumen of the duodenum it is 
converted by enterokinase that is found in the intestinal mucosa into its 
active from trypsin. Trypsin then goes on to convert chymotrypsinogen 
and procarboxypeptidase into their active forms, chymotrypsin and 
carboxypeptidase. These enzymes are responsible for the breaking of 
different peptide linkages forming a mixture of amino acids and small 
peptides (Carola et al., 1990). 
The centroacinar cells are responsible for the secretion of bicarbonate. 
Bicarbonate is alkaline and its function is to neutralise the acid that enters the 
small intestine from the stomach. 
1.4.2. The endocrine pancreas 
The endocrine portion of the pancreas makes up approximately 1 % of the 
total mass of the gland. The endocrine cells are mainly grouped into the islets 
of Langerhans. The islets of Langerhans are microscopic organelles that are 
widely distributed throughout the pancreas and are clusters of cells that are 
found embedded in the endocrine tissue (Slack, 1995). The adult pancreas 
contains between 200,000 and 2,000,000 islets throughout the gland (Carola 
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et al., 1990) and each individual islet contains approximately 2,000 cells 
(Robertson and Harmon, 2006). 
The islets of Langerhans are neuroendocrine organs that are responsible for 
the control of blood glucose homeostasis (Soria et al., 2000) and they are 
highly vascular, being supplied by arterioles that reach the islet core where 
they branch out into capillaries (Pickup and Williams, 2003). Four types of 
endocrine cell can be found in the pancreas: 
 Alpha cells (α-cells) – these cells synthesize, store and secrete the 
hormone glucagon in response to a decrease in blood glucose levels 
(hypoglycaemia). Glucagon is responsible for the stimulation of 
glycogenolysis in the liver where glycogen is converted to glucose 
resulting in increased blood glucose levels (Robertson and Harmon, 
2006). 
 Beta cells (β-cells) – these cells are the most common type of cell 
located in the islets of Langerhans (Besser and Thorner, 2002) and 
can be found near the centre of the islet surrounded by the other cell 
types (Carola et al., 1990). Elevated plasma glucose levels stimulate 
the release of insulin into the bloodstream from the secretory granules 
(Besser and Thorner, 2002). The β-cell is sensitive to changes (within 
the physiological range 1 – 10 ng/ml) in plasma glucose and is able to 
rapidly release insulin as a result of elevated glucose concentrations. 
 Delta cells (δ-cells) – these cells secrete somatostatin. Somatostatin 
is required for the inhibition of many hormones (e.g. insulin and 
glucagon) that are released. These cells can potentially behave as an 
intraislet regulator of α-cells and β-cells (Robertson and Harmon, 
2006). 
 Pancreatic polypeptide cells (PP cells) – these cells secrete 
pancreatic polypeptide in response to a decrease in blood glucose 
levels (Carola et al., 1990, Slack, 1995, Robertson and Harmon, 2006). 
The secretion of glucagon by α-cells and insulin by β-cells occurs 
simultaneously and both of these hormones help regulate metabolism (Carola 
et al., 1990). Islets rich in pancreatic polypeptide are found in the posterior 
part of the head (Slack, 1995).  
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1.5. Insulin synthesis, storage and secretion 
Insulin is a peptide hormone that is required for tissue development, growth as 
well as maintaining glucose homeostasis and acts on the liver, muscle and fat 
(Kahn and White, 1988). It does this by accelerating glucose uptake while at 
the time inhibits glucose production and lipolysis (Rorsman et al., 2000). 
After a meal, the levels of circulating levels of glucose are elevated. In 
response to the elevated concentrations of glucose in the blood, the β-cells of 
the islets of Langerhans secrete insulin. The secretion of insulin controls 
glucose homeostasis at a number of different sites. Insulin can decrease 
hepatic glucose output by decreasing gluconeogenesis and glycogenolysis. It 
can also enhance glucose uptake into striated muscle and adipose tissue. 
Insulin can also have an effect on lipid metabolism resulting in the increased 
production of lipids by liver and adipose cells as well as increasing the 
secretion of fatty acids from triglycerides in fat and muscle (Pessin and Saltiel, 
2000).  
 
 
 
Figure 1.8. The amino acid sequence of human insulin (Pickup and Williams, 
2003). 
 
Insulin is made up of 51 amino acid residues (fig 1.8) and has a molecular 
weight of 5808 Da. The insulin molecule consists of two polypeptide chains 
that are joined by two disulphide bonds. The two polypeptide chains are 
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known as the A and B chain. The A chain consists of 21 amino acids as well 
as a intrachain disulphide bridge linking amino acids residues 6 and 11 
whereas the B chain contains 30 amino acid residues (Derewenda et al., 
1989). 
1.5.1. Insulin synthesis 
Preproinsulin is rapidly secreted into the cisternal space of the rER. When in 
the rER, proteolytic enzymes cleave preproinsulin into proinsulin by removing 
the signal peptides. Proinsulin is made up of 86 amino acids and is a single 
polypeptide chain with a molecular weight of 9000 kDa. Proinsulin is further 
cleaved into insulin containing both the A and B chains that are linked together 
by a connecting peptide. This connecting peptide is known as C-peptide. This 
C-peptide is responsible for aligning the disulphide bridges that link the A and 
B chains so that the molecule can be folded correctly for cleavage. 
Microvesicles transport proinsulin to the Golgi apparatus. When it reaches the 
Golgi apparatus, proinsulin is then packed in the storage vesicles that are 
surrounded by a membrane containing an ATP-dependent proton pump. The 
conversion of proinsulin into insulin takes place in the Golgi apparatus and the 
conversion continues whilst in the secretory vesicles. The conversion of 
proinsulin into insulin is carried out by the proteolytic enzymes – prohormone 
convertases 1 and 2 (PC1 and PC2) as well as the enzyme exoprotease 
carboxypeptidase E (Besser and Thorner, 2002). These proteolytic enzymes 
are responsible for the rapid and specific cleavage of proinsulin (preventing 
the further breakdown of insulin) resulting in the removal of the C-peptide 
chain and the production of two cleavage dipeptide, finally yielding insulin 
(Pickup and Williams, 2003). Both insulin and C-peptide are then released on 
a one-to-one basis (Jia et al., 2006). 
1.5.2. Insulin storage 
Insulin has a low solubility and once it has been processed by PC1 and PC2 it 
can along with zinc ions, form the water-insoluble microcrystals of hexamer 
(Zn2insulin6) in the slightly acidic (pH 5.5) environment of the secretory 
granules where it is stored (Noormagi et al., 2010). 
1.5.3. Insulin secretion 
Glucose is the most important fuel for the body, and its plasma concentration 
is tightly controlled by a number of mechanisms.  
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The pancreatic β-cells are able to tell when there is a change in the plasma 
glucose concentration and in response they secrete insulin. The release of 
insulin from the pancreatic β-cell occurs in two stages. During the first stage, 
insulin is rapidly secreted due to elevated blood glucose concentrations. 
 
 
 
Figure 1.9. A diagram showing the processes involved in glucose-stimulated 
insulin secretion (GSIS) (Hussain and Cosgrove, 2005). 
 
The most common pathway where glucose stimulates insulin secretion (fig. 
1.9) starts with the transport of glucose into the β-cell through the GLUT2 
glucose transporter. Glucose can be phosphorylated by the β-cell specific 
glucokinase enzyme (EC 2.7.1.2) to form glucose-6-phosphate. This is the 
rate-limiting metabolic step which acts as a glucose sensor. The metabolism 
involving mitochondrial FAD- glycerophosphate dehydrogenase (GDH) leads 
to the production of ATP. An increase in glucose levels leads to increases in 
the cytoplasm ATP/ADP ratio. The ATP/ADP ratio controls the ATP-dependent 
potassium channel (K+-ATP channel) in the cell membrane of the β-cells. The 
presence of glucose increases the ATP/ADP ratio and this causes the K+-ATP 
channel to close.  
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Once these channels are closed the cell membrane becomes depolarised and 
this causes the voltage-dependent calcium (Ca2+) channels to open. Once the 
voltage-dependent Ca2+ channels have opened there is an influx of calcium 
into the cytoplasm of the cell. Increases in intracellular calcium [Ca2+]i leads to 
the activation of phospholipase C (EC 3.1.4.3). The enzyme phospholipase C, 
is then responsible for the breakdown of the membrane phospholipid, 
phosphatidylinositol-4,5-bisphosphate (PIP2) into inositol-1,4,5-triphosphate 
(IP3) and diacylglycerol (DAG). Once formed, IP3 can then bind to the receptor 
proteins found on the membrane of the endoplasmic reticulum (ER) and 
causes the release of calcium through IP3-gated channels into the cell and 
further increases the calcium concentration. The significant increases in 
calcium levels within the cell results in the release of insulin that was already 
stored in the secretory vesicles. Although this is the main mechanism for 
insulin release it may also be released after food consumption (Grill and 
Bjorklund, 2000, Koster et al., 2005, Flatt et al., 1997, Soria et al., 2000, 
Aizawa et al., 1994, Best, 2002). 
1.6. The insulin receptor and the mechanism of insulin action 
1.6.1. The insulin receptor 
The insulin receptor can be found embedded in the plasma membrane. It is a 
heterotetrametric glycoprotein that has two ligand binding α-subunits with a 
molecular weight of 135,000 Da as well as two tyrosine-specific protein kinase 
β-subunits with a molecular weight of 95,000 Da (fig. 1.10) (Kahn, 1985, 
Virkamaki et al., 1999). The subunits are linked by disulphide bonds resulting 
in the formation of a β-α-α-β structure (Siddle et al., 2001). This oligomeric 
structure divides the receptor into two functional domains (Gammeltoft and 
Van Obberghen, 1986) such that the α-subunits contain the high affinity insulin 
binding site. Even though there are two equivalent binding sites prior to the 
binding of the protein, only a single insulin molecule will bind to the site with 
high affinity. 
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Figure 1.10. The structure of the insulin receptor (IR) (Rosen, 1987). 
 
The β-subunits are transmembrane proteins and are therefore the subunits 
involved in intracellular signalling (Kahn and White, 1988). The α-subunit is 
hydrophilic, disulphide bonded, glycosylated and can be found extracellularly 
whereas, the β-subunit has a short extracellular region that links the α-subunit 
by a disulphide bridge, a hydrophobic transmembrane domain and a long 
cytoplasmic region (Gammeltoft and Van Obberghen, 1986).  
When insulin binds to the extracellular α-subunits a signal is transmitted 
across the plasma membrane resulting in the activation of the intracellular 
tyrosine kinase of one of the two β-subunits (Virkamaki et al., 1999). The 
insulin receptor then undergoes a series of intracellular transphosphorylation 
reactions where one of the β-subunits can phosphorylate the specific tyrosine 
residues of its adjacent partner. Each tyrosine residue is responsible for a 
different function. For example, when the COOH-terminal tyrosine residue is 
phosphorylated this stimulates the mitogenic actions of insulin.  
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The phosphorylation of the tyrosine residue found in the juxtamembrane 
domain results in substrate binding, however, the phosphorylation of the 
tyrosine residues found in the kinase domain controls the catalytic activity of 
the β-subunit (Pessin and Saltiel, 2000).  
1.6.2. The mechanism of insulin action 
Insulin has an important role in the regulation of pathways that result in energy 
storage as well as cell proliferation and cell differentiation. The pathway (fig. 
1.11) is initiated when insulin in the bloodstream binds to the extracellular α-
subunits and a signal is transmitted across the plasma membrane. This signal 
results in the activation of the intracellular tyrosine kinase domain belonging to 
the β-subunit of the same insulin receptor.  
 
 
 
Figure 1.11. The mechanism of insulin action (Saltiel and Kahn, 2001). 
 
The receptor then undergoes a number of intramolecular transphosphorylation 
reactions whereby one of the β-subunits can phosphorylate certain tyrosine 
residues of the adjacent partner. As well as tyrosine autophosphorylation, the 
β-subunit of the insulin receptor can also undergo serine/threonine 
phosphorylation. When the insulin receptor is activated via insulin binding, it 
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can phosphorylate a wide range of proximal substrates on tyrosine such as 
members of the insulin receptor substrate family (IRS 1/2/3/4), isoforms of the 
shc family, Gab1, Cb1 and APS. The phosphorylation of the IRS proteins 
results in the formation of recognition sites for additional effector molecules 
that have src-homology 2 (SH2) domains. The most important of these 
additional effector molecules with SH2 domains is the regulatory subunit 
belonging to the type 1A phosphatidylinositol 3-kinase (PI 3-kinase). However, 
others include small adapter proteins (e.g. Grb2 and Nck) as well as the SHP2 
protein tyrosine phosphatase (Pessin and Saltiel, 2000). 
Then p110 (a catalytic subunit of PI 3-kinase) phosphorylates PIP2 and this 
leads to the formation of PIP3. An important downstream effector of PIP3 is 
AKT (also known as PKB). So that AKT/PKB can be phosphorylated and thus 
activated, there is a need for the protein kinase 3-phosphoinositide-dependent 
protein kinase-1 (PDK-1). When AKT/PKB is activated it will enter the 
cytoplasm of the cell and it is here where AKT/PKB phosphorylates and thus 
inactivates the enzyme glycogen synthase kinase 3 (GSK3). The enzyme 
glycogen synthase is a substrate of GSK3 and is responsible for catalysing the 
final stages of glycogen synthesis. The phosphorylation of glycogen synthase 
by GSK3 leads to the inhibition of glycogen synthesis and therefore leads to 
the activation of GSK3 by AKT/PKB thus promoting glucose storage as 
glycogen (Pessin and Saltiel, 2000). 
A crucial function of insulin is to stimulate the uptake of glucose into cells via 
the glucose transporter, GLUT4. For glucose uptake to occur, insulin 
stimulates the translocation of the GLUT4 transporter from the intracellular 
storage vesicles to the plasma membrane. PI 3-kinase and AKT/PKB are 
known to be involved in GLUT4 translocation. GLUT4 translocation from the 
intracellular storage vesicles to the plasma membrane can also occur via a PI 
3-kinase independent pathway. During the PI 3-kinase independent pathway, 
Cb1 is phosphorylated. Cb1 is linked with the CAP adapter protein when the 
receptor is activated. Once phosphorylated, Cb1 will then interact with the Crk 
adapter protein which is linked with C3G. C3G is a Rho-family guanine 
nucleotide exchange factor and is responsible for the activation of TC10 which 
is a member of the GTP-binding protein family. The activation of TC10 
promotes the translocation of the GLUT4 transporter to the plasma membrane 
(Pessin and Saltiel, 2000, Siddle et al., 2005).  
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Insulin is also involved in amino acid uptake into cells as well as promoting 
protein synthesis and inhibiting protein degradation. Under normal conditions, 
the activation of GSK3 will lead to the phosphorylation and inhibition of eIF2B 
which is a guanine nucleotide exchange factor that is responsible for 
controlling protein translation. Once an insulin signal has been detected, 
AKT/PKB renders GSK3 inactive. The inactivation of GSK3 leads to the 
dephosphorylation of eIF2B and therefore promotes protein synthesis as well 
as encouraging amino acid storage. AKT/PKB will activate mammalian target 
of rapamycin (mTOR) and therefore promotes protein synthesis via p70 
ribosomal S6 kinase (p70s6k) and the inhibition of the eIF-4E binding protein 
(4E-BP1) (Pessin and Saltiel, 2000). 
Insulin also stimulates fatty acid uptake as well as lipid synthesis, however, 
insulin inhibits lipolysis. For lipid synthesis to occur there must be enhanced 
expression of the steroid regulatory element binding protein (SREBP)-1c 
transcription factor. Insulin inhibits lipid metabolism via reducing cAMP levels 
and by activating a cAMP specific phosphodiesterase in adipocytes (Pessin 
and Saltiel, 2000).  
Other signal transduction proteins such as GRB2 (an adapter protein 
containing SH3 domains) can interact with IRS and can then associate with 
the son-of-sevenless (sos) which is a guanine nucleotide exchange factor. 
This then results in the activation of the MAPK pathway resulting in the 
production of mitogenic signals. Another substrate for the insulin receptor is 
SHC. Once phosphorylated, SHC will link with GRB2 and this linkage will lead 
to the activation of the MAPK pathway independently of IRS (Pessin and 
Saltiel, 2000).  
1.7. Diabetes, its complications and the involvement of methylglyoxal 
Glucose is an important fuel for the body and the hydrolysis of carbohydrates 
(e.g. starch or sucrose) in the small intestine results in the production of 
glucose. Glucose can be absorbed into the bloodstream. Increased levels of 
glucose circulating in the blood results in the stimulation of insulin release from 
the pancreatic β-cells.  
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Depending on the target tissue, insulin can have different effects on glucose 
metabolism. Insulin has two effects on glucose metabolism: 
 Cells can take up glucose through a family of hexose transporters via 
facilitated diffusion. The most common glucose transporter, glucose 
transporter 4 (GLUT4) is located on the plasma membrane and is 
responsible for glucose uptake in the presence of insulin. The 
advantage of having this low-affinity, high-capacity glucose transporter 
on the plasma membrane of cells is that there is an instantaneous 
equilibrium between extracellular and intracellular glucose at the β-cell 
(Aizawa et al., 1994). However, if insulin is not present, GLUT4 
transporters remain in the cytoplasmic storage vesicles (Das, 1999) 
rather than being relocated to the plasma membrane and cannot 
therefore aid with the transport of glucose. When the levels of glucose 
in the blood fall and the insulin receptors are no longer occupied by the 
protein, then the GLUT4 transporters are recycled back into the 
cytoplasm of the cells (Das, 1999). 
 When blood glucose levels rise, insulin is secreted from the pancreas. 
Glucose then enters the hepatocytes of the liver where insulin 
stimulates enzymes (e.g. glycogen synthase) resulting in the 
production of glycogen. When insulin is not present in the liver, 
glycogen synthesis no longer takes place and the enzymes that are 
important for the breakdown of glycogen are activated. However, when 
the glucose levels decrease below normal levels (hypoglycaemia), 
glucagon is released. Glucagon can also stimulate the breakdown of 
glycogen.  
The inability of the body to control the blood glucose concentration causes 
hyperglycaemia and results in the development of diabetes. 
Diabetes has reached epidemic properties and the World Health Organisation 
(WHO) have quantified the prevalence and the number of people that are 
affected by diabetes throughout the world. Table 1.5 shows the number of 
people who were affected by diabetes at the start of the new millennium as 
well as the number of people this disease is likely to affect in the future.  
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Countries Year 2000 Year 2030 
Worldwide 171,000,000 366,000,000 
UK 1,765,000 2,668,000 
Europe 33,332,000 47,973,000 
Africa 7,020,000 18,234,000 
America 33,016,000 66,812,000 
Eastern Mediterranean 15,188,000 42,600,000 
South East Asia 46,903,000 119,541,000 
Western Pacific 35,771,000 71,050,100 
 
Table 1.5. The number of people potentially affected by diabetes in the future 
compared to those affected by the disease in the year 2000 (Wild et al., 2004). 
 
Table 1.5 shows that there were 171 million people diagnosed with diabetes 
worldwide in the year 2000 and it is thought that this number will rise to 
approximately 366 million by 2030 (Wild et al., 2004).  
Diabetes mellitus, simply known as diabetes, is fast becoming a common 
condition that is characterised by increased blood glucose concentrations 
(hyperglycaemia). Hyperglycaemia arises because the pancreatic β-cells are 
no longer producing insulin (type 1 diabetes) or they do not produce sufficient 
amounts of insulin to help glucose enter the cells (muscle, fat and liver cells) 
or that the insulin being produced by these cells does not work efficiently 
(insulin resistance) (type 2 diabetes) (Watkins, 1998). Elevated levels of 
glucose have been linked to the formation of the potentially toxic α-
oxoaldehydes, such as MeG. Patients with diabetes often experience a 
number of symptoms and the following are just a few examples: 
 Excessive urine production (polyuria) 
 Increased thirst and increased fluid intake (polydipsia) 
 Blurred vision 
 Extreme fatigue 
 Weight loss 
 Slow wound healing 
However, if the symptoms of diabetes are not well controlled, patients can go 
on to develop more serious conditions that are associated with the diabetes. 
These patients have an increased risk of developing serious microvascular 
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complications (e.g. retinopathy, nephropathy and neuropathy) and 
macrovascular damage (e.g. ischemic heart disease) (WHO, 2006).  
The risk of cardiovascular morbidity in patients with type 2 diabetes is between 
2- to 4-fold higher than the risk in non-diabetic individuals.   
1.7.1. Type 1 diabetes 
Type 1 diabetes is also known as insulin-dependent diabetes mellitus (IDDM). 
Approximately 5 - 15 % of all people with diabetes are diagnosed as having 
type 1 diabetes and it is therefore the least common of the two types. The 
onset of this type is usually rapid and appears before the age of 40. Type 1 
diabetes is characterised by the loss of functioning β-cells resulting in insulin 
deficiency or simply due to the body being unable to produce insulin. The β-
cells of the pancreas that are responsible for the production of insulin to 
control the glucose levels in the blood can be destroyed by the immune 
system through a process known as autoimmune attack. 
Therefore, the destruction of the β-cells prevents the removal of glucose from 
the blood and results in elevated glucose concentrations (hyperglycaemia) 
and leads to the symptoms associated with diabetes (e.g. excessive thirst). 
Increased thirst occurs when the elevated concentrations of glucose in the 
blood cause an osmotic imbalance leading to reduced reabsorption of water 
by the kidneys and results in the frequent passing of urine. This can then lead 
to severe dehydration and hence increased thirst. When there is an elevated 
concentration of glucose in the blood, glucose will filter into the renal tubes; 
this then enters the urine and is the reason behind why the urine smells sweet. 
For energy, the cells are then made to burn fat causing the patient to lose 
weight and leaves ketones (the byproducts of fat metabolism) in the urine and 
on the breath. In the absence of insulin, proteins can also be metabolised for 
energy. Decreases in stored protein causes muscle wasting, weakness and 
weight loss. This autoimmune attack also leaves antibodies in the blood 
(Turkoski, 2006). 
1.7.1.1. The causes of type 1 diabetes 
The destruction of the β-cells as a result of an autoimmune attack is the major 
factor considered to be involved in the development of type 1 diabetes. 
however, a number of other factors can also contribute to its pathogenesis 
(e.g. genetic predisposition, environmental factors and toxins). 
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The genetic predisposition  
IDDM occurs in a genetically predisposed population. In individuals with this 
type of the disease, the main genetic susceptibility factor is the major 
histocompatibility complex (MHC) which is located on chromosome 6. There 
are two combinations of genes (haplotypes) that are thought to be important: 
DR4-DQ8 and DR3-DQ2. These combinations can be found in 90 % of children 
that have been diagnosed with this type. There is a third haplotype, DR15-DQ6 
and this can be found in a small population (>1%) of children and it is 
therefore predicted that this haplotype is protective against the disease. The 
genotype that combines the two susceptibility haplotypes (DR4-DQ8-DR3-DQ2) 
is predicted to increase the probability of developing the disease. Children 
who develop this disease early in their lives have been shown to contain the 
DR4-DQ8-DR3-DQ2 genotype (Gillespie, 2006, Atkinson and Eisenbarth, 2001, 
Bresson and Von Herrath, 2004). 
There are also more than 40 non-human leukocyte antigen (HLA) 
susceptibility loci that are considered to participate in the genetic 
predisposition of type 1 diabetes. These non-HLA susceptibility loci include: 
the insulin gene (INS); the polymorphic, cytotoxic T-lymphocyte-associated 
protein 4 (CTLA4) gene and the protein tyrosine phosphatase, non-receptor 
type 22 (lymphoid) (PTPN22) located on chromosomes 11p15, 2q33, 1p13, 
respectively. Of these 3 genes, the strongest link can be found on 
chromosome 11p15 where there are a variable number of tandem nucleotide 
repeats (VNTR) 5’ of INS. The insulin promoter contains shorter forms of 
VNTR and these have been linked to the development of the disease, whilst 
longer forms of VNTR are associated with protection against the disease 
(Gillespie, 2006, Steck and Rewers, 2011). The PTPN22 and CTLA4 genes 
are responsible for preventing the spontaneous activation of T-cells and the 
modulation of the immune response, respectively (Steck and Rewers, 2011, 
Atkinson and Eisenbarth, 2001). 
Following this, other genes have also been identified that are thought to 
contribute to the predisposition of the disease such as: interleukin 2 receptor, 
alpha (IL2RA); small ubiquitin-like modifier 4 (SUMO4) and interferon induced 
with helicase C domain 1 (IFIH1). Of these 3 genes, the IL2RA gene, located 
on chromosome 10p15, has been predicted to have a strong association with 
type 1 diabetes (Steck and Rewers, 2011). 
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More recently, a number of genome wide association studies (GWAS) have 
been carried out and the results have been published. The Wellcome Trust 
Case Control Consortium (WTCCC) carried out a GWAS in 2007 and as a 
result of this study were able to confirm the identification of those previously 
identified genes (MHC region, INS, PTPN22, CTLA4, IL2RA and IFIH1) as 
well as six novel type 1 diabetes susceptibility loci: 12q13, 12q24, 16p13, 
4q27, 12p13 and 18p11. These type 1 diabetes susceptibility loci were also 
identified and confirmed in several other independent studies (Steck and 
Rewers, 2011).  
Environmental factors 
A number of environmental factors have been suggested to be involved in the 
pathogenesis of type 1 diabetes. These factors can behave as triggers as well 
as stimulators of β-cell destruction (Knip et al., 2005). In genetically 
predisposed individuals these environmental factors can trigger or enhance 
the development of the autoimmune disease (Bresson and Von Herrath, 
2004). Environmental factors that contribute to this type of diabetes can be 
separated into three groups: 
Viral infections 
Human enteroviruses like the Coxsackie B viruses (CVBs) are environmental 
factors that may trigger and/or enhance this autoimmune disease. The virus-
mediated cell damage (fig. 1.12) of target organs results in a local immune 
response that leads to the generation of cytokines like type 1 (IFN-α and IFN-
β) and type 2 (IFN-γ) interferons (IFNs). The production of these IFNs 
prevents the virus from replicating and encourages removal of the virus. 
Therefore, these IFNs and other proinflammatory cytokines are responsible for 
stimulating an immune response against the virus, however in genetically 
susceptible individuals, they can also initiate an autoimmune response via an 
immunological cross reactivity (molecular mimicry) or by the mobilisation of 
endogenous antigens. Both of these can lead to immune-mediated cell 
damage and the eventual development of the autoimmune disease in these 
individuals (Fairweather and Rose, 2002).  
The damage of pancreatic β-cells or cardiac myocytes due to the presence of 
CVB (fig. 1.12) results in a local immune response with the production of the 
IFN-α and IFN-γ cytokines. The generation of these IFNs inhibits the 
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replication of the virus as well as facilitating the removal of the virus in those 
individuals that are resistant to the virus. However, in genetically susceptible 
individuals, these IFNs and along with other proinflammatory cytokines can 
also stimulate an autoimmune response against self-antigens specific to those 
cell types (e.g. pancreatic β-cells or cardiac myocytes) again causing immune-
mediated cell damage resulting in the development of diabetes (Fairweather 
and Rose, 2002).  
 
 
 
Figure 1.12. Virus-induced autoimmune disease (Fairweather and Rose, 2002). 
 
The acute infection by CVB4 results in the development of diabetes. The 
direct effects of acute CVB4 on the insulin signalling pancreatic β-cells have 
been studied. It is known that the cytokines IFN-α and IFN-γ are responsible 
for preventing the β-cells from becoming infected by the virus.  However, the 
production of these IFNs can be inhibited by the expression of suppressor of 
cytokine signalling 1 (SOCS-1). Due to the inhibition of the IFNs by SOCS-1, 
the pancreatic β-cells are exposed to virus. Once the cells have been infected 
by the virus, the cells are then exposed to the attack by natural killer (NK) 
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cells. NK cells are responsible for the destruction of these cells once they 
have become infected. The destruction of the pancreatic β-cells results in 
hyperglycaemia and diabetes. The β-cells are damaged through apoptosis 
occurring during the innate response as opposed to the T- and B-cells of the 
adaptive immune system. This suggests that the early innate immune 
response to CVB4 may be directly responsible for the development of 
diabetes (Fairweather and Rose, 2002). 
Early infant diet 
Milk is the most important food for young mammals and is a source of protein 
for adults. Towards the end of the 1990s, it was predicted that the 
consumption of the A1 variant found in some milk types could increase the risk 
of the development of type 1 diabetes. It is predicted that the early introduction 
of dairy products containing cow’s milk into an infant’s diet could potentially 
increase the probability of the infant developing type 1 diabetes later in their 
life (Wasmuth and Kolb, 2000, Kaminski et al., 2007). 
Milk is approximately 88% water and the remaining 12% is solid. The solids 
include milk fat, protein, lactose and minerals (Wasmuth and Kolb, 2000). Milk 
contains two major protein groups: casein and whey protein. Here we will be 
focusing on the casein protein group and will be paying close attention to beta-
casein. Bovine milk consists of four caseins: alpha s1, alpha s2, beta and 
kappa (Kaminski et al., 2007). 
Both the A1 and A2 variants are the most common forms found in dairy cattle 
around the world. Holstein-Friesian dairy cattle are the most common cattle 
throughout the world. It is predicted that it is the A1 variant in the milk that 
contributes to the development of diabetes. Both the A1 and A2 variants are 
made up of 209 amino acids. The A1 variant has a histidine (His) amino acid 
residue at position 67 on the beta-casein chain, whereas the A2 variant has 
contains a proline (Pro) amino acid residue at the same position on the beta-
casein chain (fig. 1.13) (Kaminski et al., 2007).  
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Figure 1.13. A diagram showing the release of beta-casomorphin-7 (BCM-7) from 
the beta-casein variant A1 but not from the A2 variant (Kaminski et al., 2007).  
 
It is predicted that by changing the amino acid residue at position 67 of the 
beta-casein chain from proline in the A2 variant to histidine in the A1 variant 
will facilitate the release of the bioactive peptide known as β-casemorphin-7 
(BCM-7). The substitution of proline with histidine is due to a natural mutation 
occurring as a result of a single nucleotide polymorphism at codon 67 of the β-
casein gene: CCT (A2, proline)  CAT (A1, histidine). Differences observed in 
the amino acid sequence predict that there is a conformational change in the 
secondary structure of the expressed protein (Kaminski et al., 2007). 
Beta-casomorphins are proteins that originate from the beta-casein protein. 
They consist of 4 – 11 amino acids in length and they all start with a tyrosine 
residue at position 60 of the amino acid chain.  
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Beta-casomorphin (BCM) Amino acid composition 
 
Bovine BCM-4 Tyr-Pro-Phe-Pro 
Bovine BCM-5 Tyr-Pro-Phe-Pro-Gly 
Bovine BCM-6 Tyr-Pro-Phe-Pro-Gly-Pro 
Bovine BCM-7 Tyr-Pro-Phe-Pro-Gly-Pro-Ile 
Bovine BCM-8 Tyr-Pro-Phe-Pro-Gly-Pro-Ile-Pro 
Bovine BCM-11 Tyr-Pro-Phe-Pro-Gly-Pro-Ile-Pro-Asn-Ser-Leu 
 
Human BCM-7 Tyr-Pro-Phe-Val-Glu-Pro-Ile 
Human BCM-8 Tyr-Pro-Phe-Val-Glu-Pro-Ile-Pro 
 
Table 1.6. Groups of peptides that have been isolated from both bovine and 
human beta-casein (Kaminski et al., 2007). 
 
Of these BCMs, bovine BCM-7 is of particular interest as it is predicted to 
have a role in the development of diabetes. In 1979, BCM-7 was first isolated 
as a peptide with an opioid function (i.e. a morphine-like activity) in the body. It 
is a bioactive peptide and in vitro it stimulates human lymphocyte T cell 
proliferation. BCM-7 corresponds for position 60 to position 67 of the bovine 
beta-casein amino acid sequence. However, human BCM-7 corresponds for 
positions 51 to position 57 of human beta-casein. Both bovine and human 
BCM-7 peptides are made up of 7 amino acids (Kaminski et al., 2007).  
They both have a Tyr-Pro-Phe sequence at the N-terminus as well as having 
opiate properties within or close to the BCM-7 amino acid sequence (Kaminski 
et al., 2007). Bovine BCM-7 is considered to be fairly stable due to it 
containing three proline residues in its amino acid sequence.  
It has been shown in vitro that BCM-7 is produced as a result of the 
gastrointestinal proteolytic digestion of β-casein A1 (but not the A2 variant) by 
pepsin, pancreatic elastase and leucine amino peptidase. Elastase is 
responsible for breaking the peptide bond between the Ile and His residues 
thus releasing the carboxyl-terminus of BCM-7. On the other hand, pepsin and 
leucine amino peptidase are responsible for the release of the amino acid 
terminus of the peptide.  
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A number of mechanisms have been proposed to help explain the potential 
risk of developing type 1 diabetes due to milk intake. However, these 
mechanisms are based on BCM-7. BCM-7 is released from the A1 variant in 
vitro and it is known to inhibit the proliferation of human intestinal lymphocytes. 
The behaviour of BCM-7 as an immune-suppressant can influence the 
development of gut-associated immune tolerance or inhibits defence 
mechanisms against enteroviruses (such as CVB), both of which are said to 
be involved in the development of type 1 diabetes (Kaminski et al., 2007). 
Another mechanism for the association of the exposure of cow’s milk and 
autoimmune diabetes could be due to immunological cross reactivity between 
the proteins found in cow’s milk and autoantigens of the β-cell. An alternative 
concept of cross reactivity between the proteins and β-cells has been 
developed, and proposes that infants who have been exposed to cow’s milk 
formula early in their lives have elevated antibody titres to bovine insulin, a 
normal constituent of cow’s milk. Therefore, this exposure to cow’s milk at a 
young age can lead to immunisation rather than a normal tolerance to insulin, 
the only identified β-cell-specific autoantigen in type 1 diabetes (Wasmuth and 
Kolb, 2000). 
Toxins (e.g. N-nitroso derivatives) 
Nitrites (and indirectly nitrates) are commonly found in some foods. Nitrates 
are found in vegetables and both nitrates and nitrites are found in meat 
products (e.g. sausages). They are capable of reacting with amines and 
amides resulting in the formation of nitrosamines and nitrosamides. Nitrate 
can be reduced in the gut to nitrite and this is then converted into the N-nitroso 
compounds. There is a possible link between the consumption of nitrate 
containing compounds and the development of type 1 diabetes however, this 
is undergoing further investigation. If this is the case, the consumption of 
antioxidants (e.g. vitamin C and vitamin E) may protect the β-cells against 
damage caused by the N-nitroso compounds (Akerbolm and Knip, 1998). 
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1.7.1.2. The pathogenesis of type 1 diabetes 
Islet cell autoantibodies 
Type 1 diabetes is associated with a chronic autoimmune response against 
islet β-cell antigens. This autoimmunity begins in early life and the 
development of diabetes can occur several years later. There are three islet β-
cell autoantigens and these are glutamic acid decarboxylase (GAD-65), insulin 
and the protein tyrosine phosphatase related molecules (islet-cell antigen-2, 
IA2) (Achenbach et al., 2005). It has been predicted that GAD-65 is an 
important islet cell autoantigen and is localised to the synaptic-like 
microvesicles in the β-cells, but it is also expressed in all the other cells found 
in the islets of Langerhans as well as the testes, ovaries, thymus, stomach 
and the brain of mammals.  
Insulin is also an autoantigen and it is the only known β-cell specific antigen 
that has been directly associated with this particular type of diabetes. IA-2 
belongs to the protein tyrosine phosphatase (PTP) family and it is predicted to 
be another important autoantigen (Yoon and Jun, 2001). Autoantibodies to 
these islet β-cell antigens are important markers of preclinical type 1 diabetes 
(Naserke et al., 1998). Autoantibodies are generated by the immune system 
where it cannot distinguish between “self” and “nonself” antigens. The immune 
system can normally recognise and ignore the cells of the body as well as 
being able to recognise and ignore substances in the environment that pose 
no threat to the body. However, the immune system must simultaneously be 
able to generate antibodies that are able to fight certain foreign substances 
that have been detected as a potential threat to the body. A problem arises 
when the immune system is switched on to self-antigens and as a 
consequence damages target tissues (Pihoker et al., 2005).  
There are several different types of autoantibodies and these are known as 
islet cell autoantibodies (ICAs). The relevant islet autoantibodies that have 
been identified so far are the GADA (the autoantibody to GAD-65), IAAs 
(insulin autoantibodies) and IA-2A (IA-2 autoantibodies). These autoantibodies 
are present prior to the development of diabetes and can be used as markers 
of the pre-clinical disease. After a series of enterovirus infections, islet cell 
associated antibodies are generated however; the diagnosis of diabetes may 
not be identified for a number of weeks, months or even years (Cabrera-Rode 
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et al., 2005). The autoantibodies against the autoantigens GAD-65 and IA-2 
have been identified as the main constituents of ICAs.  
Early studies primarily carried out over a period of time in first-degree relatives 
demonstrated that ICAs can predict the likelihood of an individual developing 
type 1 diabetes prior to any hyperglycaemia arising (Pihoker et al., 2005). 
Around 70 – 80 % of all newly diagnosed individuals with type 1 diabetes 
already have autoantibodies to GAD-65 and approximately the same number 
have autoantibodies to IA-2 (Notkins and Lernmark, 2001). Children that 
develop type 1 diabetes early in their lives (under the age of 10 years) usually 
demonstrate the initial signs of islet autoimmunity by the time they reach the 
age of 2 and they also have a high number of insulin autoantibodies. These 
children are then more likely to develop numerous islet autoantibodies 
eventually leading to the development of type 1 diabetes (Achenbach et al., 
2005). Some patients carry autoantibodies for only one of the major 
autoantigens, but others can react to all three autoantigens. A number of 
assays that have been carried out have shown that these autoantigen-specific 
antibodies can predict the likelihood of a person developing type 1 diabetes. 
However, these assays so far have been unsuccessful at identifying which of 
these autoantibodies is a better predictor of type 1 diabetes.  
T-cell mediated destruction of β-cells 
Type 1 diabetes is mainly a T-cell mediated autoimmune disease which is 
characterised by the destruction of the insulin-producing pancreatic β-cells by 
T-cells (Gillespie, 2006, Paronen et al., 2000). 
Studies have been carried out on samples taken from the pancreatic biopsies 
obtained from pre-diabetic individuals and patients diagnosed with recent-
onset type 1 diabetes and it has shown that there are several reducing stages 
in β-cell volume in all individuals. Half of these patients studied were also 
diagnosed with an inflamed pancreas (insulitis). The samples taken from the 
patients diagnosed with insulitis showed that the infiltrate contained CD8+ 
(cytotoxic) and CD4+ (helper) T-cells, B-lymphocytes and macrophages. Even 
though the infiltrate contained all these, the majority was made up of CD8+ T-
cells. This therefore suggests a possible mechanism in which the β-cells are 
destroyed.  
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Fas was found on the β-cells located within the inflamed islets whilst the 
infiltrating mononuclear cells in the islets express Fas ligand. This suggests 
that there is an interaction between the Fas located on the β-cells and the Fas 
ligand in the infiltrating cells that may result in β-cell destruction by apoptosis 
leading to the development of type 1 diabetes (Atkinson and Eisenbarth, 
2001). Studies carried out on the pancreas of animals that have died as a 
result of recent-onset type 1 diabetes have identified auto-aggressive T-cells. 
Aggressive β-cell destruction can result in the development of the disease 
within a few months in children, however in other patients the process can 
continue for many years before the disease presents itself (Knip et al., 2005). 
It is not known how these auto-aggressive T-cells enter the pancreas and the 
islets, but blocking this process and thus avoiding the destruction of the β-cells 
could be important for the development of future therapies for the treatment of 
this disease (Bresson and Von Herrath, 2004). 
1.7.1.3. The treatment and prevention of type 1 diabetes 
If left untreated, chronic exposure of bodily tissue for long periods of time can 
result in the severe tissue damage. This results in reduced blood supply to 
vital organs leading to the increased risk of heart attack, kidney failure, stroke 
and blindness. Reduced blood supply can also result in impaired wound 
healing, infections and even gangrene (Turkoski, 2006). Although this is 
happening, the body is still able to respond to insulin, so with the daily 
intravenous administration of insulin, the symptoms disappear (Whelan, 2007). 
As well as injecting insulin, oral hyperglycaemic drugs can also be added for 
maintaining constant blood glucose concentrations.  
Individuals whose parents are diabetic can undergo tests to measure the 
amount of autoantibodies in their body and this will predict the likelihood of 
them developing the disease and thus if it is caught in time the future 
development of the disease can be prevented.  
1.7.2. Type 2 diabetes 
Type 2 diabetes is also known as non-insulin dependent diabetes mellitus 
(NIDDM). Approximately 85 – 95 % of diabetic patients have been diagnosed 
with this type and it is therefore the most prevalent type of the disease. This 
type of diabetes usually appears in individuals over the age of 40 and is 
associated with obesity, however more and more children are being 
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diagnosed with this type of the disease. The onset of type 2 diabetes is 
gradual and the diagnosis can often be missed (Turkoski, 2006, Rignell-
Hydbom et al., 2007, Whelan, 2007). 
1.7.2.1. The causes of type 2 diabetes 
Type 2 diabetes is a heterogenous disorder that is caused by a combination of 
genetic and environmental factors and the result is an effect on glucose 
metabolism (Gerich, 1999). 
The genetic predisposition 
Like type 1 diabetes, genetic factors can also contribute to the pathogenesis of 
type 2 diabetes. The inherited defects result in the more common forms of 
insulin resistance (Fujimoto, 2000), for example, if one parent suffers with this 
type of diabetes, the likelihood of this person’s offspring developing the 
disease has been calculated to be approximately 38 – 40 %. Whereas, if both 
parents suffer with the disease, the prevalence of the offspring developing the 
disease is approximately 60 – 70 % by the time they reach the age of 60 
(Stumvoll et al., 2005, Ahlqvist et al., 2011).  
The search for diabetes susceptibility genes began many years ago. During 
this time, many linkage scans and candidate gene studies for type 2 diabetes 
have been carried out (McCarthy and Zeggini, 2009). Although a large number 
of linkage studies of type 2 diabetes have been carried, only 2 genes have 
been identified: calpain 10 (CAPN10) and transcription factor 7-like 2 
(TCF7L2). Of these two genes, the TCF7L2 gene is thought to have a strong 
association with this type of the disease. However, the mechanism through 
which these genes affect diabetes remains unknown (Ahlqvist et al., 2011, 
McCarthy and Zeggini, 2009). Candidate gene studies have identified 6 genes 
that are predicted to be associated with the development of type 2 diabetes: 
peroxisome proliferator-activated receptor gamma (PPARG), insulin receptor 
substrate I (IRS1), potassium inwardly-rectifying channel, subfamily J, 
member 11 (KCNJ11), Wolfram syndrome I (wolframin) (WFS1), HNF1 
homeobox A (HNF1A) and HNF1 homeobox B (HNF1B) (Ahlqvist et al., 2011, 
McCarthy and Zeggini, 2009). 
More recently, GWAS have been proven more successful at identifying type 2 
diabetes susceptibility genes. In 2007, the results of several GWAS were 
published and this led to a greater understanding of the genetics underlying 
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the development of type 2 diabetes. In these studies the DNA of patients 
diagnosed with this type of the disease (cases) was compared with the DNA of 
healthy individuals (controls). The first GWAS of type 2 diabetes was carried 
out in France and consisted of 661 cases and 614 controls. The results of this 
study identified two new diabetes susceptibility genes: hematopoietically 
expressed homeobox (HHEX) and solute carrier family 30 (zinc transporter), 
member 8 (SLC30A8). Following the results of this study, a further four studies 
were carried out in European populations with similar case-control setups.  
The WTCCC carried out a study in the UK and it consisted of 1924 cases and 
2938 controls; the Diabetes Genetics Initiative (DGI) study consisted of 1464 
cases and 1467 controls from Sweden and Finland; Finland-United States 
Investigation of NIDDM (FUSION) genetics study was carried out in Finland 
and consisted of 1161 cases and 1174 control and finally, a study carried out 
by Steinthorsdottir et al  was carried out in Iceland and consisted of 1399 
cases and 5275 controls (Ahlqvist et al., 2011, McCarthy and Zeggini, 2009, 
Wheeler and Barroso, 2011, Steinthorsdottir et al., 2007). Before the results 
were released for publication, the WTCCC, DGI and FUSION shared their 
results. As a result of these studies, two new loci were identified – cyclin-
dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4)/cyclin-
dependent kinase inhibitor 2B (p15, inhibits CDK4) (CDKN2A/CDKN2B) and 
insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2) as well as 
confirming the identity of the previously identified loci.  
Also, each of the four studies identified a new type 2 diabetes locus: CDK5 
regulatory subunit associated protein 1-like 1 (CDKAL1) (Ahlqvist et al., 2011, 
McCarthy and Zeggini, 2009, Wheeler and Barroso, 2011). GWAS have also 
been carried out in non-European populations and have identified the 
potassium voltage-gated channel, KQT-like subfamily, member 1 (KCNQ1) as 
a new type 2 diabetes susceptibility gene and have also shown that this gene 
is expressed in the pancreas. Studies carried out within an Asian population 
have identified a further 2 diabetes loci: protein tyrosine phosphatase, receptor 
type D (PTPRD) and serine racemase (SRR) (Ahlqvist et al., 2011).  
Although these GWAS have been able to identify some type 2 susceptibility 
genes, there are still some limitations. Therefore, to overcome these 
limitations, genome wide association (GWA) meta-analyses have been carried 
out. GWA meta-analyses have been carried out to improve the ability to 
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identify genuine type 2 diabetes susceptibility genes (McCarthy and Zeggini, 
2009). Researchers from the WTCCC, DGI and FUSION came together and 
formed the Diabetes Genetics, Replication and Meta-Analysis (DIAGRAM) 
Consortium to carry out the first GWA meta-analysis. This GWA meta-analysis 
was carried out within a European population and consisted of 4549 cases 
and 5579 controls. As a result of this, six novel type 2 diabetes susceptibility 
genes were identified: JAZF zinc finger 1 (JAZF1), cell division cycle 123 
homolog-calcium/calmodulin-dependent protein kinase ID (CDC123-
CAMK1D), tetraspanin 8-leucine-rich repeat-containing G protein-coupled 
receptor 5 (TSPAN8-LGR5), thyroid adenoma associated (THADA), ADAM 
metallopeptidase with thrombospondin type 1 motif 9 (ADAMTS9) and notch 2 
(NOTCH2) (Ahlqvist et al., 2011, McCarthy and Zeggini, 2009, Wheeler and 
Barroso, 2011). 
In June 2010, a number of other GWAS were added to the DIAGRAM 
consortium thus leading to the formation of DIAGRAM plus. As a result of the 
formation of DIAGRAM plus, a further 12 novel loci were identified: B-cell 
CLL/lymphoma 11A (zinc finger protein) (BCL11A); zinc finger, BED-type 
containing 3 (ZBED3); Kruppel-like factor 14 (KLF14); dual specificity 
phosphatase 9 (DUSP9); high mobility group AT-hook 2 (HMGA2); tumour 
protein p53 inducible muclear protein 1 (TP53INP1); KCNQ1; transducin-like 
enhancer of split 4 (TLE4); protein regulator of cytokinesis 1 (PRC1); coiled-
coil-helix-coiled-coil-helix domain containing 9 (CHCHD9); zinc finger, AN1-
type domain 6 (ZFAND6) and ArfGAP with RhoGAP domain, ankyrin repeat 
and PH domain 1 (ARAP1) (Ahlqvist et al., 2011). 
Therefore it can be concluded that most of the individual type 2 diabetes 
susceptibility genes have been indentified recently as a result of GWAS and 
GWA meta-analyses. The majority of the genes identified code for proteins 
that are involved in β-cell function (Petrie et al., 2011). However, a few genes 
have been implicated in impaired β-cell function (IGF2BP2, SLC30A8 and 
CDKN2A/CDKN2B), and impaired glucose-stimulated insulin release (JAZF1, 
CDC123-CAMK1D and TSPAN8) (Ahlqvist et al., 2011). 
Environmental factors  
There are a number of environmental factors that can affect cells found within 
the islet of Langerhans in the pancreas either directly or indirectly. These 
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factors can then potentially lead to the development and/or progression of type 
2 diabetes (Marchetti et al., 2006).  
Many lifestyle factors are known to be important in the development of this 
type of diabetes. These factors include reduced physical activity and 
excessive food consumption both of which result in obesity, as well as other 
factors such as ageing, high levels of free fatty acids (FFAs) and some factors 
that individuals are exposed to during foetal and neonatal life. 
Excessive food consumption along with reduced physical activity throughout 
the world has resulted in increased prevalence of obesity and diabetes. 
Approximately between 60 and 90% of patients with type 2 diabetes are also 
suffering with obesity (Kasuga, 2006). The development of obesity due to 
reduced physical activity is the most important factor that is involved in the 
development of insulin resistance (Stumvoll et al., 2005).  
Obese patients have increased β-cell mass as a result of increased insulin 
resistance (Sweene, 1992). If insulin resistance is present along with β-cell 
dysfunction then glucose intolerance will result.  
Obese patients have elevated levels of FFAs circulating in the blood. These 
high levels of FFAs result in the inhibition of insulin-stimulated glucose uptake 
therefore leading to hyperglycaemia and eventually diabetes. By reducing the 
levels of FFAs that are circulating in the bloodstream of obese subjects, will in 
turn reduce insulin resistance (Boden et al., 1994, Qatanani and Lazar, 2007).  
Obesity is also linked with a systemic chronic inflammatory response and not 
just as a result of lipid accumulation in the liver and muscle of some 
individuals. This inflammatory response is characterised by the release of 
cytokines from the adipose tissue as well as the activation of the inflammatory 
signalling pathways. As these cytokines are released from the adipose tissue, 
they are also known as “adipokines”. The adipokines that are produced 
include – leptin, adiponectin, resistin, tumor necrosis factor-α (TNFα) and 
interleukin-6 (IL-6) (Savage et al., 2007). Of these adipokines, TNFα and IL-6 
are the most widely studied. They are biomarkers of inflammation and can be 
found at increased concentrations in individuals that are obese and resistant 
to insulin. As they are biomarkers, they can be used to predict the risk of 
obese and insulin resistant people going on to develop type 2 diabetes in the 
future. Obesity can also be characterised by the accumulation of 
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macrophages in adipose tissue and these macrophages can produce some of 
the previously described adipokines (Savage et al., 2007).  
During this inflammatory response, a number of serine/threonine kinases 
become activated. Of these serine/threonine kinases, JUN kinase-1 (JNK1) is 
considered to be important and is activated by the adipokine, TNFα. Once 
activated by TNFα, JNK1 can phosphorylate IRS-1 resulting in impaired insulin 
signalling. This may help to explain why obese individuals have demonstrated 
increased JNK1 activity. If this is the case, the removal of the JNK1 gene 
would result in increased insulin sensitivity in these obese and insulin resistant 
individuals. The TNF-induced insulin resistance mediator, IKKβ can reduce 
insulin signalling, however treatment with high doses of aspirin can counteract 
this and improve insulin signalling. IKKβ can affect insulin signalling either 
directly or indirectly. This mediator can directly affect insulin signalling via the 
phosphorylation of IRS-1 located on the inhibitory serine residues but it can 
also indirectly affect insulin signalling by activating NK-κB via the 
phosphorylation of its inhibitor IκB. NK-κB is a transcription factor that is 
responsible for the stimulation of TNFα and IL-6. Other inflammatory 
mediators, known as suppressor of cytokine signalling (SOCS) are considered 
to be involved in obesity-induced insulin resistance. Of this family of proteins, 
SOCS-3 has an important role in the association between obesity, 
inflammation and insulin resistance (Savage et al., 2007, Nandi et al., 2004, 
Qatanani and Lazar, 2007). 
Along with obesity, ageing can also contribute to the development of insulin 
resistance. Ageing is also characterised by the build of lipid in the cells of the 
liver and muscle of elderly subjects (Savage et al., 2007, Qatanani and Lazar, 
2007). 
There is a strong association between individuals that were born at a low birth 
weight and the risk of developing type 2 diabetes later in life (Ozanne and 
Hales, 2002). This association has been observed in a diverse range of ethnic 
populations throughout the world (Warner and Ozanne, 2010). 
The environmental factors a foetus is exposed to during the early stages of life 
can play a crucial role in the health and quality of life of individuals in 
adulthood. Changes in nutrition or a disturbed oxygen supply will be 
dangerous for the foetus in terms of it will not only alter the growth pattern but 
they may also contribute to the development of metabolic syndrome later in 
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life (Warner and Ozanne, 2010). A significant amount of work has been 
carried out using animal models to study and understand the mechanisms that 
contribute to the pathogenesis of disease as a result of these factors but not 
many have been carried out in humans. The mechanisms indentified as a 
result of the animal studies have shown some similarities to those that may 
also occur in humans. These mechanisms include permanent structural 
changes, permanent changes in gene expression and mitochondrial 
dysfunction (Warner and Ozanne, 2010).  
Permanent structural changes 
The early stages of life are vital for the development of the pancreas because 
by the time an individual reaches the age of 1, they will have already formed 
approximately half of their adult pancreas. Once adulthood has been reached, 
pancreatic development decreases dramatically. Therefore any changes that 
occur during the early stages can inhibit progenitor cell proliferation and/or 
differentiation as well as affecting the development of the pancreas (Warner 
and Ozanne, 2010).  
Permanent changes in gene expression 
Insulin is an important component that is required during early life 
development. Therefore any changes in protein expression that occur 
downstream of the insulin receptor can alter insulin signalling. The inhibition of 
insulin stimulated glucose uptake by adipose tissue of rats may be a result of 
reduced association between the catalytic subunit, p110β with the regulatory 
subunit p85 and this was linked with the inhibition of PI3K activity. Individuals 
that were born with a low birth weight have showed reduced expression of 
GLUT4, IRS-1, p110β and p85 and all of these may contribute to reduced 
foetal development. The inhibition of insulin-stimulated glucose uptake by the 
skeletal muscle of rats may be due to the inhibition of PKCζ expression. 
Healthy subjects that were born with a low birth weight have reduced 
expression of GLUT4, PKCζ as well as low expression of the two subunits of 
PI3K, p110β and p85 in their skeletal muscle. These healthy individuals with 
low birth weights were able to tolerate glucose, they had similar weights and 
their insulin concentrations were similar when compared to healthy individuals 
born with a normal birth weight. It can therefore be concluded that the reduced 
expression of the insulin signalling proteins mentioned above can occur prior 
to the development of the disease (Warner and Ozanne, 2010).  
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Mitochondrial dysfunction 
Mitochondria play a significant role in both normal and disease processes. The 
mitochondria are not only responsible for ATP production but they also 
generate reactive oxygen species (ROS) which can be detrimental for the 
cells. Mitochondrial dysfunction is associated with oxidative stress and an 
early exposure to oxidative stress can have an effect on many of the tissues in 
the body, particularly the pancreas. So that the pancreas can maintain 
glucose-stimulated insulin secretion, the cells require a lot of energy in the 
form of ATP. The β-cells contain low levels of antioxidant enzymes and as a 
result, when there is mitochondrial dysfunction or increased oxidative stress 
there will be a severe impact on the cells due to the lack of protection. 
Mitochondrial dysfunction can also occur in the liver and skeletal muscle. In 
the liver, the oxidation of pyruvate is decreased and this can result in 
increased glucose release whereas in skeletal muscle, the generation of ATP 
is significantly reduced thus resulting in decreased GLUT4 translocation and 
therefore inhibition of glucose uptake into the tissue. Both of these will result in 
elevated glucose concentrations that are typically associated with type 2 
diabetes (Warner and Ozanne, 2010).  
1.7.2.2. The pathogenesis of type 2 diabetes 
The pathogenesis of type 2 diabetes is complex and in the majority of cases is 
due to β-cell dysfunction and insulin sensitivity. Both β-cell dysfunction and 
insulin sensitivity result in increased glucose release from the liver and the 
kidney as well as inhibiting the removal of glucose from the bloodstream and 
therefore leading to hyperglycaemia.  
Type 2 diabetes develops when the β-cells in the islets of Langerhans are 
unable to produce enough insulin to keep up with the metabolic demand 
(hyperglycaemia). Type 2 diabetes can arise due to insulin resistance with 
slight β-cell dysfunction or due to β-cell dysfunction with slight insulin 
resistance (Fujimoto, 2000). Obesity has been predicted to cause insulin 
resistance and can therefore be considered as a factor that can lead to the 
pathogenesis of this type of diabetes. Randle et al (1963) were the first to 
suggest a relationship between the build up of triglycerides and insulin 
resistance when he described the glucose-fatty acid cycle (Randle et al., 
1963, Gordon, 1964, Frayn, 2003). 
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Insulin resistance 
Insulin resistance is how type 2 diabetes develops and can be present for 
many years and therefore precedes the development of diabetes (Fujimoto, 
2000). It is predicted that the blood glucose and insulin levels are within their 
normal ranges for many years. However, the presence of genetic (inherited) 
and environmental (e.g. obesity) factors can lead to the development of insulin 
resistance. A large proportion of patients who are known to be insulin resistant 
are still able to produce enough insulin to maintain normal blood glucose 
concentrations and are therefore not considered to be hyperglycaemic 
(Goldstein, 2002). Insulin is necessary for the uptake of glucose by both 
muscle and adipose tissue to maintain normoglycaemia. As insulin resistance 
develops, these cells can no longer take up glucose from the bloodstream as 
efficiently and the pancreatic β-cells compensate by secreting more insulin. 
This then leads to high levels of insulin in the blood and this is known as 
hyperinsulinemia. As long as there is enough insulin to overcome this 
resistance then the blood glucose concentrations remain normal. Over time 
the pancreatic β-cells become “exhausted” and will eventually tire. Once tired, 
the β-cells are no longer able to keep up with the demand of insulin secretion 
that is required for the maintenance of normal blood glucose concentrations. 
Therefore, blood glucose levels rise, initially after meals and then eventually 
leading to impaired glucose tolerance resulting in diabetes (Goldstein, 2002, 
Turkoski, 2006, Kasuga, 2006, Renstrom et al., 2007). 
Impaired β-cell function 
The development of β-cell function that is associated with the development of 
type 2 diabetes occurs well in advance of the symptoms of hyperglycaemia. 
Therefore, β-cell dysfunction may occur several years before the individual is 
diagnosed with the disease. As the development of type 2 diabetes 
progresses, there is a gradual loss of β-cell function.  
By the time an individual is diagnosed with this type of diabetes, approximately 
only 50% of β-cells are functioning efficiently (Goldstein, 2002). 
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Numerous mechanisms have been suggested to be involved in the 
development of β-cell dysfunction associated with type 2 diabetes: 
 β-cell exhaustion due to the increased release of insulin as a result of 
insulin resistance 
o Under normal conditions, the secretory function of the β-cell 
increases due to insulin resistance. The increased requirement 
for the production and secretion of insulin suggests that over a 
long periods of time, the β-cells will tire and are more likely to 
fail (Kahn, 2001)  
 Increases in glucose leads to the desensitisation of the β-cells 
o Hyperglycaemia can lead to the generation of high levels of 
reactive oxygen species (ROS) in the β-cells. The generation of 
these ROS can damage the cellular components and can 
therefore impair insulin secretion. ROS can stimulate NFκB 
activity and it is the stimulation of this that can cause β-cell 
apoptosis (Stumvoll et al., 2005, Bonora, 2008). As a result of 
impaired insulin secretion, increased glucose concentrations 
remain in the blood, and it is this high glucose concentration 
that leads to a decrease in the expression of the insulin and 
PDX-1 genes. The PDX-1 gene is responsible for β-cell 
replication. 
 Lipotoxicity 
o Excessive central fat is usually a predictor of type 2 diabetes. 
Both obese and non-diabetic and diabetic patients usually have 
increased non-esterified fatty acids (NEFA) concentrations due 
to enhanced adipocyte lipolysis. Fatty acids cause increased 
insulin secretion; however, after 24 hours these fatty acids can 
inhibit insulin secretion. When glucose is present, there is a 
build up of long chain acyl coenzyme A and fatty acid oxidation 
is inhibited in the β-cell. Long chain acyl coenzyme A can inhibit 
the insulin secretion process by opening the potassium 
channels of the β-cells. Another possible mechanism involves 
the enhanced expression of the uncoupling protein-2 which 
causes decreased ATP formation and therefore inhibits insulin 
secretion (Stumvoll et al., 2005). Also, fatty acids may cause β-
cell dysfunction through altering the [Ca2+]i signal and 
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generating ceramide which induces apoptosis (Chakravarthy 
and Semenkovich, 2007).  
 Reduced β-cell mass 
o Decreases in β-cell mass might be as a result of apoptosis due 
to changes in metabolic state where there are increases in the 
levels of glucose and NEFAs. Another possibility could be due 
to the accumulation of islet amyloid resulting in the progressive 
decline in insulin secretion and glucose tolerance (Kahn, 2001). 
 
 
 
Figure 1.14. The pathophysiology of hyperglycaemia in type 2 diabetes (Stumvoll 
et al., 2005). 
 
Figure 1.14 shows the pathophysiology of hyperglycaemia in type 2 diabetes. 
The secretion of insulin from the pancreas usually results in the inhibition of 
glucose production by the liver and therefore enhances glucose uptake from 
the bloodstream by skeletal muscle. The release of insulin from the β-cell can 
act to suppress fatty acid release from adipose tissue. 
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The inhibition of insulin secretion will lead to the inhibition of insulin signalling 
in the target tissues. Insulin resistance pathways can affect insulin action in 
each of the major target tissues resulting in hyperglycaemia and increased 
circulation of fatty acids (Stumvoll et al., 2005). There is a substantial amount 
of evidence suggesting that these abnormalities exist in most individuals prior 
to the development of diabetes (Weyer et al., 1999). If left untreated, type 2 
diabetes can causes similar problems to those observed if type 1 diabetes 
remains untreated (e.g. retinopathy, neuropathy, end-stage renal disease and 
cardiovascular problems) (Barnett, 2006). The likelihood of developing these 
conditions is particularly high in individuals with this type of diabetes because 
insulin resistance can develop over a number of years and can often go 
undiagnosed until it is too late and extensive damage has already occurred.  
1.7.2.3. The treatment and prevention of type 2 diabetes 
If this type of diabetes is diagnosed in the early stages, it can be controlled by 
diet, exercise and weight loss, but more people are requiring the need for 
insulin-sensitising drugs, such as metformin, when the lifestyle changes no 
longer control the symptoms. However, the disease can progress and many 
people then go on to require intravenous insulin administration due to β-cell 
failure (Turkoski, 2006, Rignell-Hydbom et al., 2007, Frayn, 2003, Whelan, 
2007).  
1.7.3. Type 1.5 diabetes 
Some people with diabetes have symptoms that are characteristic of type 1, 
thus suggesting the need for the injection of insulin as well as having the 
symptoms that are characteristic of type 2 diabetes suggesting that a change 
in diet along with regular exercise would be sufficient to maintain normal blood 
glucose concentrations. More and more people are visiting their doctors 
exhibiting symptoms that are somewhere between type 1 and type 2 diabetes. 
Individuals that have symptoms of both types of diabetes are said to have type 
1.5 diabetes (Donath and Ehses, 2006).  
Some patients are being diagnosed with type 1 and type 2 diabetes 
simultaneously and this helps to explain why type 1.5 diabetes is also known 
as “double diabetes”. In the majority of cases of people with double diabetes, 
they are initially diagnosed with type 1 diabetes but then go on to develop the 
symptoms associated with type 2 diabetes. It has been proposed that both 
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type 1 and type 2 diabetes are the same disease and the only difference being 
the rates in which the disease progresses. It has also been suggested that all 
cases of diabetes are triggered with weight gain.  
It is this gaining of weight that causes the body to develop a resistance to 
insulin and therefore the pancreatic β-cells are required to work harder to 
increase insulin release (hyperinsulinemia) and therefore the β-cells are more 
exposed to autoimmune attack. The exposure of β-cells to autoimmune attack 
can result in the destruction of the insulin producing cells thus preventing 
insulin from being released and eventually leading to the need for the 
intravenous administration of insulin. Patients who suffer with double diabetes 
are likely to have some of the complications that are linked with both types of 
diabetes. For example, an individual diagnosed with double diabetes can have 
small blood vessel damage (retina and kidney) which is associated with type 1 
diabetes as well as the cardiovascular disease and elevated levels of lipids in 
the blood which are associated with type 2 diabetes. However, the 
progression from type 1 to type 2 diabetes occurs at different rates and this is 
probably due to the difference in immune response (Whelan, 2007). 
1.7.4. Advanced glycation end-products and the pathogenesis of 
diabetes 
Alterations in insulin action can lead to the development of diabetes (Jia et al., 
2006). All types of diabetes are primarily characterised by chronic 
hyperglycaemia and the development of microvascular conditions, such as 
blindness, end-stage renal disease (ESRD), retinopathy and neuropathy as 
well as potentially fatal macrovascular complications, such as myocardial 
infarction and stroke (Brownlee, 2001, Peppa et al., 2003). These 
complications arise due to protein alterations that result in the irreversible 
damage of tissues (Vinson and Howard, 1996).  
The condensation reaction that occurs between a reducing sugar and the 
amino acids of a protein is not enzymatically catalysed, therefore this reaction 
is known as non-enzymatic glycosylation. The French chemist, Louis Camille 
Maillard studied this condensation reaction extensively hence why this 
reaction is also known as the Maillard reaction (Vinson and Howard, 1996, 
Turk, 2010). This process begins with the covalent interaction between the 
carbonyl groups (aldehyde or ketone) of a reducing sugar (e.g. glucose) with 
the free amino group of a protein resulting in the formation of an unstable 
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Schiff base (aldimine) (Singh et al., 2001, Riboulet-Chavey et al., 2006, 
Ahmed and Thornalley, 2007, Tan et al., 2008). During Schiff base formation, 
the aldehydic double bond (C=O) of the reducing sugar is converted to a C=N 
double bond with the free amino group of the protein. The formation of the 
Schiff base is fast and reversible.  
The Schiff bases then either dissociate   (Garlick and Mazer, 1983) or undergo 
spontaneous rearrangements (Amadori products) via an intermediate, open 
chain enol form (Ulrich and Cerami, 2001) leading to the formation of a more 
stable 1-amino-2-deoxy-2-ketose (ketoamine) compound known as Amadori 
products (Thornalley et al., 1999, Singh et al., 2001, Riboulet-Chavey et al., 
2006, Ahmed and Thornalley, 2007). For example, when the reducing sugar is 
glucose, the Amadori product is commonly known as fructosamines (Zhang et 
al., 2009).  
There is an intermediate stage during the Maillard reaction which is 
characterised by the generation of a number of secondary products. The 
sugar part of an early glycation product undergoes a number of chemical 
reactions leading to the production of reactive α-dicarbonyl compounds, such 
as MeG (Yim et al., 2001, Saraiva et al., 2006). The production of these 
reactive α-dicarbonyl compounds can damage target cells throughout the body 
thus contributing to the complications associated with diabetes.  
The reactive α-dicarbonyl compound is of particular interest as it can be found 
in all biological systems and healthy individuals have a MeG plasma 
concentration of 1.4 μM. Interestingly, the MeG plasma concentration in 
individuals that have been diagnosed with type 1 diabetes is 5- to 6-fold higher 
whereas, the MeG plasma concentration in individuals with type 2 diabetes is 
2- to 3-fold higher than the concentrations observed in healthy subjects (Jia et 
al., 2006, Wang et al., 2007, Han et al., 2009). Therefore both hyperglycaemia 
and elevated MeG plasma concentrations as a result of changes in glucose 
metabolism are considered to be associated with the microvascular and 
macrovascular symptoms of diabetes (Han et al., 2007, Hsieh and Chan, 
2009). 
MeG is a potent glycating agent because it is able to modify proteins. MeG 
can modify proteins within the cells, especially those that are involved in the 
regulation of gene transcription. However, it can also react with the free amino 
groups of proteins circulating in the blood (e.g. albumin) resulting in the 
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formation of irreversible AGEs (Mostafa et al., 2007, Thornalley, 2005, 
Brownlee, 2005, Brownlee, 2001).  
Of all the amino acid residues that can be found in proteins, MeG favours and 
reacts readily with the arginine, lysine (and cysteine) residues of circulating 
proteins.  
When MeG reacts with free arginine residues of the protein, hydroimidazolone 
adducts are formed, whereas when it reacts with free lysine residues of the 
protein, carboxyethyl-lysine (CEL) and the MeG-lysine dimer (MOLD) are 
formed. The most common AGEs that are found in the plasma are 
hydroimidazolones (Turk, 2010). The protein insulin contains an arginine and 
lysine residue on its B-chain at positions 22 and 29, respectively. In the 
presence of elevated concentrations of glucose again MeG will react with both 
of these residues resulting in the formation of irreversible AGEs at these sites. 
The glycation of these two residues on the B-chain of insulin can significantly 
alter the biological function of the protein by inhibiting insulin signalling thus 
indicating a potential role for the involvement of MeG in the development of 
insulin resistance and eventually diabetes (Jia et al., 2006). The extent of 
modification of the protein increases as the concentration of MeG in the blood 
increases.  
Modified proteins that are circulating in the blood can bind to and activate the 
AGE receptors on endothelial cells and macrophages resulting in the release 
of inflammatory cytokines, growth factors as well as ROS. The production of 
these may be implicated in the development of macrovascular complications 
(Brownlee, 2005). MeG can also irreversible modify lipids and genes over a 
period of time as has been implicated in cellular mutagenesis, a number of 
cancers, ageing, damage to blood vessels as well as some of the 
complications associated with diabetes. 
The formation of irreversible AGEs as a consequence of the reaction between 
MeG reacting and the free amino groups of proteins is only one of the many 
possible mechanisms that can lead to the complications associated with 
diabetes. Brownlee (2005) predicted that the activation of a combination of 
four pathways including the polyol pathway, increased intracellular AGE 
formation, PKC and the hexosamine pathway can result in the tissue damage 
associated with elevated intracellular concentrations of glucose. He predicted 
that when the concentration of glucose increases inside the cells of target 
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tissues, the production of ROS by the mitochondria increases. The increased 
production of ROS can then cause strand breaks in the DNA thus resulting in 
the activation of poly(ADP-ribose) polymerase (PARP). Glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) is modified once PARP becomes 
activated and therefore reduces its activity. Finally, this inhibition of GAPDH 
activity causes the activation of the polyol pathway, increases intracellular 
production of AGEs, activates PKC and NF-κB as well as activating the 
hexosamine pathway (Brownlee, 2005).  
1.8. Hypothesis, aims and experimental strategy 
1.8.1. The bacterial metabolic toxin hypothesis 
Lactose sensitivity and IBS are common reasons for referrals to 
gastroenterologists. Symptoms associated with these conditions include: 
flatulence, abdominal pain, diarrhoea or constipation, fatigue, muscle and joint 
pain, severe headaches, and heart palpitations just to name a few (Matthews 
and Campbell, 2000, Campbell and Matthews, 2005, Matthews et al., 2005, 
Waud et al., 2008, Campbell et al., 2005). 
Carbohydrates (e.g. lactose and glucose) that are not broken down and 
absorbed by the small intestine are passed to the large intestine. The large 
intestine contains approximately 1014 individual bacteria representing over 
1000 different species (Qin et al., 2010). There is very little oxygen in the large 
intestine (< 1 μM) and because of this more than 90% of the bacteria found 
here are anaerobes (approximately 25% are Bifidobacter and 75% are other 
anaerobes). So that ATP can be made via glycolysis, the bacteria need to 
remove hydrogen from the carbohydrates in the form of hydrogen gas and 
through a wide range of small organic metabolites such as MeG, diols, 
alcholols, aldehydes, ketones and acids. Once produced these get absorbed 
into the blood and can go on to effect ion channels in skeletal and cardiac 
muscle, nerves, cells of the immune system, the liver and pancreas. It is 
proposed that the production of these gases and metabolites are what 
produce the symptoms that are associated with lactose sensitivity and IBS. It 
is also thought that this mechanism may play a significant role in the 
development of diabetes.  
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The metabolite MeG produced by both bacterial and mammalian cells from the 
glycolytic intermediate DHAP (fig. 1.2, 1.4 and 1.5) is of particular interest. It 
has previously been shown to inhibit bacterial cell growth (Freedberg et al., 
1971, Ackerman et al., 1974) as well as causing impaired cell function, e.g. 
inhibiting insulin secretion and insulin action (Cook et al., 1998, Guo et al., 
2009, Jia et al., 2006, Riboulet-Chavey et al., 2006). It is also proposed that 
MeG will react non-enzymatically with specific amino groups of proteins (e.g. 
albumin and insulin) resulting in the covalent modification of these proteins 
thus altering their biological function.  
1.8.2. Overall aim and specific aims 
1.8.2.1. Overall aim 
The overall aim of this thesis was to investigate the potential role of the 
bacterial metabolic toxin hypothesis in the development of diabetes. 
1.8.2.2. Specific aims 
The specific aims of this thesis were: 
 To establish a new approach to investigate the interaction between 
bacterial metabolic toxins and insulin 
 To investigate the biological activity of insulin 
 To investigate the biological activity of these toxins on cells 
1.8.3. Experimental strategy 
 To develop the coelenterazine chemiluminescence method to 
investigate the enzymatic activity of albumin and insulin 
 To develop a tissue culture system to investigate the biological activity 
of insulin.  
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2.1. Materials 
All proteins used to catalyse the coelenterazine chemiluminescence reaction 
were obtained from Sigma-Aldrich, Dorset, UK. Coelenterazine was a kind gift 
from Bruce Bryan, Prolume Inc. All cell culture media ingredients, unless 
otherwise stated, were obtained from Gibco®, Invitrogen Ltd, Paisley, UK.  
2.2. Protein catalysed coelenterazine chemiluminescence 
2.2.1. The chemiluminometer 
Chemiluminescence can be measured using a chemiluminometer (fig. 2.1).  
 
 
Figure 2.1. The set of the chemiluminometer used. 
 
The chemiluminometer is made up of five important components: 
1. The sample housing 
2. The photomultiplier tube (PMT) 
3. The light detector 
4. The signal processor 
5. The recorder and data processor 
The following section will look at the five important components in more detail. 
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2.2.1.1. The sample housing 
The volume of a sample for chemiluminescence analysis can vary from a few 
microlitres to hundreds of millilitres. For all chemiluminescence analysis in this 
thesis, the volume of a sample was 100 μl as measurements in solution are 
normally carried out in a few microlitres to 2 ml volumes. The sample holders 
used were small test tubes. Although, spherical containers allow almost all the 
light to escape, cylinders, such as the test tubes used in the experiments were 
considered to be adequate. The main function of the test tube is to maintain 
the sample in a temperature and pressure controlled environment, as well as 
in a dark environment, to which substances can be added. Another function of 
the housing is to ensure all the light produced during the chemiluminescence 
reaction reaches the light detector. The chosen housing must take the 
following into account (Campbell, 1988): 
 It must be light-tight so that no light can escape 
 The sample volume should be adjustable, without affecting the amount 
of light reaching the detector 
 It must be possible to add to the sample 
 It must have temperature regulation 
 There must be efficient reflection of light from the chamber to the 
detector 
 It must handle the frequency of samples and analysis as well as being 
suitable for automation 
The sample housing contained a Peltier cooler. This device is a heat pump 
that when a direct current passes through it, it can transfer heat from one side 
to another (from cold to hot) against the temperature gradient as well as 
consuming electrical energy. Therefore, this device can be used for heating or 
cooling, although its main use is for cooling. This device can also be used as a 
temperature control.  
2.2.1.2. The photomultiplier tube 
A photomultiplier tube is a photosensitive device that produces electrons at 
the photocathode. These electrons are focused and multiplied by an electrode 
chain and are then collected at the anode (Campbell, 1988).  
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2.2.1.3. The detector 
This is the most important component in any chemiluminometer. In the 
majority of chemiluminometers, the light source is placed a short distance 
(only a few centimetres) away from the detector. The closer the light source is 
to the detector, the better.  
Choosing the right detector is important as using the wrong detector can 
restrict experiments and analysis. There are four requirements for choosing 
the right detector (Campbell, 1988): 
 The detector must be able to detect a light signal over several orders 
of magnitude of intensity, whether it be a few photons per second to 
tens of millions of photons per second 
 It must be sensitive over the spectral range 400 – 600 nm, but ideally it 
must be sensitive over the complete visible spectrum range including 
UV and IR, 380 – 750 nm 
 The signal output produced by the detector should be directly related 
to the light intensity hitting the detector. The signal output should be 
generated in a form that can be displayed, recorded and easily 
analysed 
 The response of the detector must be quicker than the rate of the 
coelenterazine chemiluminescence reaction. The detector in the 
chemiluminometer used was a photomultiplier tube. The 
coelenterazine chemiluminescence generates blue light and the 
photomultiplier tube was chosen because it is better at detecting light 
in the blue region of the spectrum 
A photomultiplier tube is a photosensitive device that produces electrons at 
the photocathode, which are focused and multiplied by an electrode chain. 
These electrons are then collected at the anode. The photomultiplier tube 
contains four important components (Campbell, 1988): 
 The glass envelope is important for maintaining a vacuum within it as 
well as having a glass window which allows the photons (light) to enter 
 The photocathode receives light and is responsible for the generation 
of the primary electrons 
 The dynode chain is the device that is responsible for the focusing and 
multiplication of the electrons, resulting in the production of secondary 
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electrons. The chemiluminometer used contained a 13-dynode chain, 
therefore the multiplication of electrons was repeated 13 times 
 The anode is positively charged and its function is to collect the 
electrons 
When the photomultiplier tube receives a photon at the photocathode, an 
electron is emitted due to the photoelectric effect. This is known as primary 
emission. The electron is then electrostatically accelerated and focused so 
that it will hit the first dynode. This causes the emission of several electrons 
and is known as secondary emission. Each of these electrons produced 
through secondary emission is then accelerated and focused so that they will 
hit the second dynode. At the second dynode further multiplication of electrons 
occurs. The multiplication of electrons can be repeated up to 13 times as the 
chemiluminometer used contained a 13-dynode chain. After the multiplication 
process has been completed, the resulting electrons are collected as a pulse 
of charge at the anode. The anode then passes the pulse of charge through a 
preamplifier to the discriminator. Once at the discriminator it is decided if it is 
big enough to be considered as a count (Campbell, 1988).  
2.2.1.4. Signal processing 
The signal processor amplifies the output from the detector and then shows 
this to the recording device. To be able to detect a signal from any instrument 
it must be possible to be able to distinguish it from the “noise” produced by the 
detector and the processor. An easy way to compare devices is to measure 
the background from the instrument (“noise”) and then to measure the signal 
produced by the light standard. However, the chemiluminometer can be 
optimised by minimising the “noise” and producing the highest signal to noise 
ratio (fig. 2.2) (Campbell, 1988). 
2.2.2. The optimisation of conditions 
To be able to measure the amount of light emission accurately it was 
important to ensure that there were no external sources of light that could alter 
the results. To prevent this from happening experiments were carried out in a 
dark room. Before experimentation could begin, the room temperature was left 
to reach 20 oC, the voltage was set to 1700 volts and the photomultiplier tube 
was left to reach at least -20 oC. 
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To optimise the chemiluminometer for signal to noise it was necessary to 
determine the optimum temperature of the photomultiplier tube required for 
maximum sensitivity. 
 
 
 
Figure 2.2. The optimisation of the photomultiplier tube. The optimum 
temperature was shown to be approximately -20 
o
C. The machine background 
(“noise”) and the protein readings (“signal”) were measured over a temperature range 
of +20 to -20 
o
C. The signal to noise ratio was determined by dividing the results for 
the albumin catalysed coelenterazine chemiluminescence by the corresponding 
results for coelenterazine chemiluminescence in the absence of the protein.  
 
The “noise” is the background of the instrument, which in this case was the 
coelenterazine chemiluminescence in the absence of the protein (machine 
background) and the signal was the albumin catalysed coelenterazine 
chemiluminescence over the temperature range of +20 to -20 oC. Therefore, 
the signal produced by the instrument was determined by the addition of 10 μl 
HSA (1 % (w/v) final concentration) to buffer containing 50 mM HEPES, pH 
7.4 and 10 μM coelenterazine. The signal:noise ratio was determined by 
dividing the machine background measurements by the corresponding 
albumin catalysed coelenterazine chemiluminescence measurements.  
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The albumin catalysed coelenterazine chemiluminescence increased 
dramatically when the photomultiplier tube was cooled reaching a maximum at 
-20 oC, however, further decreasing the temperature to -23 oC the 
chemiluminescence decreased. Therefore, -20 oC was considered to be the 
optimum temperature required for maximum sensitivity and was the 
temperature used in all chemiluminescence experiments.  
2.2.3. The preparation of reagents 
2.2.3.1. The preparation of 50 mM HEPES buffer, pH 7.4 
0.48 g of HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) was 
added to 40 ml of distilled water. The pH was adjusted to 7.4 using 0.1 M 
NaOH. The buffer was stored at 4.5 oC. 
2.2.3.2. The preparation of proteins 
A 1 % (w/v) solution of HSA and BSA was made by adding 500 mg of the 
protein to 50 ml of distilled water. A 1 % (w/v) solution of human insulin was 
also made by adding 10 mg of the protein to 1 ml of 10 mM HCl. The proteins 
were stored at -20 oC. For a 1 % (w/v) gelatin solution, 50 mg of the protein 
was added to 5 ml of 50 mM HEPES buffer, pH 7.4. The gelatin solution was 
heated in a microwave for a few seconds to dissolve and stored in a water 
bath at 37 oC throughout the experiment to prevent it from solidifying. For a 5 
% (w/v) solution of haemoglobin, 250 mg of haemoglobin was dissolved in 50 
mM HEPES buffer, pH 7.4. Both gelatin and haemoglobin were discarded 
after use.  
2.2.3.3. The preparation of coelenterazine 
Eppendorfs containing 20 nmol and 200 nmol coelenterazine were stored at -
20 oC. Coelenterazine is very unstable when dry. It reacts with the oxygen in 
water and other solvents and therefore degrades. Stock amounts of 
coelenterazine were stored dry and then dissolved. 20 nmol coelenterazine 
was dissolved in 100 μl methanol and the volume was topped up to 200 μl by 
adding 100 μl of 50 mM HEPES buffer, pH 7.4. 
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2.2.4. The determination of protein catalysed coelenterazine 
chemiluminescence 
In aqueous solution, coelenterazine is capable of emitting efficient 
chemiluminescence in the presence of a luciferase e.g. HSA. Figure 2.3 
shows the coelenterazine chemiluminescence reaction in the presence of a 
luciferase that can catalyse the reaction.  
In the reaction, coelenterazine reacts with oxygen resulting in the production 
of an organic dioxetanone intermediate and therefore generates enough 
energy to produce the excited-state products. The end products of this 
reaction are coelenteramide and CO2 via the breakdown of the dioxetanone 
intermediate.  
 
 
 
Figure 2.3. The pathway showing the chemiluminescence reaction of 
coelenterazine. R groups represent either a benzyl or phenyl group: R1 = phenyl 
group (C6H4OH); R2 = phenyl group (CH2C6H4OH) and R3 = benzyl group (CH2C6H5) 
(Lee, 2001). 
 
The measurement of protein catalysed coelenterazine chemiluminescence 
was carried out in a dark room to minimise light exposure thus preventing the 
degradation of coelenterazine as it is light sensitive. The voltage was set to 
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1700 volts. This was the optimum voltage that resulted in the lowest signal to 
noise ratio.  
The photomultiplier tube was allowed to reach its optimum temperature of at 
least -20 oC and the room temperature was allowed to reach 20 oC. 
First, the machine background was measured by inserting an empty test tube 
into the photomultiplier tube. Secondly, the coelenterazine chemiluminescence 
was measured by adding 10 μM coelenterazine to 80 μl of buffer containing 50 
mM HEPES, pH 7.4. Thirdly, an additional stage can be added to determine 
the effect of a cation/drug on coelenterazine chemiluminescence, whereby 10 
μl of the cation/drug is added to 80 μl of 50 mM HEPES buffer, pH 7.4, 
containing 10 μM coelenterazine. Finally, the protein chemiluminescence was 
measured by adding 10 μl HSA (0.1 % (w/v) final concentration) to 90 μl of 
buffer containing 50 mM HEPES, pH 7.4 and 10 μM coelenterazine. The 
chemiluminescence was recorded as 6 x 10 second counts.  
When the data was recorded, the results were calculated as follows: 
coelenterazine chemiluminescence minus the machine background, 
coelenterazine chemiluminescence in the presence of the cation/drug minus 
the coelenterazine chemiluminescence and protein catalysed coelenterazine 
chemiluminescence minus the coelenterazine chemiluminescence.  
2.3. Cell culture 
7F2 (mouse osteoblast progenitor cell line) cells and 3T3-L1 (mouse 
embryonic fibroblast-adipose like cell line) cells were donated from Dr 
Bronwen Evans, Department of Child Health, University Hospital of Wales, 
Heath Park Campus, Cardiff.  
2.3.1. Cell culture medium 
Specific culture media were selected for each cell-type according to 
instructions from the respective suppliers. Prepared culture media were kept 
refrigerated at 4.5 oC and warmed to room temperature or 37 oC prior to use. 
Generally, media were used within 14 days of preparation or discarded.  
2.3.1.1. DMEM for 3T3-L1 cell culture and maintenance 
Dulbecco’s Modified Eagle Medium (DMEM) containing L-glutamine, pyruvate 
and 4.5 gL-1 glucose was supplemented with 10 % foetal bovine serum (FBS) 
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and with 100 μg ml-1 streptomycin and 100 U ml-1 penicillin (penicillin-
streptomycin 10,000:10,000, Invitrogen) (Tafuri, 1996). 
2.3.1.2. MEM-α for 7F2 cell culture and maintenance 
Alpha Minimum Essential Medium (MEM-α) containing Earl’s salts, 1 mM 
sodium pyruvate and 2 mM L-glutamine, but without ribonucleosides or 
deoxyribonucleosides, was supplemented with 10 % FBS, 100 μg ml-1 
streptomycin and 100 U ml-1 penicillin.  
2.3.2. Cell husbandry 
7F2 and 3T3-L1 cells were kindly supplied by Dr Bronwen Evans, Department 
of Child Health, University Hospital of Wales, Heath Park Campus, Cardiff. 
The 7F2 cells are a mouse osteoblast progenitor cell line whereas the 3T3-L1 
cells are a mouse embryonic fibroblast-adipose like cell line. All cells were 
cultured in 25 cm2 or 75 cm2 flasks and incubated at 37 oC (5 % CO2 and 95 % 
air), with a working volume of 3 ml or 9 ml cell culture medium, respectively.  
Confluent cultures were divided weekly and the cell culture medium was 
aspirated and replaced every 2-3 days. To detach cells, cultures were washed 
with 1x D-PBS (calcium- and magnesium-free, Gibco®, Invitrogen Ltd.) and 
then 500 μl of trypsin solution (trypsin 0.025 %, EDTA 0.2 %) (trypsin from 
bovine pancreas and EDTA both purchased from Sigma) per 25 cm2 was 
added and left for up to 10 minutes. Once the trypsin solution had been 
added, the culture was closely monitored so that when all the cells had 
become detached, trypsinisation was stopped. If the trypsin solution is left on 
the cells for too long it causes the cell membranes to break down resulting in 
the destruction of the cells. Once the cells had detached, 2-3 ml of the 
respective cell culture medium was added to stop trypsinisation and the cells 
were evenly suspended by gentle pipetting. The cell suspension was 
centrifuged at 500 x G for 3 minutes at room temperature to pellet the cells, 
the supernatant was aspirated and replaced with cell culture medium. The 
pellet was resuspended by gentle pipetting resulting in an even distribution of 
cells throughout the suspension. The cells were pipetted accordingly into new 
sterile flasks.  
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2.4. Cell counting 
2.4.1. Haemocytometry 
Haemocytometry is a process in which cells are counted in order to determine 
the density of a cell suspension. The Neubauer haemocytometer is a slide that 
consists of two flat chambers and each is engraved with a microscopic grid 
containing 1 mm squares, and when fixed with a coverslip, the chambers have 
a depth of 0.1 mm.  
Therefore, each 1 mm x 1 mm square of depth 0.1 mm has a volume of 0.1 μl. 
The coverslip is considered to be attached when the interference patterns 
known as Newton’s rings can be seen.  
Cells were detached and pelleted as previously described in section 2.3.2. 
The pellet was then evenly resuspended in a known volume of cell culture 
medium by gentle pipetting. Then 8 μl of the cell suspension was added to 
each of the chambers on the haemocytometer and allowed to be drawn in by 
capillary action between the coverslip and the chamber. At 10x magnification 
under a microscope, the central 1 mm2 square of one chamber was found and 
all the cells within the boundaries were counted, including the cells that lay on 
the top and left-hand boundary lines. However, those that lay on the bottom 
and right-hand boundary lines were not included. This ensured that only 1 
mm2 was counted. If the central square contained less than 100 cells, one or 
more additional squares found in the same chamber were also counted to 
improve accuracy. The same was done for the second chamber on the 
haemocytometer. The average of the cells was calculated and the density of 
the cell suspension was determined using the following equation: 
 
 
 
 
 
number of cells per ml = 
total number of cells counted 
number of squares counted 
  x 10
4 
  
 
 
 
 
 
Chapter 3: 
 
Chemiluminescence activity  
of albumin and insulin 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3: Chemiluminescence activity of albumin and insulin 
 
66 
 
3.1. Introduction 
The bacterial metabolic toxin hypothesis predicts that putative toxins will react 
with proteins resulting in the covalent modification of these proteins (Campbell 
et al., 2010, Lo et al., 1994). This covalent modification should affect the 
biological activity of these proteins. In order to test the hypothesis, the strategy 
was to use the ability of proteins to catalyse coelenterazine 
chemiluminescence and then to investigate if the putative bacterial metabolic 
toxins affected the activity of the proteins. Bovine serum albumin (BSA) has 
been previously shown to catalyse coelenterazine chemiluminescence 
(Campbell et al., 1989). From this, the initial aim of this chapter was to 
investigate the ability of HSA to catalyse coelenterazine chemiluminescence 
and to compare it with that of three other proteins – human insulin, gelatin and 
haemoglobin. Then if these proteins were able to catalyse coelenterazine 
chemiluminescence it would then be important to determine if this was 
consistent with an enzymatic activity.  
 
3.1.1. Types of luminescence 
Luminescence is light emission from an electronically-excited state. Each type 
of luminescence is designated by a prefix. The prefix states the source of 
energy, for example: photoluminescence is produced when light is absorbed, 
thermoluminescence is a result of slight heating and chemiluminescence is 
the production of light as a result of a chemical reaction (Campbell, 1988). 
Table 3.1 that follows contains more types of luminescence and their basis of 
light emission. 
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Type of luminescence Prefix Basis of light emission 
Candoluminescence Cando- Certain materials that have been 
heated to incandescence and 
emit at shorter wavelength than 
expected 
Pyroluminescence Pyro- Luminescence of metal atoms in 
flames 
Thermoluminescence Thermo- The slight heating of solids and 
crystals resulting in light 
emission 
Photoluminescence Photo- Irradiation by UV or visible light 
Cathodoluminescence Cathodo- Irradiation by electrons 
Anodoluminescence Anodo- Irradiation by nuclei 
Radioluminescence Radio- Irradiation by γ or x-rays 
Electroluminescence and 
piezoluminescence 
Electro- and piezo- Light emission associated with 
electric discharges and fields 
Galvanoluminescence Galvano- Light emission during electrolysis 
Triboluminescence Tribo- Light emission from intense 
sound waves in a solution 
Crystalloluminescence Crystallo- Light emission on crystallisation 
Lyoluminescence Lyo- Light emission on dissolving 
crystals 
Chemiluminescence Chemi- Light emission as a result of a 
chemical reaction 
Bioluminescence Bio- Light emission as a result of a 
chemical reaction in a biological 
system 
 
Table 3.1. Types of luminescence and the basis of light emission (Campbell, 
1988). 
 
3.1.1.1. Chemiluminescence and its discovery 
In the 17th century, Robert Boyle invented the air pump and later demonstrated 
that by removing the air surrounding what he called “shining wood” or “shining 
flesh” would result in a significant decrease in the intensity of light emission 
and in some cases extinguished the luminescence altogether. He then 
showed that if he exposed these materials to air again they both glowed 
brightly. However, it was unknown what important component in the air made 
these materials glow. It was not until 100 years later that the important 
component in the air was identified as molecular oxygen by Scheele and 
Priestly. Therefore, this experiment by Boyle was the first demonstration 
showing that oxygen or one of its derivatives is required in all bioluminescent 
reactions (Campbell, 1988, Lee, 2001).  
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Since this discovery by Boyle, many more experiments have been carried out 
to further study bioluminescence. At the end of the 19th century (between 1885 
and 1887) Raphael Dubois carried out experiments on the “click beetle,” 
Pyrophorus. It is the results of these experiments that have had a significant 
impact on the study of bioluminescence.  
He extracted the light organ and placed it in cold water and this produced a 
suspension that glowed, however, this glow diminished with time. He then 
placed a luminous organ in hot water but this time no light emission was 
observed. It was the results of these studies that led to the discovery of the 
enzyme-substrate property of many bioluminescence reactions. The enzyme 
that is stable in the cold is now known as the “luciferase” and the substrate 
that is heat stable is known as the “luciferin”. Dubois argued that the 
luminescence observed in cold water was due to a chemical reaction 
occurring, hence the term chemiluminescence (Campbell, 1988, Lee, 2001). 
It is as a result of these discoveries that chemiluminescence and 
bioluminescence have since been defined. Chemiluminescence is the light 
produced as a result of a chemical reaction whereas bioluminescence is the 
light produced as a result of a chemical reaction in a biological system with the 
help of an enzyme (Campbell and Herring, 1990, Shimomura and Teranishi, 
2000). Therefore all known bioluminescence is due to chemiluminescence 
(Campbell and Herring, 1990). 
3.1.1.2. Bioluminescence 
Bioluminescence is the light emitted as a result of a chemical reaction in a 
biological system. It is also known as living light. Living light can be found on 
land, in the air, but is most commonly found in deep-sea waters where 
approximately 97 % of the species found there are bioluminescent (Rees et 
al., 1998, Thomson et al., 1997).  
Luminous species include bacteria, fungi, dinoflagellates, jellyfish, shrimps, 
worms, insects, some squid and fish. These living organisms use the ability to 
produce light for a number of purposes: 
 Attraction and hunting – many deep-sea creatures use the light 
generated to attract their mates, whereas others can use the light they 
produce to attract or lure prey (e.g. anglerfish) (Lee, 2001) 
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 Repulsion and warning – some species of squid can produce light to 
warn their predators. Squids can also release a cloud of ink to repel 
the predator, this ink is also luminescent as it contains bioluminescent 
bacteria (Lee, 2001) 
 Communication and illumination – many species of bacteria can use 
bioluminescence for communication (Lee, 2001) 
3.1.2. Light emission due to these reactions 
3.1.2.1. Light emission as a result of a chemical reaction 
(chemiluminescence) 
If a chemical reaction is to generate light, molecules must be generated in an 
electronically-excited state and must be capable of releasing its energy either 
as a photon or by transferring its energy to another molecule thus making this 
second molecule the light emitter (Campbell, 1988).  
When two molecules chemically react there is a release of energy 
(exothermic). Rather than heat, this energy can show itself in the form of light, 
hence why the light emitted due to a chemiluminescent reaction is sometimes 
called “cold light”. The energy that is produced leads to the production of an 
electronically-excited product. If this excited product is allowed to relax to the 
ground state, light is generated and this is known as type I 
chemiluminescence. However, if the electronically-excited product is not 
allowed to relax to the ground state, the excited product transfers its energy to 
a second molecule and it is then this second molecule that becomes the light 
emitter. This process of energy transfer is known as type II 
chemiluminescence or energy transfer chemiluminescence (Campbell, 1988). 
 
Reactant + O2  dioxetanone intermediate  excited products products + hv 
 
Figure 3.1. The equation for a chemiluminescence reaction (Campbell, 1988). 
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From this information there are three main features for a chemiluminescence 
reaction: 
 The reaction must produce enough energy to generate a molecule in 
an electronically-excited state 
 There must be a pathway through which the energy can pass leading 
to the production of an electronically-excited state 
 The electronically-excited product must be able to lose its energy as a 
photon or be capable of transferring its energy to a fluorescent protein 
(Campbell, 1988). 
3.1.2.2. Light emission as a result of a chemical reaction in a biological 
system (bioluminescence) 
Even though bioluminescence can vary between species the general 
mechanism is similar. For a bioluminescence reaction to occur it requires the 
presence of oxygen or one of its metabolites to oxidise a small organic 
molecule (the luciferin) and a protein to catalyse the reaction (the luciferase) 
(Campbell and Herring, 1990). 
 
 
Figure 3.2. The equation for a bioluminescence reaction (Campbell, 1988). 
 
The oxidation of the luciferin by oxygen or one of its metabolites is catalysed 
by the presence of a luciferase. In the absence of the protein catalyst, 
oxidation of the luciferin is usually slow, resulting in poor chemiluminescence 
and the production of the wrong colour light. The oxidation of the luciferin 
produces the electronically-excited state oxyluciferin. The excited oxyluciferin 
then relaxes to the ground state, oxyluciferin and then blue light is emitted 
(Campbell, 1988). 
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As well as oxygen (or one of its metabolites), the luciferin and the luciferase 
other components such as cofactor(s), cation(s) and fluorescent proteins may 
be necessary for the bioluminescence reaction: 
Oxygen, or one of its metabolites (e.g. hydrogen peroxide, H2O2) 
All chemiluminescent and thus all bioluminescent reactions require oxygen 
whether it is molecular oxygen or a metabolite. However, aequorin, a 
photoprotein extracted from the jellyfish, Aequorea victoria can generate light 
with or without the presence of oxygen (Shimomura, 1986). 
Luciferin (e.g. coelenterazine) 
For light to be generated the oxidation of a small organic molecule, such as 
coelenterazine is required for the production of the electronically-excited 
product. The excited product may be fluorescent and is therefore the emitter 
(Cormier et al., 1975). The luciferin usually has a molecular weight of less than 
1000. Many luciferins are unstable and can oxidise spontaneously in a weak 
chemiluminescent reaction. For example, if a solution of coelenterazine is left 
on a work surface in sunlight, more than 80 % can be destroyed within an hour 
(Campbell, 1988). 
Luciferase 
All bioluminescence reactions require a protein and the protein is known as a 
luciferase. The luciferase catalyses the reaction, therefore, making it go fast 
enough to generate efficient light for it to be visible. Proteins can be found in 
any biological reaction but the oxidation of these proteins by either oxygen or 
one of its metabolites would not generate visible light unless a luciferin is 
present (Cormier et al., 1975). 
Cofactor(s) 
If the chemiluminescent components are isolated as a photoprotein another 
component is required to trigger the bioluminescence reaction. Cofactors can 
include ATP and the calcium ion (Ca2+) (Campbell, 1988). 
Cation(s) 
Cations such as the alkaline earth metals (Mg2+ or Ca2+) or transition metals 
(Fe2+, Fe3+, Cu+ or Cu2+) are sometimes required. Transition metals are 
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involved in oxidant processing resulting in a change in the valency state during 
chemiluminescence (Campbell, 1988). 
Fluorescent protein 
A fluorescent protein can interact directly or indirectly with a chemiluminescent 
reaction. When fluors interact directly with the chemiluminescence reaction 
they enhance the rate of reaction and yield. When fluors interact indirectly 
their role is to act as a passive acceptor of the energy from the excited state 
reaction product through a non-radiative process, therefore making the fluor 
the light emitter. This then changes the spectrum of light and yield from that of 
the initial chemiluminescence reaction (Campbell, 1988). 
3.1.3. The jellyfish, Aequorea victoria and the discovery of 
coelenterazine 
Aequorea victoria is also known as the crystal jellyfish. It is a bioluminescent 
hydrozoan jellyfish. The active extract, the photoprotein aequorin, was isolated 
by Shimomura et al (Adamczyk et al., 2001, Shimomura et al., 1962). 
Aequorin is a protein with a molecular weight of 22 kDa and is a charged 
complex that is very stable as well as having a high energy (Ohmiya and 
Hirano, 1996). The luciferin, coelenterazine and oxygen are bound to aequorin 
(Adamczyk et al., 2001, Lee, 2001). Photoproteins like aequorin can hold on to 
the bound oxygen, either as molecular oxygen or in the form of H2O2 
(Campbell, 1988) whereas coelenterazine is bound to the protein through a 
peroxidic bond (Teranishi et al., 1994). The addition of calcium (Ca2+) ions to 
the non-luminous photoprotein results in the protein undergoing a 
conformational change thus triggering the bioluminescence reaction and 
results in the emission of blue light (465 nm) either in the presence or absence 
of oxygen (Adamczyk et al., 2001, Shimomura and Johnson, 1978).Therefore, 
the intensity of light emitted by the jellyfish, Aequorea victoria, does not 
directly depend on oxygen (Lee, 2001).  
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Figure 3.3. Aequorea victoria (Ohmiya and Hirano, 1996). 
 
Therefore, as a result of this discovery, coelenterazine is now known as the 
luciferin responsible for the “blue glow” emitted by the jellyfish. The isolation 
and extraction of coelenterazine from marine organisms is not only laborious 
but is also low yielding. Nowadays, coelenterazine is commercially available 
but is very expensive where 1 mg costs approximately $1240 (Adamczyk et 
al., 2001). 
3.1.4. Coelenterazine and its role in bioluminescence 
3.1.4.1. Coelenterazine 
Coelenterazine is a well characterised luciferin (Oba et al., 2004) for a number 
of luciferases. It is also known to be the light emitter of photoproteins in a 
number of jellyfish and ctenophores (Shimomura and Teranishi, 2000). It is 
known as 3,7-dihydro-2-(p-hydroxybenzyl)-6-(p-hydroxyphenyl)-8-
benzylimidazo-[1,2-a]pyrazin-3-one (De Wergifosse et al., 2004). 
 
Figure 3.4. The structure of coelenterazine (Shimomura, 1987). 
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Coelenterazine has an imidazopyrazine skeleton (Hastings and Krause, 2005) 
with three lateral groups (Dubuisson et al., 2005). These lateral groups are 
either phenyl or benzyl groups. It is widely distributed in bioluminescent 
organisms such as Renilla, Oplophorus, Periphylla and Gaussia and can be 
found within the light organs of these animals (Dubuisson et al., 2005, 
Shimomura and Johnson, 1978). This imidazolopyrazine has been reported so 
far in 18 phyla and approximately 92 genera of both luminous and non-
luminous marine species (Thomson et al., 1997, Vassel et al., 2012). 
It is also found in various non-luminescent organisms (Shimomura, 1987, 
Campbell and Herring, 1990). Coelenterazine is present in the liver of a 
number of species (e.g. some fish and squid) (Thomson et al., 1997), 
however, as there is such a widespread distribution among distantly related 
marine organisms it is possible that these organisms can obtain 
coelenterazine through their diet via the food chain (Mallefet and Shimomura, 
1995, Shimomura, 1987). 
When coelenterazine is dissolved in a suitable aprotic organic solvent (e.g. 
dimethylformamide, DMF or dimethyl sulphoxide, DMSO) it spontaneously 
oxidises and emits blue chemiluminescence (465 nm) (Shimomura and 
Teranishi, 2000). 
3.1.4.2. The bioluminescence reaction of coelenterazine 
The luciferin, coelenterazine is part of the photoprotein and is involved in 
bioluminescence. Bioluminescence can occur either in a living organism and 
this is known as in vivo bioluminescence or in aqueous medium and this is 
known as in vitro bioluminescence (Lee, 2001). In vitro bioluminescence 
requires the presence of a protein, i.e. luciferase such as albumin or the 
presence of an apoprotein to catalyse the oxidation reaction as well as 
providing a sufficient environment for light emission. The need for a luciferase 
makes this reaction more complex than that of chemiluminescence, especially 
when the protein undergoes a significant conformational change as that seen 
in aequorin (Shimomura and Teranishi, 2000). 
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Figure 3.5. The pathway of the chemiluminescence reaction of coelenterazine. R 
groups represent either a benzyl or phenyl group: R1 = a phenyl group (C6H4OH); R2 = 
a phenyl group (CH2C6H4OH) and R3 = a benzyl group (CH2C6H5) (Lee, 2001). 
 
In an aqueous solution, coelenterazine is capable of emitting sufficient light 
emission providing a luciferase (e.g. Renilla luciferase or albumin) is present. 
In the reaction, coelenterazine reacts with oxygen producing an organic 
dioxetanone intermediate and therefore generates enough energy to produce 
an excited-state product. The dioxetanone intermediate is broken down and 
leads to the production of the endproducts, coelenteramide and CO2. 
Coelenteramide only emits faint fluorescence in aqueous solution, however, it 
does fluoresce bright blue (λmax 465 nm) in organic solvents. This wavelength 
does not suggest that coelenteramide is responsible for the blue light emission 
but it is now known that the amide ion is the light emitter (Shimomura and 
Teranishi, 2000). 
For aequorin to emit blue light of wavelength 460 nm it must bind calcium ions. 
When calcium binds to the photoprotein it causes an intermolecular reaction 
where coelenterazine is oxidised to coelenteramide resulting in the production 
of blue light (465 nm), CO2 and blue fluorescent protein (BFP). Light emission 
occurs when the bound coelenteramide relaxes from the excited state to the 
ground state (Shimomura and Teranishi, 2000).  
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However, in vivo bioluminescence of Aequorea victoria is green. It was 
proposed that there was another component involved in the bioluminescence 
reaction that emits light with a wavelength that is consistent with the green 
bioluminescence observed. It was then proposed that a mechanism of energy 
transfer was involved as this second compound accepts the energy. This 
second compound was discovered by Shimomura in 1979 and is now known 
as “green fluorescent protein (GFP)” (Lee, 2001, Shimomura, 1979). 
3.1.5. Overall aim, specific aims and experimental strategy 
3.1.5.1. Overall aim 
The overall aim of this chapter was to confirm that HSA displays enzymatic 
activity and to also determine if insulin also displays this property. 
3.1.5.2. Specific aims 
 To investigate if HSA and insulin were able to catalyse coelenterazine 
chemiluminescence 
 If so to demonstrate if this was consistent with enzymatic activity 
 To use coelenterazine chemiluminescence to test if bacterial metabolic 
toxins can alter the activity of key proteins in the blood, specifically 
HSA and insulin 
 To demonstrate whether the covalent modification of proteins altered 
coelenterazine chemiluminescence 
Four criteria were used to determine if protein catalysed coelenterazine 
chemiluminescence was enzymatic: (1) heat denaturable; (2) saturable by the 
substrate (coelenterazine); (3) inhibition or activation by specific cations that 
are known to bind to the proteins and (4) inhibition by drugs that are known to 
bind to the proteins (Chapter 4). 
3.1.5.3. Experimental strategy 
Coelenterazine chemiluminescence was selected as the model to characterise 
the enzymatic activity of albumin and to determine if human insulin also has 
enzymatic activity. 
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3.2. Materials and methods 
3.2.1. Materials 
Coelenterazine was a generous gift from Bruce Bryan, Prolume Inc. All other 
compounds were purchased from Sigma-Aldrich unless otherwise stated. 
3.2.2. Preparation of reagents 
All reagents such as proteins and coelenterazine were made as previously 
described in Chapter 2.  
3.2.3. The determination of protein enzymatic activity 
The photomultiplier tube was allowed to reach its optimum temperature and all 
reagents required were prepared prior to the start of experimentation as 
described previously in Chapter 2. 
The addition of 10 μM coelenterazine to 90 μl of HEPES buffer, pH 7.4 
containing 10 μl HSA demonstrated that the activity decreased by < 10 % over 
the time course of 6 x 10s counts. From this it can be concluded that the 
reaction rates were linear across the time course chosen. The ability of a 
protein to act as an enzyme was determined using the method described in 
2.2.4. However, at this stage the aim was to determine which proteins 
demonstrated enzymatic activity and there was no need for the addition of a 
test compound (e.g. cation or drug).  
3.2.4. The effect of thermal denaturation on protein enzymatic activity 
Albumin and human insulin were prepared as previously described in 2.2.3.2. 
Half the protein suspension was then denatured using a thermocycler for 15 
minutes at a temperature of 95 oC. Experimentation was then carried out as 
previously described in section 2.2.4. 
3.2.5. The effect of increasing substrate concentration on 
chemiluminescence 
The photomultiplier tube was allowed to reach its optimum temperature and all 
reagents required were prepared prior to the start of experimentation as 
described previously in Chapter 2. Experimentation was then carried out as 
previously described in section 2.2.4 using coelenterazine over a 
concentration range (0.5 – 50 μM). 
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3.2.6. The effect of increasing pH on protein enzymatic activity 
The method used to determine the effect of increasing pH on protein catalysed 
coelenterazine chemiluminescence was similar to that described in section 
2.2.4 but here it was the pH of the buffer that changed.  
3.2.7. The effect of divalent cations on protein enzymatic activity 
The method used to determine the effect of divalent cations on protein 
catalysed coelenterazine chemiluminescence was the same as that described 
in section 2.2.4 with the additional testing compound (e.g. iron (III) chloride) 
step to determine if the addition of the cation would modulate the 
coelenterazine chemiluminescence catalysed by a protein.  
3.2.8. Statistical analysis 
Statistical analysis was carried out on the means using a t-test and the results 
were considered to be statistically different when p < 0.05. 
 
3.3. Results 
 
In order to establish albumin chemiluminescence it was necessary to compare 
albumin chemiluminescence with that of three other proteins: human insulin, 
gelatin and haemoglobin. Four criteria were used to determine if protein 
catalysed coelenterazine chemiluminescence was enzymatic: (1) heat 
denaturable; (2) saturable by the substrate (coelenterazine); (3) inhibition or 
activation by specific cations that are known to bind to the proteins and (4) 
inhibition by specific drugs that bind to the proteins. The inhibition by specific 
drugs that bind to proteins (4) is investigated in Chapter 4 that follows.  
 
3.3.1. The effect of HSA and other proteins on coelenterazine 
chemiluminescence 
 
An important feature of bioluminescent enzymes is to form a solvent cage 
around the luciferin with the ability to catalyse a light-emitting reaction. In order 
to test this it was important to demonstrate the ability of both bovine (BSA) and 
human (HSA) serum albumin to catalyse coelenterazine chemiluminescence. 
With increasing concentrations of coelenterazine, the chemiluminescence 
increased linearly.  
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BSA and HSA, over the concentration range 0.01 – 0.5 % (w/v) which was 
equivalent to 0.15 to 7.5 μM, caused a 100- to 3000-fold increase in light 
emission (fig. 3.6). The addition of 0.5 % (w/v) (or 7.5 μM) BSA resulted in a 5-
fold increase in light emission when compared to the light emission produced 
with the same concentration of HSA suggesting that BSA was better than HSA 
at catalysing coelenterazine chemiluminescence. 
 
 
 
 
 
Figure 3.6. The stimulation of coelenterazine chemiluminescence catalysed by 
human (HSA) and bovine (BSA) albumin. The machine background produced an 
average of 36 counts.s
-1
. The coelenterazine chemiluminescences prior to the addition 
of the proteins were between 71 and 74 counts.s
-1
 for HSA and 63 and 65 counts.s
-1
 
for BSA. Protein catalysed coelenterazine chemiluminescence was measured by 
adding 10 μl of albumin (0.01 – 0.5 % (w/v); 0.1 – 5 g.l
-1
 final concentration) to 90 μl of 
50 mM HEPES buffer pH 7.4, containing 10 μM coelenterazine. The results represent 
the mean +/- SEM of three experiments. Asterisk indicates significant difference where 
p < 0.01 when compared to 0.5 % (w/v) HSA. 
 
 
In order to test the ability of three other proteins: human insulin, gelatin and 
haemoglobin at catalysing coelenterazine chemiluminescence the light 
emission produced by these three proteins was compared with HSA 
chemiluminescence.  
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Human insulin, another important protein found in mammalian plasma, over 
the concentration range 0.01 - 0.5 % (w/v) which was equivalent to 1.7 to 86 
μM caused a 20- to 100-fold increase in chemiluminescence (fig. 3.7). In 
contrast, the addition of gelatin and haemoglobin (fig. 3.7) also over a 
concentration range of 0.01 – 0.5 % (w/v) (equivalent to 0.2 to 10 μM for 
gelatin and 0.6 to 29 μM for haemoglobin) only produced very small light 
emission and was approximately 1,000 to 10,000 times less than the light 
emission produced with albumin.  
 
 
 
 
 
Figure 3.7. The stimulation of coelenterazine chemiluminescence by human 
insulin, compared with that of gelatin and haemoglobin. The machine background 
produced an average of 32 counts.s
-1
. The coelenterazine chemiluminescences prior 
to the addition of the proteins were between 80 and 115 counts.s
-1
 for insulin, 66 and 
70 counts.s
-1
 for gelatin and 67 and 70 counts.s
-1
 for haemoglobin. Protein catalysed 
coelenterazine chemiluminescence was measured by adding 10 μl of human insulin, 
gelatin or haemoglobin (0.01 – 0.5 % (w/v); 0.1 – 5 g.l
-1
 final concentration) to 90 μl of 
50 mM HEPES pH 7.4, containing 10 μM coelenterazine. The results represent the 
mean +/- SEM of three experiments. Asterisk indicates significant difference where p < 
0.01 when compared to 0.5 % (w/v) HSA.  
 
 
After comparing the abilities of these 5 proteins at catalysing coelenterazine 
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was best at catalysing coelenterazine chemiluminescence: BSA > HSA > 
human insulin > gelatin > haemoglobin. 
 
3.3.2. Investigating the enzymatic activity of HSA and insulin 
 
It was shown that albumin catalysed coelenterazine chemiluminescence and 
the next aim was to determine if this was consistent with the protein having an 
enzymatic activity. Therefore to test if the coelenterazine chemiluminescence 
produced by albumin was enzymatic it was necessary to investigate protein 
denaturation, if it could be saturated by the substrate (coelenterazine) and if 
certain cations would result in either the inhibition or activation of the protein.  
 
3.3.2.1. The effect of denatured HSA and insulin on coelenterazine 
chemiluminescence 
 
In order to determine the enzymatic activity of HSA it was important to 
investigate if the protein was heat denaturable. HSA was denatured as 
described in section 3.2.4. Once the protein had been denatured its ability at 
catalysing coelenterazine chemiluminescence was determined and compared 
with the coelenterazine chemiluminescence catalysed by normal HSA. 
Heating HSA inhibited coelenterazine chemiluminescence by approximately 
50 % (fig. 3.8). 
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Figure 3.8. The inhibition of human serum albumin (HSA) catalysed 
coelenterazine chemiluminescence by thermal denaturation. The coelenterazine 
chemiluminescence prior to the addition of normal HSA produced between 84 and 105 
counts.s
-1
 whereas the coelenterazine chemiluminescence prior to the addition of 
denatured HSA produced between 86 and 127 counts.s
-1
. To determine the effect of 
thermal denaturation on HSA catalysed coelenterazine chemiluminescence, 1 % (w/v) 
albumin was heated in a thermocycler at 95 
o
C for 15 minutes. Protein catalysed 
coelenterazine chemiluminescence was measured by adding 10 μl of normal or 
denatured albumin (0.01 – 0.5 % (w/v); 0.1 – 5 g.l
-1
 final concentration) to 90 μl of 50 
mM HEPES buffer pH 7.4, containing 10 μM coelenterazine. The results represent the 
mean +/- SEM of three experiments. Asterisk indicates significant difference where p < 
0.01 when compared to 0.5 % (w/v) normal HSA.  
 
 
In order to investigate the enzymatic activity of human insulin it was necessary 
to determine if this protein was also heat denaturable. Human insulin was 
denatured as described in section 3.2.4. The coelenterazine 
chemiluminescence catalysed by denatured human insulin was compared with 
the coelenterazine chemiluminescence catalysed by normal human insulin. 
Heating human insulin under these conditions had no significant effect on the 
light emission produced (fig. 3.9). 
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Figure 3.9. The effect of thermal denaturation on human insulin catalysed 
coelenterazine chemiluminescence. The coelenterazine chemiluminescence prior to 
the addition of normal insulin produced between 86 and 121 counts.s
-1
 whereas the 
coelenterazine chemiluminescence prior to the addition of denatured insulin produced 
between 95 and 119 counts.s
-1
. To determine the effect of thermal denaturation on 
human insulin catalysed coelenterazine chemiluminescence, 1 % (w/v) human insulin 
was heated in a thermocycler at 95 
o
C for 15 minutes. Protein catalysed 
coelenterazine chemiluminescence was measured by adding 10 μl of normal and 
denatured human insulin (0.01 – 0.5 % (w/v); 0.1 – 5 g.l
-1
 final concentration) to 90 μl 
of 50 mM HEPES buffer pH 7.4, containing 10 μM coelenterazine. The results 
represent the mean +/- SEM of three experiments.  
 
 
3.3.2.2. The effect of increasing coelenterazine concentration on HSA 
catalysed coelenterazine chemiluminescence 
 
In order to test the enzymatic activity of albumin the ability of the protein to 
become saturated by the substrate (coelenterazine) was also investigated. As 
the concentration of coelenterazine increased the chemiluminescence 
increased plateauing with the addition of 40 μM coelenterazine. This 
suggested that at a concentration of 40 μM coelenterazine the protein was 
saturated by the substrate. Therefore, it can be said that the light emission 
was saturable by the substrate, coelenterazine (fig. 3.10; half maximum ~ 20 
μM). 
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Figure 3.10. The effect of varying coelenterazine concentration on human serum 
albumin (HSA) catalysed chemiluminescence. The coelenterazine 
chemiluminescence produced between 42 and 195 counts.s
-1
. To determine the effect 
of varying coelenterazine concentration on HSA catalysed coelenterazine 
chemiluminescence 10 μl of HSA (0.1 % (w/v); 1 g.l
-1
 final concentration) was added 
to 90 μl of 50 mM HEPES buffer pH 7.4, containing 0.1 – 50 μM coelenterazine. The 
results represent the mean +/- SEM of three experiments.  
 
 
3.3.2.3. The effect of increasing pH on protein catalysed coelenterazine 
chemiluminescence 
 
In order to further investigate the enzymatic activity of albumin, the effect of 
increasing pH on HSA catalysed coelenterazine chemiluminescence was 
determined. The coelenterazine chemiluminescence catalysed by HSA 
increased with alkaline pH (fig. 3.11). The half maximum for HSA was pH 8.2 
and plateaued at approximately pH 9.0 (fig. 3.11). The large increase in HSA 
catalysed coelenterazine chemiluminescence with increasing alkaline pH 
suggested that at least one basic amino acid was involved in catalysis.  
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Figure 3.11. The effect of pH on human serum albumin (HSA) catalysed 
coelenterazine chemiluminescence. The effect of increasing pH on HSA catalysed 
coelenterazine chemiluminescence was determined by adding 10 μl of HSA (0.1 % 
(w/v); 1 g.l
-1
 final concentration) to 90 μl of 50 mM phosphate buffer pH 4 – 10, 
containing 10 μM coelenterazine. The results represent the mean +/- SEM of three 
experiments. Coelenterazine chemiluminescence increased from 40 counts.s
-1
 at pH 
4.8 to 2,677 counts.s
-1
 at pH 10 in the absence of albumin, whereas coelenterazine 
chemiluminescence increased from 1,852 counts.s
-1
 at pH 4.8 to 100,189 counts.s
-1
 at 
pH 10 in the presence of albumin.  
 
 
In order to investigate the enzymatic activity of human insulin, the effect of 
increasing pH on protein catalysed coelenterazine chemiluminescence was 
determined. The coelenterazine chemiluminescence catalysed by human 
insulin increased with alkaline pH (fig. 3.12). The half maximum for human 
insulin was pH 7.8. Again the large increase in human insulin catalysed 
coelenterazine chemiluminescence with increasing alkaline pH suggested that 
at least one basic amino acid was involved in catalysis. 
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Figure 3.12. The effect of pH on human insulin catalysed coelenterazine 
chemiluminescence. The effect of increasing pH on human insulin catalysed 
coelenterazine chemiluminescence was determined by adding 10 μl of human insulin 
(0.1 % (w/v); 1 g.l
-1
 final concentration) to 90 μl of buffer containing 50 mM sodium 
phosphate pH 4 – 10, containing 10 μM coelenterazine. The results represent the 
mean +/- SEM of three experiments. Coelenterazine chemiluminescence increased 
from 38 counts.s
-1
 at pH 4.8 reaching a maximum of 145 counts.s
-1
 at pH 9.5 in the 
absence of insulin, whereas coelenterazine chemiluminescence increased from 623 
counts.s
-1
 at pH 4.8 to reaching a maximum of 6,562 counts.s
-1
 at pH 9.5 in the 
presence of insulin. 
 
 
3.3.2.4. The effect of divalent cations on HSA (and insulin) catalysed 
coelenterazine chemiluminescence 
 
In order to test the enzymatic activity of HSA, cations that are known to bind to 
the protein were added and the effect on coelenterazine chemiluminescence 
was investigated. HSA catalysed coelenterazine chemiluminescence was 
inhibited by all the cations tested. The inhibition observed ranged from 50 – 
100 % (fig. 3.13 – fig. 3.17). The HSA catalysed coelenterazine 
chemiluminescence was significantly inhibited by FeCl3 (p < 0.001; fig. 3.13). 
The results show that FeCl3 alone (fig. 3.13A) over the concentration range 10
-
7 to 10-3 M did not significantly affect chemiluminescence when compared to 
the control in the absence of the cation. However, 10-2 M FeCl3 alone did 
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significantly inhibit chemiluminescence (p < 0.001; fig. 3.13A). The maximum 
inhibition of HSA catalysed coelenterazine chemiluminescence by FeCl3 over 
the concentration range 10-7 to 10-3 M was approximately 40 %, however the 
addition on 10-2 M FeCl3 inhibited HSA catalysed coelenterazine 
chemiluminescence by 100 % (fig. 3.13B).  
 
 
 
 
 
 
 
Figure 3.13. The inhibition of human serum albumin (HSA) catalysed 
coelenterazine chemiluminescence by Fe
3+
. The machine background produced an 
average of 35 counts.s
-1
 whereas the coelenterazine chemiluminescence produced 
averages of between 51 and 58 counts.s
-1
. The effect of Fe
3+
 on HSA catalysed 
coelenterazine chemiluminescence was measured by adding 10 μl of HSA (0.1 % 
(w/v); 1 g.l
-1
 final concentration) to 90 μl of 50 mM HEPES buffer pH 7.4, containing 10 
μM coelenterazine and FeCl3 (0.0001 – 10 mM final concentration). The results 
represent the mean +/- SEM of three experiments. Asterisks indicate a significant 
difference where p < 0.001 when compared with the control in the absence of the 
FeCl3.  
 
FeSO4 alone, over a concentration range of 10
-6 – 10-5 M had no significant 
effect on chemiluminescence. However, the addition of FeSO4 over the 
concentration range 10-4 – 10-2 M significantly inhibited chemiluminescence 
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between 30 - 100 % (p < 0.001; fig. 3.14A). The addition of increasing 
concentrations of FeSO4 significantly inhibited HSA catalysed coelenterazine 
chemiluminescence reaching maximum inhibition in the presence of 10-2 M 
FeSO4  (p < 0.001; fig. 3.14B). 
 
 
 
 
 
 
 
 
Figure 3.14. The inhibition of human serum albumin (HSA) catalysed 
coelenterazine chemiluminescence by Fe
2+
. The machine background produced an 
average of 24 counts.s
-1
 whereas the coelenterazine chemiluminescence produced 
averages of between 49 and 56 counts.s
-1
. The effect of Fe
2+
 on HSA catalysed 
coelenterazine chemiluminescence was measured by adding 10 μl of HSA (0.1 % 
(w/v); 1 g.l
-1
 final concentration) to 90 μl of 50 mM HEPES buffer pH 7.4, containing 10 
μM coelenterazine and FeSO4 (0.001 – 10 mM final concentration). The results 
represent the mean +/- SEM of three experiments. Asterisks indicate a significant 
difference where p < 0.001 when compared with the control in the absence of the 
FeSO4.  
 
In order to determine which of the iron containing compounds were better at 
inhibiting HSA catalysed coelenterazine chemiluminescence, the inhibition by 
both FeCl3 and FeSO4 were compared (fig 3.15). FeSO4 over the 
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concentration range 10-6 – 10-3 M decreased HSA catalysed coelenterazine 
chemiluminescence linearly, and a concentration of 10-2 M FeSO4 resulted in 
maximum inhibition. The addition of FeCl3 over the same concentration range 
also inhibited protein catalysed chemiluminescence linearly. However, FeCl3 
at a concentration of 10-3 M resulted in maximum inhibition of 
chemiluminescence. It can be concluded that FeCl3 was better at inhibiting 
HSA catalysed coelenterazine chemiluminescence as maximum inhibition was 
observed with a concentration of 10-3 M whereas 10-2 M FeSO4 was required 
for maximum inhibition. 
 
 
 
 
 
Figure 3.15. The inhibition of human serum albumin (HSA) catalysed 
coelenterazine chemiluminescence by Fe
2+
 and Fe
3+
. 10 μl of HSA (0.1 % (w/v); 1 
g.l
-1
 final concentration) was added to 90 μl of 50 mM HEPES buffer pH 7.4, 
containing 10 μM coelenterazine and FeSO4 or FeCl3 (0.001 – 10 mM final 
concentration). The results represent the mean +/- SEM of three experiments. FeCl3 
and FeSO4 over the concentration range 10
-6
 – 10
-2
 M significantly inhibited HSA 
catalysed coelenterazine chemiluminescence. As the concentration of FeCl3 and 
FeSO4 increased the HSA catalysed coelenterazine chemiluminescence decreased 
from 4800 and 7100 counts.s
-1
, respectively to 0 counts.s
-1
.  
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CaCl2 over the concentration range 10
-3 – 10-1 M had no significant effect on 
chemiluminescence in the presence or absence of HSA (fig. 3.16).  
 
 
 
 
 
 
 
 
Figure 3.16. The inhibition of human serum albumin (HSA) catalysed 
coelenterazine chemiluminescence by Ca
2+
. The machine background produced an 
average of 28 counts.s
-1
 whereas the coelenterazine chemiluminescence produced 
averages of between 86 and 134 counts.s
-1
. The effect of Ca
2+
 on HSA catalysed 
coelenterazine chemiluminescence was measured by adding 10 μl of HSA  (0.1 % 
(w/v); 1 g.l
-1
 final concentration) to 90 μl of 50 mM HEPES buffer pH 7.4, containing 10 
μM coelenterazine and CaCl2 (1 – 100 mM final concentration). The results represent 
the mean +/- SEM of three experiments.  
 
 
ZnCl2 over the concentration range 10
-7 – 10-3 M had no significant effect on 
the chemiluminescence in the absence of HSA (fig.3.17A). However, ZnCl2 at 
a concentration of 10-2 M increased chemiluminescence, but this increase was 
not significant. The addition of ZnCl2 at a concentration of 10
-5 M or higher 
significantly inhibited HSA catalysed coelenterazine chemiluminescence and 
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maximum inhibition was observed in the presence of 10-2 M ZnCl2 (p < 0.001; 
fig. 3.17B).  
 
 
 
 
 
 
 
 
Figure 3.17. The inhibition of human serum albumin (HSA) catalysed 
coelenterazine chemiluminescence by Zn
2+
.  The machine background produced 
an average of 27 counts.s
-1
 whereas the coelenterazine chemiluminescence produced 
averages of between 49 and 57 counts.s
-1
. The effect of Zn
2+
 on HSA catalysed 
coelenterazine chemiluminescence was measured by adding 10 μl of HSA (0.1 % 
(w/v); 1 g.l
-1
 final concentration) to 90 μl of 50 mM HEPES buffer pH 7.4 containing 10 
μM coelenterazine and  ZnCl2 (0.0001 – 10 mM final concentration). The results 
represent the mean +/- SEM of three experiments. Asterisks indicate a significant 
difference where p < 0.001 when compared with the control in the absence of ZnCl2.  
 
 
ZnCl2 over the concentration range 10
-5 – 10-2 M significantly increased 
chemiluminescence in the absence of human insulin (p < 0.001; fig. 3.18A). 
The addition of ZnCl2 over the concentration range 10
-5 – 10-2 M significantly 
increased insulin catalysed coelenterazine chemiluminescence between 100 
and 250 % (p < 0.0001; fig. 3.18B).  
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Figure 3.18. The stimulation of human insulin catalysed coelenterazine 
chemiluminescence by Zn
2+
. The machine background produced an average of 24 
counts.s
-1
 whereas the coelenterazine chemiluminescence produced averages of 
between 85 and 100 counts.s
-1
. The effect of Zn
2+
 on human insulin catalysed 
coelenterazine chemiluminescence was measured by adding 10 μl of human insulin 
(0.1 % (w/v); 1 g.l
-1
 final concentration) to 90 μl of 50 mM HEPES buffer pH 7.4 
containing 10 μM coelenterazine and ZnCl2 (0.01 – 10 mM final concentration). The 
results represent the mean +/- SEM of three experiments. Asterisks indicate a 
significant difference where p < 0.0001 when compared with the control in the 
absence of ZnCl2.  
 
 
Interestingly ZnCl2 over the concentration range 10
-5 – 10-2 M inhibited HSA 
catalysed chemiluminescence but it activated human insulin catalysed 
coelenterazine chemiluminescence. ZnCl2 over the concentration range 10
-5 – 
10-2 M inhibited HSA catalysed coelenterazine chemiluminescence between 
20 – 50 % whereas ZnCl2 over the same concentration range significantly 
enhanced human insulin catalysed coelenterazine chemiluminescence 
between 100 – 250 % (fig. 3.19).  
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Figure 3.19. The effect of Zn
2+
 on human serum albumin (HSA) and human 
insulin catalysed coelenterazine chemiluminescence. 10 μl of HSA or human 
insulin  (0.1 % (w/v); 1 g.l
-1
 final concentration) was added to 90 μl of 50 mM HEPES 
pH 7.4 containing 10 μM coelenterazine and ZnCl2 (0.01 – 10 mM final concentration). 
The coelenterazine chemiluminescence prior to the addition of the protein was 
subtracted from the chemiluminescence catalysed by the protein. The results 
represent the mean +/- SEM of three experiments. As the concentration of ZnCl2 
increased, albumin catalysed coelenterazine chemiluminescence decreased from 
3800 to 2100 counts.s
-1
 however, insulin catalysed coelenterazine chemiluminescence 
increased from 1600 to 5400 counts.s
-1
.  
 
 
It can be concluded that all the cations tested inhibited HSA catalysed 
coelenterazine chemiluminescence by 50 – 100 %. The cations can be ranked 
in order starting with the best at inhibiting HSA catalysed protein 
coelenterazine chemiluminescence: Fe2+/Fe3+ > Zn2+. 
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3.4. Discussion and conclusions 
The results in this chapter show that the two main plasma proteins, albumin 
and insulin can catalyse coelenterazine chemiluminescence (fig. 3.6 and fig. 
3.7). Surprisingly, haemoglobin, an oxygen carrier, produced very small 
chemiluminescence and was approximately 1000 times lower than the 
chemiluminescence observed with albumin. The ability of albumin to catalyse 
coelenterazine chemiluminescence was consistent with the protein having a 
mono-oxygenase activity in which one atom of oxygen is transferred to 
coelenterazine and the other to carbon dioxide, CO2. Albumin was considered 
to have a mono-oxygenase activity because it was heat denaturable (fig. 3.8), 
it exhibited saturable substrate characteristics (fig. 3.10) and was inhibited or 
stimulated by cations that are known to bind to the protein (fig. 3.12 to fig. 
3.15). 
The increase in chemiluminescence observed with alkaline pH was consistent 
with the presence of at least one basic amino acid residue being involved in 
the binding of coelenterazine. Only a few important amino acids in the 
coelenterazine binding site are required for the binding of coelenterazine 
and/or to catalyse chemiluminescence. The pH at the half maximum, pH 8.2 
and pH 7.8 for albumin and human insulin, respectively, represent the pKa of 
the group in the protein that is important for catalysis. The chemiluminescence 
from both albumin and human insulin increased with alkaline pH. The albumin 
catalysed coelenterazine chemiluminescence curve was different to the 
coelenterazine chemiluminescence curve before the addition of the protein, 
this implicates that there is a direct effect on the protein taking place. 
However, with human insulin, the human insulin catalysed coelenterazine 
chemiluminescence curve was not significantly different from the 
coelenterazine chemiluminescence curve prior to the addition of the protein, 
this may be due to coelenterazine possessing different ionic forms or that 
insulin is not actually binding coelenterazine but is in fact producing 
superoxide instead. 
The addition of the cations, Fe2+, Fe3+ and Zn2+ inhibited albumin catalysed 
coelenterazine chemiluminescence. The addition of FeCl3 (0.0001 – 1 mM 
final concentration) did not affect chemiluminescence and this suggested that 
there was a direct effect on the protein; however the addition of 10 mM FeCl3 
completely abolished chemiluminescence.  
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The complete inhibition observed with the addition of 10 mM FeCl3 could be 
due to the removal of oxygen from the solution. The addition of 3 mM FeSO4 
also completely abolished chemiluminescence and again this could be due to 
the complete removal of oxygen from the solution. HSA plays an essential role 
in the transport and metabolism of Zn2+ (Masuoka et al., 1993). Interestingly, 
Zn2+ that is known to bind to insulin and form crystals in pancreatic β-cells 
produced opposite effects on HSA and human insulin catalysed 
coelenterazine chemiluminescence. The addition of Zn2+ significantly 
enhanced human insulin catalysed coelenterazine chemiluminescence, 
increasing light emission by 4-fold.  
HSA has enzymatic activity or coelenterazine-luciferase activity, and is 
responsible for catalysing the conversion of the luciferin, coelenterazine, to 
coelenteramide in the presence of oxygen via an intermediate, resulting in the 
generation of light. Although BSA and HSA have a 78 % sequence similarity, 
BSA exhibited a higher luciferase activity and was significantly better at 
catalysing the coelenterazine chemiluminescence reaction.  
As well as its ligand binding properties, it is known that the interaction between 
a small molecule and albumin can result in the protein displaying enzymatic 
activity. Albumin can also act as a thioesterase due to the presence of a free 
sulphydryl (free-SH) group at Cys34 (Varshney et al., 2010). The enzymatic 
properties displayed by HSA can be stereospecific. Molecular dynamic 
simulation studies have shown the presence of both a deprotonated Lys199 
and a protonated Lys195, and it is predicted that these residues are what 
facilitate the enzymatic activity of the protein. The short distance of 6.73 Å 
between these two residues determined by x-ray crystallography supports this 
(Kragh-Hansen et al., 2002). 
The HSA subdomain IIIA has a well known esterase-like activity towards 
substrates. The esterase-like activity of this particular domain is due to the 
close proximity and protrusion of two residues, Arg410 and Tyr411 into the 
centre of site II. The distance between the reactive group of the tyrosine 
residue and the nitrogen atoms of the arginine residue in the crystal structure 
is short, measuring approximately 2.7 Å. This may explain the unusual 
reactivity of this residue towards nucleophilic substitution.  
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These residues are important for the different functions of HSA and this is 
emphasised by the finding of both these residues in other mammalian 
albumins (Kragh-Hansen et al., 2002, Yang et al., 2007). 
Watanabe et al (2000) have shown that Arg410 is closely involved in the 
esterase-like activity of HSA. They replaced the Tyr411 residue that is 
predicted to be the nucleophile involved in the hydrolytic reaction of HSA with 
alanine or phenylalanine and they found that the hydrolytic activity towards p-
nitrophenyl acetate was completely abolished. However, the addition of serine 
at position 411 produced about 21 % activity, suggesting it is the presence of 
a hydroxyl group at this position as well as the nature of its surroundings that 
are crucial for the enzymatic activity of HSA (Varshney et al., 2010, Watanabe 
et al., 2000).  
For proteins that have been confirmed to have enzymatic activity, denaturation 
is defined as the loss of enough structure leading to the inactivation of the 
enzyme. Increasing temperature is a factor that is known to denature proteins. 
When proteins become exposed to increasing temperature, they lose their 
enzymatic activity. This change in the protein may be reversible or irreversible 
but that depends on the protein and the severity of the heating, for example, a 
temperature of 95 oC would be sufficient enough to cause irreversible 
denaturation of HSA. Depending on the conditions to which the protein has 
been exposed, HSA can undergo reversible and irreversible thermal unfolding 
and refolding (Mitra et al., 2007). 
It has been shown that the thermal denaturation of HSA produces two 
transitions, A and B. Transition A is a minor transition that corresponds to 
temperatures below 65 oC. This transition is due to the reversible 
conformational changes that take place before protein unfolding. Transition A, 
also has 3 sub-transitions known as sub-transitions i, ii and iii. These sub-
transitions occur one after another and are said to be related to the links 
between the three structural domains of HSA. Sub-transitions i, ii and iii occur 
at temperatures 27, 35 and 42 oC, respectively. A mild conformational change 
in protein structure and thus reversible denaturation without the exposure of 
the pockets, leads to HSA aggregation during the first sub-transition. However, 
transition B is a major transition that corresponds to the thermal unfolding of 
the protein through an irreversible process (Rezaei Tavirani et al., 2006). 
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Therefore, it can be said that HSA is denatured through this multi-step 
unfolding pathway: 
N  E  I  U 
Where N is the native form of HSA, E is the expanded form, I is an 
intermediate in which domain II of the protein is unfolded but domain I is intact 
and U is the unfolded protein. 
When the temperature is below 50 oC HSA domain separation occurs, 
resulting in the irreversible separation of domains I and II generating a 
conformational change in the protein structure.  
Further increasing the temperature above 50 oC but still keeping it below 70 oC 
causes irreversible unfolding of domain II and when the temperature is 
increased above 70 oC it leads to the irreversible unfolding of domain I. 
Domain II of HSA needs to be completely unfolded before domain I can 
unfold. The U state is partially unfolded and is therefore not a completely 
unfolded random coil. This is due to the unfolding of the pocket containing the 
free-SH group of Cys34 enabling disulphide bonds to be formed within various 
domains, and/or the presence of some intramolecular cooperation in the 
thermal denaturation that act to maintain some degree of the structure (Rezaei 
Tavirani et al., 2006).  
From this it can therefore be concluded that when the protein was exposed to 
a temperature of 95 oC for 15 minutes HSA was irreversibly denatured thus 
preventing it from refolding when cooled, resulting in its reduced enzymatic 
activity, hence the significant decrease in HSA catalysed coelenterazine 
chemiluminescence that was observed. However, it has since been shown 
that under more extreme circumstances HSA activity was inhibited by > 90 % 
by heat denaturation (Vassel et al., 2012). Surprisingly, human insulin was not 
denatured under the same conditions as those used with HSA. This may be 
due to human insulin being a much smaller protein than HSA, thus making it 
more difficult to denature. Therefore, further work needs to be carried out to 
determine the conditions required for the denaturation of human insulin, for 
example, heating the protein at 95 oC for a longer period of time.  
To determine the maximum speed of the coelenterazine chemiluminescence 
reaction (fig. 3.8), the coelenterazine concentration was increased until a 
constant rate of product formation was seen. From this the substrate 
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concentration (Km) at which the rate is half of the Vmax can be determined. It 
can be seen that at a coelenterazine concentration of 40 μM the protein 
became saturated. Saturation occurs because as the coelenterazine 
concentration increased, more of the free-HSA is converted to the 
coelenterazine-HSA form. Therefore, the apparent Km was shown to be 
approximately 20 μM.  
It was not possible to determine the Km for insulin as an experiment to 
determine the chemiluminescence in the presence of increasing 
coelenterazine concentrations was not carried out. Further work can be 
carried out to demonstrate whether the effect of insulin on coelenterazine 
chemiluminescence is saturable and to test if it is binding or generating 
superoxide which is an established oxidant for coelenterazine. The maximum 
number of substrate molecules that an enzyme can convert into product for 
each catalytic site in a unit of time is known as the turnover number or kcat. 
Turnover numbers (kcat) can vary quite dramatically from 6 x10
5 s-1 for the 
enzyme carbonic anhydrase to 4, 1 and 1 s-1 for the bioluminescent enzymes 
Obelin, Renilla luciferase and Aequorea, respectively (Vassel et al., 2012). 
The kcat of HSA has been calculated to be approximately 1 x 10
-3 s-1 which is 
significantly slower than those mentioned above.  
In a solution of neutral pH the amino acids of a protein exist as zwitterions 
(dipolar ions). When in the dipolar form, the amino group of the amino acid is 
protonated (+NH3
+) whereas the carboxyl group of the amino acid is 
deprotonated (-COO-). Under acidic conditions, the amino group of the amino 
acid is protonated whereas the carboxyl group is not dissociated (-COOH). As 
the pH rises and the solution becomes more alkaline, the carboxylic acid is the 
first to lose a proton. The amino acids maintain the dipolar form until pH 9 has 
been reached and it is then the turn of the amino group to lose a proton (Berg 
et al., 2002). 
HSA undergoes pH-dependent reversible conformational isomerisation. At 
neutral pH, HSA presents itself in the neutral or native (N) form which is 
characterised by its heart-shaped structure (Fasano et al., 2005). In acidic 
conditions, the protein undergoes a conformational transition, resulting in the 
production of two isomeric forms, the fast (F) and the expanded (E) form 
(Muzammil et al., 1999). When the native albumin is exposed to a solution of 
pH 6.0 to 3.0 it forms the N-F transition. This N-F transition results in reduced 
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α-helical content but an increase in β-sheet content. However, when the 
protein is exposed to a more acidic solution, pH 3.0 and below, it forms the F-
E transition and it is here where the protein further unfolds. It is called the 
expanded form because it expands as much as the disulphide bonds will allow 
it. The F-E transition leads to a further decrease in α-helical content as well as 
an increase in β-sheet content (Dockal et al., 2000). 
Under slightly alkaline conditions, from neutral pH to pH 9.0, albumin can 
undergo a further conformational change producing the basic (B) form and this 
change is known as the N-B transition. However, this N-B transition is more 
subtle as well as having a gradual onset.  
Within this pH range, HSA displays a small decrease in α-helical content and a 
slight increase in β-sheet content (Dockal et al., 2000). Also when in this pH 
range, HSA has an increased affinity for some ligands (e.g. warfarin).  
As previously mentioned, when the pH rises above 9.0 it becomes the turn of 
the amino group to lose a proton (Berg et al., 2002). Therefore, as the pH 
rises, only the imidazole groups of the histidines and the terminal amino group 
of the protein are able to lose protons (Bos et al., 1989). 
Albumin is negatively charged but cations can bind weakly and reversibly to 
the protein (Varshney et al., 2010). Several cations are known to bind to both 
albumin and insulin. Of the cations tested, Fe2+, Fe3+ and Zn2+ (p < 0.001; fig. 
3.13 – fig. 3.15 and fig. 3.17) significantly inhibited coelenterazine 
chemiluminescence catalysed by HSA, however, this was dependent on the 
concentration and had a potency of Fe2+/Fe3+ > Zn2+. The addition of Ca2+ (fig. 
3.16) did not affect the coelenterazine chemiluminescence catalysed by HSA. 
The cation binding site is unknown and it is possible that the effect produced 
by these cations was due to an allosteric effect. Interestingly, zinc produced 
opposite effects on coelenterazine chemiluminescence modulated by HSA 
and human insulin. The addition of zinc significantly inhibited coelenterazine 
chemiluminescence catalysed by HSA (fig. 3.17) whereas the addition of zinc 
significantly enhanced the coelenterazine chemiluminescence catalysed by 
human insulin (fig. 3.18).  
Albumin is the main zinc transporter in the plasma and can bind approximately 
80 % of all zinc found in the plasma. As well as zinc, albumin has been shown 
to bind many other metal ions (e.g. Ca(II)). Zinc can bind with a high affinity to 
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albumin and this site is the primary binding site for Zn(II). The zinc binding site 
is located at the boundary between domain I and domain II (Lu et al., 2008). 
This high affinity of zinc for albumin explains why when the concentration of 
zinc increased the light emission decreased. As the concentration of zinc 
increased, these ions are more likely to become bound to the protein, due to 
their high affinity for albumin, thus inhibiting the binding of coelenterazine 
leading to decreased light emission.  
The biologically active insulin that circulates in the bloodstream is a monomer 
consisting of an A and a B chain made up of 21 and 30 amino acids, 
respectively. Insulin can pair with itself at micromolar concentrations resulting 
in the formation of a dimer. Dimerisation occurs when hydrogen bonds are 
formed between the ends of the two B-chains of the two insulin monomers (De 
Meyts, 2004). Still at micromolar concentrations but also in the presence of 
zinc ions, three dimers (6 monomers) can join together resulting in the 
formation of a hexamer (De Meyts, 2004). The 3D structure of insulin is 
composed of three helices and 3 disulphide bridges. The hydrophobic amino 
acid residues are clustered on the inner surface of the molecule whereas the 
polar amino acid residues are on the outside of the molecule. This 
arrangement of hydrophobic and polar amino acid residues results in the 
stabilisation of the molecule. The three disulphide bridges are formed between 
the –SH groups on cysteine residues. There are six cysteine residues found 
on the structure explaining why three disulphide bridges are formed.  
Two of the disulphide bridges are formed between the A and B chains of the 
structure and the third disulphide bridge is formed within the A chain. These 
also contribute to stability to the molecule.  
Insulin is synthesised by the pancreatic β-cells in the islets of Langerhans via 
the two insulin precursors – preproinsulin and proinsulin. In the Golgi 
apparatus of the cells, proinsulin is gathered in the storage vesicles that are 
rich in zinc. Here proteolytic enzymes remove the C-peptide from proinsulin 
resulting in insulin. In the secretory vesicles zinc will then interact with the 
insulin resulting in the formation of stable water-insoluble crystals of the zinc-
insulin hexamer (Zn2Insulin6) (Dunn, 2005, Noormagi et al., 2010). The 
addition of zinc to insulin causes the protein to undergo a conformational 
change. This conformational change enhances the binding of insulin to the 
insulin receptor (Faure et al., 1992).  
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Aggregation usually occurs at high concentrations where there are increased 
numbers of the insulin monomers (Hua and Weiss, 2004). It is known that the 
formation of the Zn2Insulin6 hexamer prevents insulin aggregation. For 
example, insulin concentrations in the storage vesicles are high (~ 21 mM) but 
no aggregation occurs due to the presence of zinc ions (~ 11 mM) which 
stabilise the high insulin concentrations by forming water-insoluble crystals of 
Zn2Insulin6 (Noormagi et al., 2010).  
However, when no zinc ions are present, it is possible for insulin to still form 
hexamers and prevent insulin aggregation at high concentrations. Insulin 
aggregation at high concentrations is slower than aggregation at low 
concentrations, suggesting that oligomerization prevents insulin aggregation 
(Noormagi et al., 2010).  
Enhanced coelenterazine chemiluminescence in the presence of human 
insulin may be due to zinc causing the protein to undergo a conformational 
change and it is this change that allows the coelenterazine to bind more 
effectively thus resulting in increased light emission. It is possible that at the 
high concentration used for the catalysis of coelenterazine 
chemiluminescence that insulin was in the hexameric form and was not 
subjected to aggregation even in the absence of zinc ions.  
At neutral pH and in the presence of zinc, dimeric insulin can further assemble 
to form a relatively stable hexamer that consists of three dimeric units. 
Conformational changes in tertiary structure of the hexamer may alter the 
biological activity of the protein. The hexamer can take one of three 
conformations but the importance of each of these individual conformations 
still remains unknown. However, what is known is that these conformational 
changes will affect receptor binding (Chausmer, 1998). When zinc ions were 
added along with human insulin, coelenterazine chemiluminescence was 
enhanced. This suggested that the presence of zinc caused the protein to 
undergo a conformational change and it is potentially this change that allows 
coelenterazine to bind more effectively, thus resulting in the increased light 
emission observed.  
The plasma is rich in HSA and it is this protein that plays a significant role in 
the transport and metabolism of drugs (Yang et al., 2007). It was necessary to 
use the coelenterazine chemiluminescence model to investigate if this model 
has the potential to be developed into a clinical test that can determine the 
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pharmacokinetics of new drugs before they are placed on the market for sale. 
To test this using this model, drugs that are already known to bind to insulin, 
such as warfarin, should affect the biological activity of the protein.  
The results showed that albumin has mono-oxygenase activity, however, the 
mono-oxygenase activity of albumin in physiology and pathophysiology needs 
to be investigated. The results showed that cations can inhibit or stimulate 
protein catalysed coelenterazine chemiluminescence. A further prediction is 
that drugs that are known to bind to albumin should inhibit chemiluminescence 
if they bind to the same site as coelenterazine. In order to confirm this it would 
be necessary to do molecular 3D modelling. The next aim would be to 
investigate the covalent modification of proteins by MeG (and potentially other 
toxins) on protein catalysed coelenterazine chemiluminescence. 
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4.1. Introduction 
It has been shown in the previous chapter that both albumin and surprisingly 
insulin catalyse coelenterazine chemiluminescence. For a protein to be 
considered as an enzyme it must adhere to 4 criteria: denaturable, saturable 
by the substrate, cations and drugs that are known to bind to the protein 
should affect the biological activity of the protein. The previous chapter has 
shown that HSA is denaturable, saturable by the substrate and that cations 
can either inhibit or activate protein catalysed coelenterazine 
chemiluminescence. It is predicted that coelenterazine binds to a site on 
albumin and since albumin contains two major binding sites for 
pharmaceuticals it is possible to determine to which of these sites 
coelenterazine would bind. Molecular 3D modelling can also be used to either 
predict or confirm the coelenterazine binding site on albumin.  
Proteins are macromolecules that are made up of amino acids arranged in 
different sequences of varying lengths, enabling them to form different 3D 
structures and to carry out a range of biological functions. Under natural 
conditions, the protein is flexible. Regulatory proteins have different binding 
sites and can undergo a conformational change when a ligand binds to one of 
these sites. Some monomeric proteins are able to bind more than one ligand 
at a time at different sites. This is one feature of human serum albumin (HSA) 
as it is able to bind a diverse range of biologically active molecules (Deeb et 
al., 2009). 
4.1.1. Human serum albumin 
Human serum albumin (HSA) is synthesised in and secreted from liver cells 
(Fasano et al., 2005). HSA is part of a multi-gene family of proteins. They are 
large globular proteins that have many domains and as it is the major soluble 
protein in the blood it has many physiological roles. HSA aids the transport, 
distribution, metabolism and excretion of many endogenous and exogenous 
ligands. Ligands can include molecules such as fatty acids, steroids, metals 
(e.g. calcium and zinc) (He and Carter, 1992), as well as a number of 
commonly used drugs with acidic or electronegative features, such as 
warfarin, diazepam and ibuprofen (Ghuman et al., 2005). 
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4.1.2. The structure of HSA 
HSA is a major extracellular protein and has a concentration of 0.6 mM (40 
mg/ml) in blood plasma (Tajmir-Riahi, 2007), therefore approximately 50 – 60 
% of the total plasma protein found in humans is HSA (Simard et al., 2006). It 
is a single polypeptide chain made up of 585 amino acids and has a molecular 
weight of 66,500 Da. At neutral pH, the polypeptide forms a heart-shaped 
structure with the dimensions of 80 x 80 x 80 x 30 Å (Otagiri, 2005).  
 
 
 
Figure 4.1. Ribbon diagram of human serum albumin (HSA) showing the three 
major domains (domains I, II and III) and the six subdomains. The six subdomains 
are coloured as follows: subdomain IA: light blue; subdomain IB: green; subdomain 
IIA: red; subdomain IIB: pink; subdomain IIIA: purple and subdomain IIIB: dark blue. 
The two primary binding sites, Sudlow’s sites I and II, named after their founder are 
also shown. The lone tryptophan residue (Trp214) located in the middle of subdomain 
IIA is indicated (Abou-Zied and Al-Shihi, 2008). 
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HSA is formed from three topologically similar homologous domains (fig. 4.1). 
Domain I consists of residues 1 to 195, domain II consists of residues 196 to 
383 and domain III consists of residues 384 to 585. Each of these domains is 
then made up of two separate helical subdomains known as subdomains A 
and B. Subdomain A consists of six α-helices flanked by two short α-helices 
whereas subdomain B consists of 4 α-helices (Sugio et al., 1999). This shows 
that approximately 67 % of the HSA structure is made up of α-helices, 
however, no β-sheets exist in the structure (Otagiri, 2005). There are 35 
cysteine residues throughout the structure and all but one of these residues 
(Cys34) are involved in the formation of 17 disulphide bridges to stabilise the 
subdomains (Fasano et al., 2005, Tajmir-Riahi, 2007).The terminal regions of 
sequential domains can form interdomain helices. The N-terminal region was 
formed by linking subdomain IB to subdomain IIA, whereas, the C-terminal 
region was formed by linking subdomain IIB to subdomain IIIA (Fasano et al., 
2005). Crystallographic studies of HSA complexed with a diverse range of 
drugs and other biomolecules have revealed the binding sites as well as their 
locations on the protein. Until now, the binding sites for fatty acids, ions, 
thyroxine, bilirubin and a range of drugs have been identified (Varshney et al., 
2010). 
4.1.3. HSA binding regions 
Where the ligand will bind on HSA will largely depend on both the molecular 
and physical properties of the ligand and this helps to explain why all ligands 
do not bind to the same site on the protein (Sahoo et al., 2008). 
4.1.3.1. The fatty acid binding regions 
Many fatty acid (FA) binding sites are widely distributed throughout the protein 
across all six subdomains. High-resolution crystal structures of fatty acids 
bound to HSA have identified seven binding sites with different affinities 
distributed throughout the protein. FA binding sites can be found in 
subdomains IB, IIIA, IIIB as well as on the interfaces of the subdomains 
(Varshney et al., 2010).  
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Figure 4.2. Ribbon diagram of human serum albumin (HSA) showing the seven 
fatty acid binding sites distributed throughout the protein. The subdomains are 
coloured as follows: subdomain IA: light blue; subdomain IB: dark blue; subdomain 
IIA: dark green; subdomain IIB: light green; subdomain IIIA: red and subdomain IIIB: 
orange (Fasano et al., 2005). 
 
If a compound is unable to bind to HSA, the compound can couple to a ligand, 
such as a FA and then bind to the protein (Varshney et al., 2010). Therefore, 
the FA binding sites are also capable of binding other ligands as well as fatty 
acids.  Sudlow et al (1975) identified and characterised two specific drug 
binding sites, now typically known as Sudlow’s site I and site II after their 
founder. These two binding sites can overlap with some of the FA binding 
sites (fig. 4.2). Sudlow’s site I which is located in subdomain IIA overlaps with 
FA site 7. FA site 7 is a low affinity binding site and at least two of its amino 
acid side-chains are shared with FA site 2. FA site 2 can be found at the 
interface between subdomains IA, IB and IIIA. A FA site found in subdomain 
IB also acts as a heme binding site. Sudlow’s site II which is located in 
subdomain IIIA overlaps with both FA site 3 and FA site 4. FA site 1 not only 
binds fatty acids but it is also the primary binding site for haemin. FA site 5 is 
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located within subdomain IIIA and is also a secondary binding site for the drug 
propofol (a general anaesthetic) and thyroxine. Finally, FA site 6 is a low 
affinity binding site and is a secondary binding site for non-steroidal anti-
inflammatory drugs (e.g. ibuprofen) (Simard et al., 2006, Fasano et al., 2005).  
4.1.3.2. The metal-binding regions 
A number of studies have been carried out on the metal-binding properties of 
HSA and the results have shown that metal ions can bind to various sites on 
the protein (Chan et al., 1995). The lone cysteine residue at position 34 
(Cys34) is found at the base of a hydrophobic pocket and it favours the 
binding of hydrophobic complexes belonging to heavy metal ions (e.g. gold, 
Au+). However, there are three other sites that are more versatile and easier to 
access. The best characterised metal-binding site is located on the N-terminal 
and it is made up of the first three amino acid residues of the HSA sequence 
(Sokolowska et al., 2010). This metal-binding site and the N-terminal have a 
high affinity for copper and nickel (Tajmir-Riahi, 2007, Varshney et al., 2010, 
Chan et al., 1995). 
4.1.3.3. The two main drug binding regions  
HSA can bind, either covalently or reversibly, a diverse range of endogenous 
and exogenous compounds. There are multiple drug binding sites that are 
distributed throughout the protein (fig. 4.3), however many drugs can bind to 
one or very few high-affinity sites that have association constants (Ka) within 
the range of 10-4 to 10-6 M-1 (Table 4.1) (Kragh-Hansen et al., 2002). The two 
main drug binding sites are known as Sudlow’s site I and II and are named 
after their founder (Sudlow et al., 1975, Varshney et al., 2010). The in vivo 
concentration of a drug is significantly lower than the HSA concentration in the 
blood and therefore at therapeutic drug concentrations, only a small number of 
the available binding sites on HSA are occupied (Yamasaki et al., 1996). The 
next section will focus on these two binding sites in detail. 
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Figure 4.3. The ligand binding capacity of human serum albumin (HSA). The six 
subdomains are coloured as follows: subdomain IA: pink; subdomain IB: purple; 
subdomain IIA: light green; subdomain IIB: dark green; subdomain IIIA: light blue and 
subdomain IIIB: dark blue (Varshney et al., 2010).  
 
4.1.4. Ligand binding at Sudlow’s site I 
Sudlow’s site I, also known as the warfarin binding site and can be found 
within subdomain IIA (Fujiwara and Amisaki, 2006). It is a pre-formed binding 
pocket (containing the FA site 7). It is composed of 6 α-helices and a loop 
helix (residues 148-154) that is donated from subdomain IB. The interior of the 
binding pocket is mostly apolar but does contain two groups of polar residues. 
One group of polar resides can be found on the base of the pocket and 
consists of residues Tyr150, His242 and Arg257 whereas the other polar 
group can be found at the entrance to the pocket and consists of residues 
Lys195, Arg218 and Arg222 (Otagiri, 2005, Sugio et al., 1999).  
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This site is a large conformationally adaptable region (Varshney et al., 2010) 
thus allowing large ligands (e.g. bilirubin; Mr ~ 585 Da) to bind. As well as 
being large, this site is flexible and adaptable as it is capable of binding 
ligands that have very different chemical structures with high-affinity (Table 
4.1). This site contains a large number of ligand binding sites (Otagiri, 2005). 
Ligand-binding sites in this pocket are individual and are therefore 
independent of each other, but they are also capable of influencing one 
another. Compounds that favour this site are dicarboxylic acids and/or bulky 
heterocyclic anions that have a negative charge localised in the middle of the 
molecule (fig. 4.4) (Kragh-Hansen et al., 2002, Baroni et al., 2001). X-ray 
diffraction studies have identified 4 residues that contribute to binding, two of 
which contribute positively (Trp214 and Arg218) and two which contribute 
negatively (Lys199 and His242). The positive residue, the lone tryptophan at 
position 214 is found in the centre of the binding pocket and is thought to have 
a crucial role (Bos et al., 1988, Kragh-Hansen et al., 2002). 
 
 
 
Figure 4.4. The chemical structures of some of the drugs that bind to Sudlow’s 
site I. A) warfarin; B) indomethacin; C) furosemide and D) tolbutamide (Petitpas et al., 
2001). 
  
Drugs such as warfarin cluster in the centre of the binding site. The planar 
group fits “snugly” between the apolar side-chains of the Leu238 and Ala291 
residues. However, compounds can occupy the apolar compartments of this 
site to different extents. For example, warfarin can occupy the right-side and 
front sub-chambers.  
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All ligands that are able of binding at this site are positioned so that they form 
hydrogen bonds with the hydroxyl group of the Tyr150 residue. Therefore, the 
Tyr150 residue is important for drug interaction (Ascenzi and Fasano, 2010). 
4.1.5. Ligand binding at Sudlow’s site II 
Sudlow’s site II, also known as the indolebenzodiazepine or diazepam site can 
be found within subdomain IIIA (Fujiwara and Amisaki, 2006). It is composed 
of the six α-helices of subdomain IIIA. The inside of the pocket is lined with 
hydrophobic side-chains and the Arg210 side-chain is found at the entrance of 
the pocket whilst the hydroxyl group belonging to the Tyr411 residue faces 
towards the inside of the pocket (Sugio et al., 1999). In comparison to binding 
site I, this site has one polar patch that can be found at one side of the 
entrance to the pocket and centred on the Tyr411 residue but does also 
include the Arg410, Lys414 and Ser489 residues. The Arg410 and Ser489 
residues also take part in salt-bridge and hydrogen-bond formation.  
This binding site only possesses one sub-compartment compared to site I. 
The hydrophobic sub-chamber is found towards the right rear side of the 
pocket. However, access to this sub-chamber is only possible after ligand-
induced side-chain movements. This site is smaller and narrower than site I 
therefore explaining why no large ligands are able to bind to it. It is also less 
flexible because binding is significantly affected by stereoselectivity. If a large 
ligand is replaced by a small ligand this would significantly influence the 
binding, thus increasing the chances of the smaller ligand binding. Although 
this site can bind several ligands (Table 4.1) with high affinity, it is said to be 
more restricted than binding site I. The amino acids thought to be of 
importance for binding are Arg410 and Tyr411 (Kragh-Hansen et al., 2002) 
and the hydroxyl group of the Tyr411 residue (Lejon et al., 2008).  
Compounds that favour this site are aromatic carboxylic acids that have a 
negatively charged acidic group on one end of the molecule that is away from 
the hydrophobic centre (fig. 4.5) (Kragh-Hansen et al., 2002, Baroni et al., 
2001). 
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Figure 4.5. The chemical structures of some of the drugs that bind to Sudlow’s 
site II. A). diazepam; B). phenytoin and C) ibuprofen (Chen et al., 2006). 
 
The binding of the benzodiazepine, diazepam, a compound with a large-
branched structure and a molecular weight of 285 Da causes the Leu387 and 
Leu453 side-chains to rotate. This rotation allows the phenyl ring of the 
compound to gain access to the single sub-chamber of the pocket. Drugs such 
as ibuprofen can cluster in the centre of the drug binding site and form 
interactions with the hydroxyl group of the Tyr411 residue. However, the 
presence of a basic polar patch found at one end of the binding pocket is the 
preferred site of interaction for drugs that contain a peripheral electronegative 
group (Ascenzi and Fasano, 2010). Other compounds that are capable of 
binding to site II can also interact at additional sites out of this subdomain.  
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Sudlow’s site I Ka (M
-1
) Sudlow’s site II Ka (M
-1
) 
 
Warfarin 
Acenocoumarol 
Azapropazone 
Benzylthiouracil 
Canrenoate 
Chlorpropamide 
Furosemide 
Indomethacin 
Iodipamide 
Iophenoxate 
Oxyphenbutazone 
Phenylbutazone 
Piretanide 
Quercetin 
R-Sulbenicillin 
Salicylate 
S-Carbenicillin 
Spironolactone 
Sulphadimethoxine 
Sulphathiazole 
Tenoxicam 
Tolbutamide 
Valproate 
 
3.4 X 10
5
 
2.2 X 10
5
 
2.8 X 10
5
 
4.1 X 10
4
 
2.0 X 10
5
 
3.3 X 10
5
 
1.9 X 10
5
 
1.4 X 10
6
 
9.9 X 10
6
 
7.7 X 10
7
 
3.5 X 10
5
 
1.5 X 10
6
 
9.5 X 10
4
 
2.7 X 10
5
 
5.2 X 10
3
 
1.9 X 10
5
 
2.4 X 10
3 
3.0 X 10
3
 
9.0 X 10
4
 
2.5 X 10
4
 
3.7 X 10
5
 
4.0 X 10
4
 
2.8 X 10
5
 
 
Diazepam 
Chlofibrate 
Chlorothiazide 
Diclofenac 
Ethacrynate 
Ibuprofen 
Iopanoate 
Ketoprofen 
Phenytoin 
Pirprofen 
S(-)-Thiamylal 
S-Etodolac 
S-Naproxen 
 
 
 
3.8 X 10
5
 
7.6 X 10
5
 
5.5 X 10
4
 
3.3 X 10
6
 
1.7 X 10
6
 
2.7 X 10
6
 
6.7 X 10
6
 
2.5 X 10
6
 
1.7 x 10
4
 
3.9 X 10
5
 
8.7 X 10
4
 
2.0 X 10
5
 
3.7 X 10
6
 
 
 
Table 4.1. Drugs that bind to Sudlow’s sites I and II on human serum albumin 
(HSA) with high affinities (Kragh-Hansen et al., 2002, Kober et al., 1980). 
 
4.1.6. The competitive binding properties of ligands 
Many drug molecules are known to be enzyme inhibitors. An enzyme inhibitor 
is molecule that has the ability to bind to an enzyme and decrease its 
enzymatic activity. The binding of an enzyme inhibitor, such as a drug, can 
prevent a substrate, such as coelenterazine from entering the binding pocket 
as well as preventing the enzyme from catalysing the coelenterazine 
chemiluminescence reaction. Inhibitors can bind either reversibly or 
irreversibly. The irreversible binding of an inhibitor can induce changes in the 
enzyme, for example, inhibitors can modify the key amino acid residues 
required for enzymatic activity. However, the binding of reversible inhibitors 
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can produce different types of inhibition depending on where the inhibitors 
bind (i.e. enzyme, enzyme-substrate complex or both). 
4.1.7. The covalent modification of proteins by methylglyoxal 
It is known that the covalent modification of a protein has a significant 
influence on its conformational and functional properties (Otagiri, 2005). MeG 
is a potent glycating agent that at physiological concentrations can bind to and 
irreversibly modify plasma proteins such as HSA (Lo et al., 1994). Glycation is 
a reaction that occurs between the free amino group of a protein and the 
carbonyl group belonging to a reducing sugar leading to the production of the 
stable advanced glycation end-products (AGEs) (Dhar et al., 2009, Thornalley, 
2008). The formation of these stable AGEs under physiological concentrations 
occurs directly and relatively rapidly. An example showed that when 1 μM 
MeG was added to human plasma ex vivo and incubated at 37 oC it resulted in 
the complete and irreversible binding of MeG to the plasma protein within 24 
hours. MeG is known to target and irreversibly modify arginine and lysine 
residues as well as amino-terminal amino groups however; MeG particularly 
favours arginine residues (Lo et al., 1994, Thornalley, 1996, Ahmed et al., 
2005, Thornalley, 2008). The possible modification sites on HSA that play a 
role in glycation or AGE formation include the 59 lysine residues, the 23 
arginine residues and the N-terminal amine (Wa et al., 2007). When MeG 
irreversibly reacts with lysine residues, it results in the production of Nε-
carboxymethyl-lysine (CML) and Nε-carboxyethyl-lysine (CEL). The most 
important AGEs quantitatively are the MeG-derived hydroimidazolones (MG-
H) and these are formed when MeG modifies the arginine residues of the 
protein (Dhar et al., 2009, Thornalley, 2008). There are three MG-H, they are 
structural isomers and are known as: Nδ-(5-hydro-5-methylimidazol-4-on-2-
yl)ornithine (MG-H1), 2-amino-5-(2-amino-5-hydro-5-methyl-4-imidazolon-1-
yl)pentanoic acid (MG-H2), and 2-amino-5-(2-amino-4-hydro-4-methyl-5-
imidazolon-1-yl)pentanoic acid (MG-H3) (Dhar et al., 2009). Of these MG-H, 
MG-H1 residue formation has been noticed at Arg410 on HSA as a result of 
MeG modification. It is the formation of this MG-H at Arg410 that inhibits drug 
binding and function.  
Interestingly, MG-H1 residue formation in albumin and other proteins has been 
found at increased levels in patients suffering with diabetes (Thornalley, 
2008). Therefore, the formation of these hydroimidazolones at these sites can 
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cause distortion of the protein structure, loss of side-chain charge and reduced 
function (Thornalley, 2008). Hydroimidazolones have a moderate half-life of 
around 2 – 6 weeks as well as slow dynamic reversibility. Therefore, the 
protein content of these hydroimidazolones can be decreased if the 
concentration of MeG is also decreased. From this it can be concluded that 
the modification of proteins by MeG can be harmful when the amino acid 
residues that are modified are found at sites where protein-protein 
interactions, enzyme-substrate interactions and protein-DNA interactions take 
place (Ahmed et al., 2005, Thornalley, 2008). 
4.1.8. Hypothesis, aims and experimental strategy  
4.1.8.1. Hypothesis 
The bacterial metabolic toxin hypothesis proposes that MeG and other 
metabolic toxins cause the covalent modification of proteins, such as albumin 
and insulin, thus leading to the pathogenesis of diseases such as diabetes. It 
is predicted that the covalent modification of both HSA and insulin by the 
bacterial metabolic toxin, MeG would reduce their enzymatic activity. 
4.1.8.2. Aims 
The overall aim of this chapter was to investigate the effect of drugs that are 
known to bind to HSA on protein catalysed coelenterazine chemiluminescence 
and to determine the covalent modification of both HSA and human insulin by 
MeG and hydrogen peroxide (H2O2).  
It has been shown in the previous chapter that both HSA and human insulin 
can catalyse the coelenterazine chemiluminescence reaction and the aims of 
this chapter were as follows: 
 To investigate the effect of compounds, such as clinically used drugs 
on the activity of these proteins 
 To determine the coelenterazine binding site using drugs that are 
known to bind to either Sudlow’s site I (warfarin) and Sudlow’s site II 
(diazepam) on HSA 
 To demonstrate that both MeG and H2O2 covalently modify these 
proteins thus altering their activity 
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 To investigate if molecular 3D modelling can be used to confirm or 
predict the binding sites of compounds on these proteins 
4.1.8.3. Experimental strategy 
To use the coelenterazine chemiluminescence model to investigate the effect 
of clinically used drugs on the activity of HSA and human insulin, to determine 
the coelenterazine binding site on HSA and to demonstrate the covalent 
modification of both HSA and human insulin. To investigate if molecular 3D 
modelling can be used to characterise the two main binding sites on HSA. 
 
4.2. Materials and methods 
4.2.1. Materials 
Coelenterazine was a kind gift from Bruce Bryan, Prolume Inc. Snakeskin 
pleated dialysis tubing (pore size: 25 μm) was purchased from Fisher 
Scientific. All other compounds were purchased from Sigma-Aldrich unless 
otherwise stated.  
4.2.2. Preparation of reagents 
All reagents including proteins, coelenterazine and buffer were prepared as 
previously described in section 2.2.3. In this chapter there was also the need 
for 50 mM sodium-phosphate buffer, pH 8.3. 1 L of 50 mM basic Na2HPO4 
was made and the pH was adjusted to 8.3 using the same concentration of 
acidic NaH2PO4. To make 1 L of 50 mM basic Na2HPO4, 7 g was dissolved in 
distilled water and to make 500 ml of 50 mM NaH2PO4, 3 g was dissolved in 
distilled water. 
4.2.3. To investigate the effect of drugs on HSA catalysed coelenterazine 
chemiluminescence 
All reagents were prepared as previously described in section 2.2.3 and the 
photomultiplier tube was allowed to reach its optimum temperature. The 
machine background was measured. The coelenterazine chemiluminescence 
(or chemical background) was measured by adding 10 μM coelenterazine to 
70 μl of buffer containing 50 mM HEPES buffer, pH 7.4. Then the drug 
chemiluminescence was measured by adding 10 μl of the drug to 80 μl of 
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buffer containing 50 mM HEPES buffer, pH 7.4 and 10 μM coelenterazine. 
The protein chemiluminescence was measured by adding 10 μl HSA (0.1 % 
(w/v) final concentration) to 90 μl of buffer containing 50 mM HEPES buffer, 
pH 7.4, 10 μM coelenterazine and 10 μl of drug. The background or 
chemiluminescence was recorded as 6 x 10 second counts and the mean was 
taken.  
4.2.4. The production of covalently modified proteins and their effect on 
protein catalysed coelenterazine chemiluminescence 
Albumin and human insulin (1 % (w/v)) were incubated with MeG or hydrogen 
H2O2 (10 mM) for 1 week at room temperature. Also, albumin and human 
insulin (without toxins) were incubated under the same conditions so that any 
modifications could be determined. A week later sections of dialysis tubing 
were prepared by boiling in water containing EDTA. The tubing was rinsed 
with distilled water and one end tied securely. 1 ml of normal HSA was added 
to the tubing and the opposite end was tied securely. This was done for both 
normal and modified proteins. The tubing containing the solutions was placed 
into a beaker containing 50 mM sodium-phosphate buffer, pH 8.3 and placed 
on a stirrer in a cold room to dialyse for 24 hours. The buffer was replaced 
twice. Following dialysis, the solutions were removed from the tubing and 
transferred into universal tubes.  
All reagents were prepared as previously described in section 2.2.3 and the 
photomultiplier tube was allowed to reach its optimum temperature. The 
machine background was measured. The coelenterazine chemiluminescence 
was measured by adding 10 μM coelenterazine to 80 μl of buffer containing 50 
mM HEPES buffer, pH 7.4. The protein chemiluminescence was measured by 
adding 10 μl of HSA (0.1 % (w/v) final concentration) to 90 μl of buffer 
containing 50 mM HEPES buffer, pH 7.4 and 10 μM coelenterazine. The 
background or chemiluminescence was recorded as 6 x 10 second counts and 
the mean was taken.  
4.2.5. To determine if molecular 3D modelling can be used to predict the 
coelenterazine binding site 
All molecular modelling studies were performed on a MacPro dual 2.66 GHz 
Xeon running Ubuntu 8. The albumin structure was downloaded from the 
Protein Data Bank (PDB) (http://www.rcsb.org/ - PDB code: 2BXD) (Ghuman 
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et al., 2005). Hydrogen atoms were added to the protein using Molecular 
Operating Environment (MOE), and minimised keeping all the heavy atoms 
fixed until a RMSD gradient of 0.05 kcal mol-1 Å-1 was reached. Ligand 
structures were built with MOE and minimised using the MMFF94X forcefield 
until a RMSD gradient of 0.05 kcal mol-1 Å-1 was reached. The docking 
simulations were performed using PLANTS with the default settings (Korb et 
al., 2006). 
4.2.6. Statistical analysis 
Statistical analysis was carried out on the mean using a t-test and the results 
were considered to be statistically different when p < 0.05. 
 
4.3. Results 
The two well characterised drug binding sites on HSA, Sudlow’s site I and 
Sudlow’s site II can bind a diverse range of drugs. Drugs that bind to Sudlow’s 
site I include warfarin, furosemide, indomethacin and tolbutamide, whereas 
drugs that bind to Sudlow’s site II include diazepam, phenytoin and ibuprofen. 
The initial aim was to determine the coelenterazine binding site on HSA by 
using drugs that are known to bind to either Sudlow’s site I or Sudlow’s site II. 
The results that follow predict that coelenterazine binds to Sudlow’s site I 
because only drugs that can bind to this site significantly inhibited HSA 
catalysed coelenterazine chemiluminescence (p < 0.001; fig. 4.6 – fig. 4.9).  
4.3.1. The effect of drugs on HSA catalysed coelenterazine 
chemiluminescence 
In order to determine the coelenterazine binding site, drugs that are known to 
bind to either Sudlow’s site I or Sudlow’s site II were used and their effects on 
HSA catalysed coelenterazine chemiluminescence were determined.  
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4.3.1.1. The effect of drugs that are known to bind to Sudlow’s site I on 
HSA catalysed coelenterazine chemiluminescence 
In order to determine if Sudlow’s site I was the coelenterazine binding site, 
drugs that are known to bind to this site – warfarin, furosemide, indomethacin 
and tolbutamide were used and their effect on HSA catalysed coelenterazine 
chemiluminescence was determined. The results that follow show that the 
addition of these four particular site I drugs significantly inhibited HSA 
catalysed coelenterazine chemiluminescence. However, the extent of the 
inhibition observed by each of these drugs varied.  
From the results that follow, the drugs that bind to Sudlow’s site I can now be 
ranked in order of producing maximum inhibition of HSA catalysed 
coelenterazine chemiluminescence: indomethacin > tolbutamide > furosemide 
> warfarin. The inhibition of HSA catalysed coelenterazine chemiluminescence 
was not consistent with the binding constants (Kd) for these drugs and this 
may be due to the high concentrations (10-4 M) of the protein used. The Kd 
values included in this chapter were obtained from published literature. 
The HSA catalysed coelenterazine chemiluminescence was significantly 
inhibited by warfarin (p < 0.001; fig. 4.6). The results show that warfarin alone 
(fig. 4.6A) did not significantly affect chemiluminescence when compared to 
the control in the absence of the drug, and this suggested that there was a 
direct effect on the protein. In the presence of 10 μM coelenterazine (fig. 4.6B) 
the maximum inhibition of HSA catalysed coelenterazine chemiluminescence 
(10-6 to 10-3; Kd = 2.9 x 10
-6 M) was approximately 50 %. 
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Figure 4.6. The inhibition of human serum albumin (HSA) catalysed 
coelenterazine chemiluminescence by warfarin. The machine background 
produced an average of 29 counts.s
-1
 whereas the coelenterazine chemiluminescence 
produced averages of between 66 and 83 counts.s
-1
. The effect of warfarin on HSA 
catalysed coelenterazine chemiluminescence was measured by adding 10 μl of HSA 
(0.1 % (w/v); 1 g.l
-1
 final concentration) to 90 μl of buffer containing 50 mM HEPES 
buffer pH 7.4, 10 μM coelenterazine and 10
-6
 – 10
-3
 M warfarin. Results represent the 
mean +/- SEM of six determinations. Asterisks indicate a significant difference where 
p < 0.001 when compared with the control in the absence of warfarin. 
 
The HSA catalysed coelenterazine chemiluminescence was significantly 
inhibited by furosemide (p < 0.001; fig. 4.7). The results show that furosemide 
alone (fig. 4.7A) did not significantly affect chemiluminescence when 
compared to the control in the absence of the drug and this suggested that 
there was a direct effect on the protein. In the presence of 10 μM 
coelenterazine (fig. 4.7B) the maximum inhibition of HSA catalysed 
coelenterazine chemiluminescence (10-6 to 10-3 M; Kd = 5.3 x 10
-6 M) was 
approximately 60 %.  
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Figure 4.7. The inhibition of human serum albumin (HSA) catalysed 
coelenterazine chemiluminescence by furosemide. The machine background 
produced an average of 24 counts.s
-1
 whereas the coelenterazine chemiluminescence 
produced averages of between 63 and 75 counts.s
-1
. The effect of furosemide on HSA 
catalysed coelenterazine chemiluminescence was measured by adding 10 μl of 
albumin (0.1 % (w/v), 1 g.l
-1
 final concentration) to 90 μl of buffer containing 50 mM 
HEPES buffer, pH 7.4, 10 μM coelenterazine and 10
-6
 – 10
-3
 M furosemide. Results 
represent the mean +/- SEM of six determinations. Asterisks indicate a significant 
difference where p < 0.001 when compared with the control in the absence of 
furosemide.  
 
The HSA catalysed coelenterazine chemiluminescence was significantly 
inhibited by indomethacin (p < 0.001; fig. 4.8). The results show that 
indomethacin alone (fig. 4.8A) did not significantly affect chemiluminescence 
when compared to the control in the absence of the drug and this suggested 
that there was a direct effect on the protein. In the presence of 10 μM 
coelenterazine (fig. 4.8B) the maximum inhibition of HSA catalysed 
coelenterazine chemiluminescence (10-6 to 10-2 M; Kd = 7.1 x 10
-7 M) was 
approximately >95 %. 
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Figure 4.8. The inhibition of human serum albumin (HSA) catalysed 
coelenterazine chemiluminescence by indomethacin. The machine background 
produced an average of 29 counts.s
-1
 whereas the coelenterazine chemiluminescence 
produced averages of between 48 and 58 counts.s
-1
. The effect of indomethacin on 
HSA catalysed coelenterazine chemiluminescence was measured by adding 10 μl of 
albumin (0.1 % (w/v); 1 g.l
-1
 final concentration) to 90 μl of buffer containing 50 mM 
HEPES buffer, pH 7.4, 10 μM coelenterazine and 10
-6
 – 10
-2
 M indomethacin. Results 
represent the mean +/- SEM of six determinations. Asterisks indicate a significant 
difference where p < 0.001 when compared with the control in the absence of 
indomethacin. 
 
Tolbutamide significantly inhibited HSA catalysed coelenterazine 
chemiluminescence (p < 0.001; fig. 4.9). Tolbutamide alone (fig. 4.9A) at 
concentrations 10-6 to 10-3 M did not significantly affect chemiluminescence 
when compared to the control in the absence of the drug therefore suggesting 
that there was a direct effect on the protein. However, 10-2 M tolbutamide did 
significantly increase chemiluminescence (p < 0.01; fig. 4.9A) when compared 
to the control in the absence of the drug. In the presence of 10 μM 
coelenterazine (fig. 4.9B) the maximum inhibition of HSA catalysed 
coelenterazine chemiluminescence (10-6 to 10-2 M; Kd = 2.5 x 10
-5 M) was 
approximately >90 %. 
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Figure 4.9. The inhibition of human serum albumin (HSA) catalysed 
coelenterazine chemiluminescence by tolbutamide. The machine background 
produced an average of 30 counts.s
-1
 whereas the coelenterazine chemiluminescence 
produced averages of between 59 and 62 counts.s
-1
. The effect of tolbutamide on 
HSA catalysed coelenterazine chemiluminescence was measured by adding 10 μl of 
albumin (0.1 % (w/v); 1 g.l
-1
 final concentration) to 90 μl of buffer containing 50 mM 
HEPES buffers, pH 7.4, 10 μM coelenterazine and 10
-6
 – 10
-2
 M tolbutamide. Results 
represent the mean +/- SEM of six determinations. Asterisks indicate significant 
difference where p < 0.001 when compared to the control in the absence of 
tolbutamide. 
 
4.3.1.2. The effect of drugs that are known to bind to Sudlow’s site II on 
HSA catalysed coelenterazine chemiluminescence 
In order to determine if Sudlow’s site II was the coelenterazine binding site, 
drugs that are known to bind to this site – diazepam, phenytoin and ibuprofen 
were used and their effect on HSA catalysed coelenterazine 
chemiluminescence was determined. The HSA catalysed coelenterazine 
chemiluminescence was significantly inhibited by diazepam (p < 0.001; fig. 
4.10). The results show that diazepam alone (fig. 4.10A) did not significantly 
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affect chemiluminescence when compared to the control in the absence of the 
drug and this suggested that there was a direct effect on the protein. In the 
presence of 10 μM coelenterazine (fig. 4.10B) the maximum inhibition of HSA 
catalysed coelenterazine chemiluminescence (10-6 to 10-4 M; Kd = 2.6 x 10
-6 
M) was approximately 20 %.  
 
 
 
 
Figure 4.10. The inhibition of human serum albumin (HSA) catalysed 
coelenterazine chemiluminescence by diazepam. The machine background 
produced an average of 25 counts.s
-1
 whereas the coelenterazine chemiluminescence 
produced between 67 and 78 counts.s
-1
. The effect of diazepam on HSA catalysed 
coelenterazine chemiluminescence was measured by adding 10 μl of albumin (0.1 % 
(w/v); 1 g.l
-1
 final concentration) to 90 μl of buffer containing 50 mM HEPES buffer, pH 
7.4, 10 μM coelenterazine and 10
-6
 – 10
-4
 M diazepam. Results represent the mean 
+/- SEM of nine determinations.  
 
Phenytoin (10-6 to 10-4 M; Kd = 5.9 x 10
-5 M) had no significant effect on HSA 
catalysed coelenterazine chemiluminescence (fig. 4.11). The results show that 
phenytoin alone (fig. 4.11A) did not significantly affect chemiluminescence 
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when compared to the control in the absence of the drug and this suggested 
that there was a direct effect on the protein. In the presence of 10 μM 
coelenterazine (fig. 4.11B) there was no significant effect on HSA catalysed 
coelenterazine chemiluminescence.  
 
 
 
 
Figure 4.11. The inhibition of human serum albumin (HSA) catalysed 
coelenterazine chemiluminescence by phenytoin. The machine background 
produced an average of 25 counts.s
-1
 whereas the coelenterazine chemiluminescence 
produced averages of between 65 and 75 counts.s
-1
. The effect of phenytoin on HSA 
catalysed coelenterazine chemiluminescence was measured by adding 10 μl of 
albumin (0.1 % (w/v); 1 g.l
-1
 final concentration) to 90 μl of buffer containing 50 mM 
HEPES buffer, pH 7.4, 10 μM coelenterazine and 10
-6
 – 10
-4
 M phenytoin. Results 
represent the mean +/- SEM of nine determinations. 
 
Ibuprofen (10-6 to 10-3 M; Kd = 3.7 x 10
-7 M) had no significant effect on HSA 
catalysed coelenterazine chemiluminescence (fig. 4.12). The results show that 
ibuprofen alone (fig. 4.12A) did not significantly affect chemiluminescence 
when compared to the control in the absence of the drug and this suggested 
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that there was a direct effect on the protein. In the presence of 10 μM 
coelenterazine (fig. 4.12B) there was no significant effect on HSA catalysed 
coelenterazine chemiluminescence.  
 
 
 
 
Figure 4.12. The inhibition of human serum albumin (HSA) catalysed 
coelenterazine chemiluminescence by ibuprofen. The machine background 
produced an average of 26 counts.s
-1
 whereas the coelenterazine chemiluminescence 
produced averages of between 65 and 78 counts.s
-1
. The effect of ibuprofen on HSA 
catalysed coelenterazine chemiluminescence was measured by adding 10 μl of 
albumin (0.1 % (w/v); 1 g.l
-1
 final concentration) to 90 μl of buffer containing 50 mM 
HEPES buffer, pH 7.4, 10 μM coelenterazine and 10
-6
 – 10
-3
 M ibuprofen. Results 
represent the mean +/- SEM of six determinations. 
 
From the data presented in sections 4.3.1.1 and 4.3.1.2 it can be concluded 
that the coelenterazine binding site is Sudlow’s site I on HSA since only drugs 
that were able to bind to this site inhibited HSA catalysed coelenterazine 
chemiluminescence.  
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4.3.2. The mixed enzyme kinetics of albumin 
Michaelis-Menten kinetics is the most common model used to demonstrate 
single substrate enzyme kinetics. The Michaelis-Menten equation describes 
the rate of an enzymatic reaction by linking the reaction rate (v) with the 
substrate concentration [S]. The maximum rate produced by the reaction in 
the presence of the maximum substrate concentration is known as Vmax, 
whereas the Michaelis constant (Km) is the substrate concentration when the 
reaction rate is half that of the Vmax. The Km is an inverse measure of the 
substrates binding affinity for the enzyme.  
 
 
 
Fig 4.13. The competitive binding properties of warfarin on human serum 
albumin (HSA) catalysed coelenterazine chemiluminescence. 10 μl of albumin 
(0.1 % (w/v) final concentration) was added to buffer containing 50 mM HEPES buffer, 
pH 7.4, coelenterazine (1 – 20 μM final concentration) and warfarin (0.03, 0.1 or 0.3 
mM). Results represent the mean +/- SEM of three determinations.  
 
A small Km suggests that the substrate has a high affinity for the enzyme 
resulting in the rate reaching Vmax quickly whereas a high Km suggests that the 
substrate has a low affinity for the enzyme resulting in the rate reaching Vmax 
slowly.  
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As the rate of catalysis of an enzymatic reaction in the presence of increasing 
substrate concentration is not linear it is difficult to accurately estimate values 
for Km and Vmax. A linearization of the Michaelis-Menten equation known as a 
Lineweaver-Burk plot has been developed and is commonly used for the 
illustration of kinetic data. Lineweaver-Burk plots can be used to estimate 
values for Km and Vmax as well as the type of enzyme inhibition. The x- and y-
intercepts on these plots represent -1/Km and 1/Vmax, respectively. The 
inhibition observed in the presence of warfarin exhibited mixed enzyme 
kinetics because the inhibitors had different x- and y-intercepts (fig. 4.13). This 
inhibition was consistent with the warfarin reducing both the binding and 
catalytic activity of the HSA. 
4.3.3. Molecular 3D modelling used to identify the coelenterazine binding 
site 
Coelenterazine chemiluminescence predicted that Sudlow’s site I on HSA is 
also the coelenterazine binding site. Molecular 3D modelling was carried out 
to confirm this prediction. Using this method, it was possible to identify both of 
Sudlow’s drug binding sites on HSA (fig. 4.14). The images that follow show 
the binding of coelenterazine at Sudlow’s site I (fig. 4.14A) and at Sudlow’s 
site II (fig. 4.14B). Warfarin (green) and diazepam (red) were also included at 
their respective sites for comparison. 
The results show that coelenterazine was able to fit “snugly” into Sudlow’s site 
I (fig. 4.14A) but when it was inserted into Sudlow’s site II it formed 
interactions with the surface of the protein (fig. 4.14B). Therefore molecular 3D 
modelling confirmed that Sudlow’s site I as the preferred binding site for 
coelenterazine and identified five important amino acid residues - Tyr150, 
Lys195, Arg222, His242 and Arg257 (fig. 4.14A).  
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Figure 4.14. Molecular 3D modelling showing coelenterazine binding to both 
Sudlow’s site I and Sudlow’s site II on human serum albumin (HSA). A) shows 
Sudlow’s site I and the important amino acid residues (Tyr150, Lys195, Arg222, 
His242 and Arg257) for the binding of coelenterazine (orange). Warfarin (green) was 
included for comparison. B) shows the binding of coelenterazine (blue) to Sudlow’s 
site II. Diazepam (red) was included for comparison. 
 
4.3.4. The inhibition of albumin and insulin catalysed coelenterazine 
chemiluminescence by methylglyoxal  
In order to test the ability of covalently modified HSA and human insulin to 
catalyse coelenterazine chemiluminescence, the proteins were incubated with 
10 mM MeG for 1 week. The normal and modified protein catalysed 
coelenterazine chemiluminescences were compared. The incubation of 
albumin and human insulin (fig. 4.15B) with MeG significantly inhibited 
chemiluminescence by approximately 50 %.  
 
 
 
 
 
 
 
A. B. 
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Figure 4.15. The inhibition of protein catalysed coelenterazine 
chemiluminescence by methylglyoxal (MeG). 1 ml of albumin and insulin (1 % 
(w/v)) were incubated with MeG (10 mM) and without MeG for 1 week at room 
temperature. Solutions were dialysed for 24 hours in 500 ml sodium-phosphate buffer, 
pH 8.3 to remove the toxin. A) Compares normal and modified HSA catalysed 
coelenterazine chemiluminescence. The machine background produced an average of 
25 counts.s
-1
. The coelenterazine chemiluminescence prior to the addition of the 
proteins averaged  between 52 and 58 counts.s
-1
 for normal HSA and 49 and 56 
counts.s
-1
 for modified HSA; B) Compares normal and modified human insulin 
catalysed coelenterazine chemiluminescence. The machine background produced an 
average of 28 counts.s
-1
. The coelenterazine chemiluminescences prior to the addition 
of the proteins averaged between 80 and 115 counts.s
-1
 for normal human insulin and 
67 and 73 counts.s
-1
 for modified human insulin. Results represent the mean +/- SEM 
of three determinations. Asterisks represent significant difference where p < 0.01 
when compared with the same concentration of normal protein. 
 
4.3.5. The increased albumin and insulin catalysed coelenterazine 
chemiluminescence by hydrogen peroxide 
The proteins were also incubated with hydrogen peroxide, H2O2 (10 mM) for 1 
week. The abilities of the normal and covalently modified proteins at catalysing 
coelenterazine chemiluminescence were investigated. Interestingly, the 
incubation of HSA and human insulin with H2O2 significantly enhanced 
chemiluminescence.  
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Following incubation with H2O2, the HSA catalysed coelenterazine 
chemiluminescence increased by 5-fold (fig. 4.16A) and human insulin 
catalysed coelenterazine chemiluminescence increased by approximately 2.5-
fold (fig. 4.16B) with the addition of 0.5 % (w/v) protein.  
 
 
 
Figure 4.16. The inhibition of protein catalysed coelenterazine 
chemiluminescence by hydrogen peroxide (H2O2). 1 ml of albumin and insulin (1 % 
(w/v)) were incubated with H2O2 (10 mM) and without H2O2 for 1 week at room 
temperature. Solutions were dialysed for 24 hours in 500 ml sodium-phosphate buffer, 
pH 8.3 to remove the toxin. A) Compares normal and modified HSA catalysed 
coelenterazine chemiluminescence. The machine background produced an average of 
22 counts.s
-1
. The coelenterazine chemiluminescences prior to the addition of the 
proteins were between 52 and 58 counts.s
-1
 for normal HSA and 65 and 79 counts.s
-1
 
for modified HSA; B) Compares normal and modified human insulin catalysed 
coelenterazine chemiluminescence. The machine background produced an average of 
25 counts.s
-1
. The coelenterazine chemiluminescences prior to the addition of the 
proteins were between 80 and 115 counts.s
-1
 for normal human insulin and 68 and 77 
counts.s
-1
 for modified human insulin. Results represent the mean +/- SEM of three 
determinations. Asterisks indicates significant difference where p < 0.01 when 
compared to 0.5 % (w/v) normal HSA and human insulin.  
 
4.4. Discussion and conclusions 
This chapter has predicted that coelenterazine must bind to Sudlow’s site I, 
since only drugs that were able to bind to this site significantly inhibited (p < 
0.001) the HSA chemiluminescence (fig. 4.6 – fig. 4.9).  
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The inhibition demonstrated by warfarin suggested mixed inhibition enzyme 
kinetics (fig. 4.13) which was consistent with reduced ligand binding and 
reduced catalysis. Molecular 3D modelling was used and confirmed Sudlow’s 
site I as the coelenterazine binding site (fig. 4.14). It was also demonstrated in 
this chapter that albumin and insulin were covalently modified after incubation 
with either MeG or H2O2. However, the covalent modification of albumin by 
MeG significantly inhibited protein catalysed chemiluminescence (p < 0.01; fig. 
4.15A) whereas the covalent modification of these proteins by H2O2 
significantly enhanced protein catalysed coelenterazine chemiluminescence (p 
< 0.01; fig. 4.16).  
Drugs that are known to bind to Sudlow’s site I (e.g. warfarin, furosemide, 
indomethacin and tolbutamide) significantly inhibited HSA catalysed 
coelenterazine chemiluminescence. The maximum inhibition of HSA catalysed 
coelenterazine chemiluminescence by warfarin (10-6 to 10-3 M, Kd = 2.9 x 10
-6 
M), furosemide (10-6 to 10-3 M, Kd = 5.3 x 10
-6 M), indomethacin (10-6 to 10-2 M, 
Kd = 7.1 x 10
-7 M) and tolbutamide (10-6 to 10-2 M, Kd = 2.5 x 10
-5 M) was 50 %, 
60 %, > 95 % and > 90 %, respectively, in the presence of 10 μM 
coelenterazine (fig. 4.6 – fig. 4.9). Thus, these drugs can now be ranked in 
order of maximum inhibition of HSA catalysed coelenterazine 
chemiluminescence: indomethacin > tolbutamide > furosemide > warfarin.  
The data suggested that coelenterazine binds to Sudlow’s site I and therefore 
competition is expected to exist between the drug and coelenterazine but the 
compound with the highest affinity will displace the other (Rahman et al., 
2005). The concentration of each of the compounds will determine which will 
become bound to HSA. If the concentration of the drug is lower than the 
coelenterazine concentration (<10-5 M), more substrate is present and 
therefore coelenterazine will bind to HSA hence why there was no significant 
change in HSA catalysed coelenterazine chemiluminescence. When the 
concentration of the drug reached the same concentration as that of 
coelenterazine, the compound with the highest affinity for HSA will bind to the 
site. As the concentration of the drug increases above that of coelenterazine, 
more drug is present and able to bind, thus preventing coelenterazine from 
binding and hence why a decrease in chemiluminescence was observed. The 
addition of the site II drug, diazepam, significantly inhibited HSA catalysed 
coelenterazine chemiluminescence (p < 0.001; fig. 4.10).  
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The maximum inhibition of HSA catalysed coelenterazine chemiluminescence 
by diazepam was 20 %. However, the addition of increasing concentrations of 
the other site II drugs, phenytoin and ibuprofen (fig. 4.11 and fig. 4.12) did not 
affect HSA catalysed coelenterazine chemiluminescence. This helps to 
explain why Sudlow’s site I was predicted to be the coelenterazine binding 
site.  
Table 4.1 lists the Ka values for drugs that are known to bind with high affinity 
to site I or site II on HSA. The Ka of a drug describes the binding affinity 
between two molecules at equilibrium whereas the dissociation constant (Kd) 
is the inverse of the Ka (Kd = 1/Ka) and can therefore be determined (Table 
4.2). The Kd describes the ability of a large compound to dissociate reversibly 
into smaller components at equilibrium. When a ligand (i.e. drug) binds to a 
protein, the Kd is used to describe the binding affinity of the ligand to the 
protein. The binding affinities are influenced by non-covalent intermolecular 
interactions between the ligand and the protein, such as hydrogen bonding, 
electrostatic interactions, hydrophobic and Van der Waals.  
 
Drug Association constant  
(Ka) (M
-1
) 
Dissociation constant 
(Kd) (M) 
Warfarin 3.4 x 10
5
 2.9 x 10
-6
 
Furosemide 1.9 x 10
5
 5.3 x 10
-6
 
Indomethacin 1.4 x 10
6
 7.1 x 10
-7
 
Tolbutamide 4.0 x 10
4
 2.5 x 10
-5
 
Diazepam 3.8 x 10
5
 2.6 x 10
-6
 
Phenytoin 1.7 x 10
4
 5.9 x 10
-5
 
Ibuprofen 2.7 x 10
6
 3.7 x 10
-7
 
Glibenclamide 3.6 x 10
4
 2.8 x 10
-5
 
 
Table 4.2. The association (Ka) and dissociation (Kd) constants of drugs that are 
known to bind with high affinity to HSA (Kragh-Hansen et al., 2002, Kober et al., 
1980). 
The Kd values of the drugs used in this chapter will determine how tightly each 
of the drugs will bind to the protein. If a drug has a low Kd, that particular drug 
is able to bind to the protein with high affinity and vice versa. Taking this into 
account, drugs that bind with a high affinity will require relatively low 
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concentrations for maximum occupancy of the protein binding site and drugs 
that bind with a low affinity will require higher concentrations for maximum 
occupancy of the protein binding site. Warfarin has a Kd of 2.9 x 10
-6 M and is 
known to have a high affinity for HSA. However, tolbutamide and furosemide 
have higher Kd values of 2.5 x 10
-5 M and 5.3 x 10-6 M, respectively, when 
compared to that of warfarin. Both tolbutamide and furosemide have lower 
binding affinities than warfarin for site I, thus for maximum occupancy of the 
binding site, higher concentrations of both of these drugs would be required. 
The Kd for indomethacin, was lower than that of warfarin (7.1 x 10
-7 M) and it 
has a higher affinity for the binding site thus requiring lower concentrations for 
maximum occupancy of the binding site.  
The inhibition of HSA catalysed coelenterazine chemiluminescence observed 
in the presence of drugs that bind to Sudlow’s site I was not consistent with 
the known Kd values. The IC50 values for the site I drugs used were much 
higher than the Kd for the drugs (i.e. warfarin: Kd = 2.9 x 10
-6 M; IC50 ~ 10
-4 M 
(fig. 4.6)). The IC50 values for all site I inhibitors were very similar and hence 
much higher (~ 10-4 M) than their respective Kd values. The IC50 values of 
these drugs may be high for all site I inhibitors due to the high concentrations 
of HSA used (10-4 M). Drugs that bind to Sudlow’s site II (e.g. diazepam, 
phenytoin and ibuprofen) did not have a significant effect on HSA catalysed 
coelenterazine chemiluminescence (fig. 4.10 – fig. 4.12). From this 
information, it can be concluded that coelenterazine must bind to Sudlow’s site 
I, as site I and not site II drugs inhibited HSA catalysed coelenterazine 
chemiluminescence. 
Ligand binding experiments were used to investigate the high affinity binding 
of drugs to the protein (Kragh-Hansen, 1991). Binding may occur competitively 
to one site (Brodersen et al., 1977) and it was therefore necessary to 
investigate the binding properties of warfarin and coelenterazine on albumin 
catalysed coelenterazine chemiluminescence. Unbound warfarin has weak 
fluorescence, however when it binds to HSA, the fluorescence is enhanced. If 
a second ligand is present (i.e. coelenterazine), there is a decrease in 
fluorescence as both ligands will compete for the same site (Sahoo et al., 
2008).  
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In the experiment used to determine the type of enzyme inhibition, the 
concentration of HSA was similar to or higher than the coelenterazine 
concentration, thus a key condition for the Michaelis-Menten equation is that 
the enzyme does not significantly reduce the substrate concentration, 
therefore to a first approximation the equation may not hold. This is why the 
results state that the approximate Km was 20 μM as it was not possible to do a 
precise Lineweaver-Burk plot.  
Molecular 3D modelling is widely used throughout the pharmaceutical industry 
to create new drugs and to help understand the molecular interactions that 
occur in protein-ligand binding. Molecular 3D modelling was used to 
confirm/predict the coelenterazine binding site. This method demonstrated the 
importance of Sudlow’s site I as the major catalytic site on HSA (fig. 4.14A and 
fig. 4.14B) therefore confirming this site as the coelenterazine binding site. 
Figure 4.14A shows that coelenterazine fits “snugly” into site I, where warfarin 
is also capable of binding, but when it was placed in the pocket containing site 
II, it did not fit comfortably and resulted in interactions with the surface of the 
protein.  
 
 
Figure 4.17. The binding of coelenterazine and warfarin to Sudlow’s site I on 
HSA demonstrated using molecular 3D modelling. Structures: grey = 
coelenterazine and green = warfarin. 
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Warfarin and coelenterazine fit “snugly” between the apolar side-chains of 
Leu238 on the floor of the pocket and Ala291 on the roof of the pocket. The 
Trp214 residue is found in the hydrophobic part of the binding pocket and is 
an important part of the drug binding site. The Trp214 residue can interact 
hydrophobically with the non-polar part of the warfarin molecule (Petitpas et 
al., 2001, Ascenzi and Fasano, 2010, Watanabe et al., 2001). 
It can be seen in figure 4.17 that a number of hydrogen bonds are formed 
between the protein and coelenterazine. A hydrogen bond was formed 
between the side chain of Arg257 and the carboxyl group of coelenterazine 
and another hydrogen bond was formed between the side chain of Lys195 
and the hydroxyl group of coelenterazine. A hydrogen bond was also formed 
between the side chain of His242 and a nitrogen atom belonging to 
coelenterazine. The His242 side chain is known as a tautomer as it contains 
two nitrogen atoms on a benzyl ring that have the potential to readily 
interconvert via a process known as tautomerisation. This reaction causes the 
migration of the hydrogen atom that formed the hydrogen bond with the 
nitrogen atom of coelenterazine to the second nitrogen atom on the benzyl 
ring. The migration of the hydrogen atom to this position then has the potential 
of forming a hydrogen bond with the product of the coelenterazine 
chemiluminescence reaction, coelenteramide. This may be an important step 
in catalysing the coelenterazine chemiluminescence reaction. All compounds 
that bind to this site are positioned so that they form a hydrogen bond with the 
hydroxyl group of the Tyr150 residue thus this residue is considered to be 
important for drug binding (Ascenzi and Fasano, 2010).  The drug binding site 
is split into two sub-chambers and these sub-chambers accommodate 
different portions of the drug structure. For example, the coumarin and benzyl 
parts of the warfarin structure fit into different but adjacent chambers in what is 
known as a “sock-shaped” pocket. The main chamber, located furthest away 
from the entrance of the pocket, holds the coumarin ring. The back end of the 
coumarin ring makes contact with Ile264, Ile290 as well as with the aliphatic 
portions of Arg257 and Ser287. The benzyl group of the warfarin structure 
binds to the sub-chamber that is made up of the Phe211, Trp214, Leu219 and 
Leu238 residues as well as making contact with the aliphatic portions of 
Arg218 and His242 (Petitpas et al., 2001). Also, the acetonyl group that 
branches from the chrial carbon can be found at the entrance of the pocket. 
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Arg218 is located at the entrance of the binding pocket and it contributes 
positively to the binding of warfarin (Watanabe et al., 2001).  
Residues Lys199 and His242 are placed close to each other at the opening of 
the binding site. Mutations at either of these residues, increases drug binding 
significantly. However, when both of these residues are present, they can 
prevent warfarin from accessing the binding pocket (Watanabe et al., 2001). 
Molecular 3D modelling also highlighted five basic amino acid residues – 
Tyr150, Lys195, Arg222, His242 and Arg257 (fig. 4.14A). These residues fit 
with and support the pH profile of HSA shown in Chapter 3 (fig. 3.11) where 
an increase in chemiluminescence at alkaline pH was consistent with at least 
one basic amino acid being involved in coelenterazine binding and/or 
catalysis. Interestingly, similar basic amino acid residues have been found in 
the coelenterazine binding site of aequorin and obelin. Obelin is a calcium-
regulated single subunit photoprotein with a molecular weight of approximately 
22 kDa. Once calcium binds, the coelenterazine-oxygen complex undergoes 
oxidative decarboxylation resulting in light emission. Obelin is composed of 8 
helices. These helices are known as helices A – H and each helix is 
composed of varying numbers of amino acid residues. The 8 helices are 
divided into two groups of 4. Helices A (residues 16-29), B (residues 39-54), C 
(residues 58 – 74) and D (residues 85-105) make up one group and are found 
in the N-terminal domain whereas helices E (residues 110-112), F (residues 
132-142), G (residues 148-157) and H (residues 168-180) make up a second 
group and are found in the C-terminal domain. Both the N-terminal and the C-
terminal can form a “cup” and the two can link together to form the overall 
structure of obelin. The inside of these “cups” are lined with hydrophobic 
residues. As with Sudlow’s site I on HSA, the coelenterazine-oxygen complex 
can fit comfortably in the pocket surrounded by the hydrophobic residues of 
the helices (Liu et al., 2000). A number of residues from the 8 helices can 
contribute to the highly hydrophobic pocket in which the coelenterazine-
oxygen complex fits. These residues include the Met25, Leu29, Ile42, Ala46, 
Ile50, Phe72, Phe88, Trp92, Ile111, Trp114, Val118, Phe199, Trp135, Ile144, 
Met171 and Trp179. This structure of the coelenterazine-oxygen binding 
pocket has not only been found in obelin, but other photoproteins such as 
aequorin are also thought to have the same binding pockets (Liu et al., 2000). 
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It can be seen that obelin contains a number of Trp residues and these can 
interact closely with the coelenterazine-oxygen complex. For example, the 
side chains of the Trp92 and Trp179 residues are above and below the 
hydroxyphenyl ring of coelenterazine whereas the side chains of the Trp114 
and Trp135 residues can be found near the hydroxyl-benzyl group of 
coelenterazine (Liu et al., 2000). The presence of a Trp residue at position 86 
in aequorin may play an important role in the production of the excited state 
product during the bioluminescence reaction.  
Two His residues can be found at positions 22 and 175 in obelin and may play 
a role in the binding of oxygen to coelenterazine due to their close location to 
the coelenterazine-oxygen complex. Therefore any mutations at these two His 
residues may alter the bioluminescence. These photoproteins contain 
between 3 and 5 Cys residues and at least one of these may contribute to light 
emission. Obelin also contains two Tyr residues at positions 138 and 190 and 
these surround the coelenterazine-oxygen complex and can form strong 
hydrogen bonds with the complex. The Pro residue found at the C-terminal is 
crucial for light emission. This Pro residue acts as a “clip” to hold the 
coelenterazine in place and it has been shown that the removal of this 
particular residue will completely inhibit the ability of the photoprotein to emit 
light (Liu et al., 2000, Vassel et al., 2012).Therefore, of all the amino acid 
residues found in the photoproteins, the Trp, His, Cys as well as the C-
terminal Pro are considered to be important for light emission. From this, it can 
be concluded that the active site located in the pocket of these photoproteins 
is highly hydrophobic and consists of a trio of amino acid residues including 
Trp, Tyr and His. Of these, one is responsible for the catalysis of the reaction 
and the other two are responsible for the binding of the coelenterazine-oxygen 
complex to the photoprotein (Woo et al., 2008).  
Renilla luciferase can also catalyse the bioluminescence reaction. This 
luciferase also has a large hydrophobic binding pocket to which 
coelenterazine can bind. The active site in this binding pocket also consists of 
a trio of amino acid residues and these include Asp120, Glu144 and His285. 
Of these three amino acid residues, His285 is responsible for the catalysis 
whereas both Asp120 and Glu144 are responsible for the binding of 
coelenterazine (Woo and Von Arnim, 2008). 
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The covalent modification of HSA by MeG significantly inhibited protein 
catalysed coelenterazine chemiluminescence by approximately 50 % (fig. 
4.15A). The covalent modification of insulin also resulted in the inhibition of 
protein catalysed coelenterazine chemiluminescence but not to the same 
extent as that seen with albumin (fig. 4.15B). Interestingly, the covalent 
modification of 0.5 % (w/v) albumin (fig. 4.16A) and insulin (fig. 4.16B) by H2O2 
significantly enhanced coelenterazine chemiluminescence by approximately 5- 
and 2.5-fold, respectively.  
The conditions used to covalently modify both HSA and insulin in vitro varied 
significantly when compared to the conditions the same proteins are exposed 
to in vivo. The albumin concentration used in vitro (10 mg/ml) was 
approximately 5-fold lower than the concentration of albumin found in vivo (50 
mg/ml). The concentration of insulin in vitro (10 mg/ml) exceeds both the 
normal and pathophysiological ranges in vivo (Jia et al., 2006). The 
concentration of MeG (10 mM) used in vitro was significantly higher than the 
concentrations found in healthy individuals and was also higher than the 
reported elevated concentrations observed in patients with either type of 
diabetes. However, to determine the interaction of MeG with insulin in vitro, 
higher concentrations of MeG are required (Jia et al., 2006). The proteins 
were incubated with MeG for one week but it has been shown by Jia et al 
(2006) that insulin appeared modified after 24 hours in the presence of much 
lower concentrations of the toxin.  
The incubation of both albumin and insulin with MeG (fig. 4.15A and fig. 
4.15B) for one week at room temperature resulted in the covalent modification 
of the proteins. It is know that arginine residues are the preferred target for 
MeG irreversible modification (Gao and Wang, 2006) and results in the 
formation of MG-H residues (Lo et al., 1994, Thornalley, 2008). The 
modification of albumin by MeG resulted in high quantities of MG-H1 adduct 
formation at residues Arg114, Arg186, Arg218, Arg410 and Arg428. Both 
Arg114 and Arg186 have high surface exposure, whereas Arg218, Arg410 
and Arg428 have low surface exposure and are also modified. There are also 
arginine residues at positions 81 and 209 with high surface exposure but 
these are not modified by MeG. Therefore, MeG modification only occurs at 
the residues that are exposed to the solvent (Gao and Wang, 2006). 
Depending on how accessible the arginine residues are on HSA to the toxin 
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will determine which of these residues will be modified. Residues Arg218 and 
Arg410 found in the binding pockets of drug sites I and II, respectively, are 
accessible to drugs and fatty acids, this indicates that these sites are also 
capable of binding other small molecules such as MeG and are therefore 
susceptible to modification. The modification of arginine residues by MeG 
leading to the formation of hydroimidazolones results in the subsequent loss of 
the positively charged arginine side chains as well as causing a change in the 
protein structure. These features are important for ligand binding, positioning 
of the substrate as well as stabilisation.  
The majority of AGEs in the plasma of diabetic and non-diabetic patients are 
hydroimidazolones (Turk, 2010). The Tyr411 residues also located in the 
binding pocket containing Sudlow’s site II can also be modified by MeG and 
forms an initial hemiacetal linkage that attaches this residue to the 
neighbouring Arg10 residues.  
The B-chain of the insulin molecule also contains an arginine and lysine 
residue at positions 22 and 29, respectively. In the presence of elevated MeG 
concentrations as observed in diabetic patients, MeG will react with these 
residues resulting in the formation of irreversible AGEs (Turk, 2010).  
The data in this chapter has identified Sudlow’s site I as the coelenterazine 
binding site, and has also shown how the production of bacterial metabolic 
toxins as a result of carbohydrate metabolism can lead to the covalent 
modification of proteins such as insulin, thus altering their biological activity. 
Alterations in the biological activity of insulin can lead to insulin resistance and 
eventually type 2 diabetes (Lo et al., 1994, Jia and Wu, 2007). Therefore, the 
coelenterazine chemiluminescence technique has the potential to be 
developed into a clinical test and can be used in the pharmaceutical industry 
to investigate the pharmacokinetics of new drugs prior to their release on to 
the market.  
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5.1. Introduction 
Insulin has a number of roles in the human body where it is responsible for 
regulating carbohydrate and fat metabolism. Methylglyoxal has been predicted 
to alter the structure and function of insulin. This aim of this chapter was to 
determine the effect of MeG on insulin action by investigating the effect of the 
toxin on glucose uptake and 3T3-L1 cell adipogenesis.  
5.1.1. Glucose homeostasis 
For cells to survive they need a stable environment. The process in which 
living organisms maintain this stable environment is known as homeostasis. 
This process ensures that the temperature, pH, ions and water balance of any 
living organism remains constant. If there are any environmental changes, 
cells are programmed to release molecules (e.g. hormones) so that the stable 
environment is maintained. This is known as negative feedback. For example, 
this negative feedback mechanism is the mechanism in which the body 
maintains normal glucose levels circulating in the blood via the release of 
hormones such as glucagon and insulin. This process is known as glucose 
homeostasis. 
Cells use glucose as their main source of energy and levels of the sugar in the 
blood can vary due to a number of reasons. Elevated glucose concentrations 
occur after a meal and decreased glucose concentrations can occur as a 
result of glucose uptake by insulin-sensitive tissues. It is vital that the 
concentration of glucose in the blood stream is maintained well. If the blood 
glucose concentrations increase and are not controlled this can be toxic to the 
cells whereas if the blood glucose concentrations decrease and are not within 
the normal range this can result in starvation. Therefore, to ensure that blood 
glucose levels stay within the normal range the pancreas produces two 
important hormones: 
 Glucagon is a catabolic hormone that is produced by the α-cells of the 
islets of Langerhans and is responsible for increasing blood glucose 
levels at times of starvation 
 Insulin is an anabolic hormone that is produced by the β-cells of the 
islets of Langerhans and is responsible for decreasing blood glucose 
levels back within the normal range 
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5.1.2. Decreased blood glucose levels and the role of glucagon 
Hypoglycaemia is the term used to describe reduced blood glucose 
concentrations. Blood glucose levels can fall below the normal range during 
exercise or during periods of fasting. Once this decrease in blood glucose 
concentration has been detected the α-cells of the islets of Langerhans 
release glucagon whilst inhibiting the release of insulin from the β-cells of the 
islets of Langerhans. The release of insulin is inhibited as any further release 
of the hormone would further reduce blood glucose levels. Both the liver and 
skeletal muscle store glucose in the form of glycogen. Glucagon stimulates the 
breakdown of glycogen in the hepatocytes of the liver via a process known as 
glycogenolysis. Once glycogen has been broken down, glucose is released 
into the blood stream through the GLUT2 transporter by facilitated diffusion 
ready for the uptake by other cells. Glucagon is also responsible for 
stimulating the breakdown of lipids stored in adipose tissue into fatty acids and 
glycerol. The fatty acids and glycerol are released into the bloodstream where 
other cells are able to use these for energy. The glycerol released into the 
blood as a result of lipolysis can be converted into glucose in the liver by 
glucagon. At times when glucose levels in the blood are low, glucose can be 
released into the blood from non-carbohydrate precursors such as amino 
acids via a process known as gluconeogenesis. These processes result in the 
release of glucose into the blood and help maintain normoglycaemia thus 
preventing hypoglycaemia.  
5.1.3. Increased blood glucose and the role of insulin 
Hyperglycaemia is the term used to describe elevated blood glucose 
concentrations. Blood glucose levels can increase above the normal range 
after a meal has been consumed. As a result of increased glucose levels, the 
glucose transporters, located on the surface on the β-cells of the islets of 
Langerhans detect this increase and as a result they release insulin. Insulin is 
important for reducing blood glucose levels by: 
 Stimulating glucose uptake into insulin-sensitive tissues (e.g. adipose 
tissue and skeletal muscle) 
 Stimulating the conversion of glucose to glycogen ready for storage in 
the liver until it is required 
 Stimulating the conversion of glucose into lipids when the liver is no 
longer able to store glucose as glycogen 
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 Stimulating protein synthesis 
5.1.3.1. Glucose transporters and glucose uptake by insulin-sensitive 
tissues 
Glucose is mainly consumed through the diet. Once it reaches the small 
intestine it is ready to be transported in the blood until it reaches its target cell 
(Wood and Trayhurn, 2003). The majority of mammalian cells are able to 
transport glucose across the plasma membrane and occurs via specific 
transport proteins (Miki et al., 2002). These specific transport proteins can be 
divided into two groups with different structures and functions (Wood and 
Trayhurn, 2003). 
The Na+-dependent glucose cotransporters (SGLTs) 
This family of transporters transport glucose (as well as galactose) via a 
secondary active transport mechanism. The Na+-K+ ATPase pump generates 
a Na+-electrochemical gradient, therefore for glucose transport into the cell, 
glucose must travel against the concentration gradient. This type of transport 
mainly occurs across the luminal membrane of cells that line the small 
intestine and in the cells found in the proximal tubules of the kidneys (Wood 
and Trayhurn, 2003). 
The facilitative glucose transporters (GLUTs) 
The facilitative glucose transporters are a large family of transporters that are 
found in mammals. These transporters form an aqueous pore across the 
plasma membrane therefore allowing glucose to flow freely into the cell. This 
family of transporters are proteins consisting of 12-transmembrane spanning 
domains (fig. 5.1). Individual transporters have different tissue distributions, 
different kinetic properties and different sugar specificities (Bryant et al., 2002, 
Khan and Pessin, 2002). 
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Figure 5.1. The structure of the facilitative glucose transporters (GLUTs) (Gould 
and Holman, 1993). 
 
The 12-transmembrane spanning domains are arranged so that the N- and C-
terminals are at the cytoplasmic surface. Two large loops can be found 
between helices 1 and 2 and helices 6 and 7, however, the large loop between 
helices 6 and 7 splits the structure in half. One half of the structure contains 
the N-terminal domain and the other contains the C-terminal domain. The 
loops linking the other helices are very short since they are made up of 8 
residues and this is a common feature of this family (Gould and Holman, 
1993).  
Thirteen members of this family, GLUTs 1-12 and the H+-coupled myo-inositol 
transporter (HMIT), have been identified. These transporters are responsible 
for the transport of glucose down its concentration gradient without the need 
for energy (Watson et al., 2004). The identified members have been divided 
into three classes: 
 Class I facilitative glucose transporters 
o This group of transporters is made up of GLUTs 1-4. These 
GLUTs are the most widely characterised in regards to their 
structure, function and tissue distribution (Wood and Trayhurn, 
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2003). The first member of this class to be identified was 
GLUT1, it is has a wide distribution and is found in the brain 
and erythrocytes as well as having moderate levels in 
adipocytes, myocytes and hepatocytes (Khan and Pessin, 
2002, Olson and Pessin, 1996, Gould and Holman, 1993). The 
GLUT2 transporter is highly expressed in the β-cells of the 
pancreas as well as in the liver and kidneys. This transporter 
has a low affinity (high Km) for glucose. In the α- and β-cells of 
the pancreas, GLUT2 has been predicted to have a role in the 
glucose sensing mechanism (Khan and Pessin, 2002, Wood 
and Trayhurn, 2003). GLUT2 transporters can also be found on 
the sinusoidal membrane of the liver cells and are responsible 
for the transport of glucose in and out of the cells. In contrast to 
GLUT2, GLUT3 has a high affinity (low Km) for glucose and can 
be found in tissues where there is a need for glucose as a fuel 
(e.g. the brain) (Khan and Pessin, 2002). GLUT4 is also known 
as the insulin-sensitive glucose transporter and is found in 
cardiac myocytes, adipocytes and skeletal myocytes. GLUT4 
transporters have also been identified in the brain (Wood and 
Trayhurn, 2003). The mechanism in which insulin stimulates 
glucose uptake into the insulin-sensitive tissues via this 
transporter follows below. 
 Class II facilitative glucose transporters 
o This group of transporters comprises GLUT5, GLUT7, GLUT9 
and GLUT11. GLUT5 is the fructose-specific transporter and 
can be located in the small intestine, testes and kidneys. 
However, GLUT7 and GLUT9 have not been functionally 
characterised. GLUT7 expression is unknown whereas GLUT9 
is expressed in the liver and kidneys (Wood and Trayhurn, 
2003, Watson et al., 2004). 
 Class III facilitative glucose transporters 
o This group of transporters comprises GLUT6, GLUT8, GLUT10, 
GLUT12 and HMIT (Wood and Trayhurn, 2003). The GLUT6 
transporter is a pseudogene that is not expressed at the protein 
level (Mueckler, 1994). The GLUT8 transporter is expressed in 
the testes, brain as well as in adipocytes. GLUT10 can be 
found in insulin-sensitive tissues (e.g. skeletal and cardiac 
Chapter 5: The effect of methylglyoxal on insulin action 
 
145 
 
myocytes) as well as being expressed in the liver and 
pancreas. GLUT12 can be found in the small intestine, prostate 
as well as in adipocytes and in cardiac and skeletal myocytes. 
The HMIT transporter can be found in the brain (Wood and 
Trayhurn, 2003, Watson et al., 2004).  
The GLUT4 transporter and its role in insulin-stimulated glucose uptake 
Insulin enables glucose to pass through the insulin-sensitive glucose 
transporter, GLUT4, into the cells of muscle (striated and cardiac) and adipose 
tissue via facilitated diffusion. In the presence of low concentrations of insulin, 
GLUT4 transporters are found packed into storage vesicles in the cytoplasm 
of the cell. When in the storage vesicles, the GLUT4 transporters are not able 
to transport glucose. In contrast, when the glucose transporters on the surface 
of the pancreatic β-cells detect an increase in glucose levels, insulin is 
released. Insulin then binds to its receptor and the storage vesicles containing 
the GLUT4 transporters move from the cytoplasm to the plasma membrane. 
This is known as GLUT4 translocation. The storage vesicles then fuse with the 
plasma membrane thus enabling glucose to enter the cell. Once the glucose 
levels decrease and are back within the normal range, the receptors are no 
longer occupied by insulin and the GLUT4 transporters are recycled back into 
the cytoplasm in the storage vesicles (Watson and Pessin, 2001, Bryant et al., 
2002, Watson et al., 2004). 
5.1.3.2. Insulin stimulates glycogenesis 
At times when blood glucose concentrations are raised, insulin promotes the 
addition of glucose molecules to glycogen in the liver ready for storage. This 
process is known as glycogenesis. 
5.1.3.3. Insulin stimulates lipogenesis and inhibits lipolysis 
When the liver can no longer store the glucose that has been converted to 
glycogen the glucose is converted into lipids and stored in adipose tissue until 
it is required when blood glucose levels fall. This process is known as 
lipogenesis. Insulin also prevents the breakdown of lipids (lipolysis) that are 
stored in adipose tissue into fatty acids and glycerol (Kahn and Flier, 2000). 
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5.1.4. The role of insulin in cell differentiation 
3T3-L1 cells were first isolated by Green and Kehinde and when confluent 
they are capable of differentiating into adipocytes (Chang and Polakis, 1978). 
This differentiation is also known as adipogenesis and involves the conversion 
of the 3T3-L1 cells from their undifferentiated fibroblast-like preadipocyte form 
into adipocytes that are round in shape and are filled with triglycerides as well 
as expressing adipose-associated genes (Reed et al., 1977, Hausman et al., 
2001, Reusch et al., 2000). The induction of adipogenesis depends on the cell 
culture model used due to their ability to respond to certain agents (Gregoire, 
2001). When the 3T3-L1 cells were maintained in cell culture medium 
supplemented with foetal calf serum (FCS) they can spontaneously 
differentiate into adipocytes over a number of weeks. However, these cells will 
not express the adipocyte phenotype until confluency has been reached and 
cell division has stopped (Gregoire et al., 1998, Reed et al., 1977). The 
expression of the adipocyte phenotype by these cells at confluency can be 
controlled by specific agents or hormones that are known to have an effect on 
lipogenesis or lipolysis (Reed et al., 1977). The standard adipogenic cocktail 
used for the accelerated induction of maximal differentiation at confluence 
contains supraphysiological concentrations of insulin, dexamethasone (DEX) 
and isobutylmethylxanthine (IBMX). DEX is a synthetic glucocorticoid agonist 
that is used for the activation of the glucocorticoid receptor pathway and IBMX 
is a cAMP-phosphodiesterase inhibitor that is used for the activation of the 
cAMP-dependent protein kinase pathway (Gregoire, 2001, Reed et al., 1977, 
Gregoire et al., 1998, Ntambi and Young-Cheul, 2000, Schmidt et al., 1990). 
The requirement of these two compounds for the acceleration of the 
differentiation process suggests the involvement of insulin, the glucocorticoid 
receptor pathway and the cAMP-dependent protein kinase pathway in 
adipogenesis (Gregoire, 2001). DEX plays a role in the induction of 3T3-L1 
cell differentiation whereas IBMX has been predicted to potentiate the effects 
of the glucocorticoids (e.g. DEX) (Schmidt et al., 1990). 
5.1.5. Overall aim, specific aims and experimental strategy 
5.1.5.1. Overall aim 
Insulin is known to be important for the accelerated differentiation of cells. The 
initial aim of this chapter was to characterise the differentiation of 3T3-L1 cells 
from their fibroblastic form to the adipocytic form.  
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The next aim was to demonstrate the importance of insulin for cell 
differentiation and to investigate the effect of MeG on cell differentiation. 
5.1.5.2. Specific aims 
 The initial aim of this chapter was to demonstrate the differentiation of 
3T3-L1 cells induced by the differentiation cocktail containing insulin 
 To confirm the importance of insulin in the differentiation process by 
comparing 3T3-L1 differentiation induced by the differentiation cocktail 
in the presence and absence of insulin 
 To demonstrate that the addition of relevant channel blockers to the 
differentiation cocktail can result in the inhibition of 3T3-L1 cell 
differentiation 
 To investigate the effect of covalently modified insulin on the 
differentiating ability of these cells 
5.1.5.3. Experimental strategy 
To set up an adipogenesis assay, using an adipogenic cocktail supplemented 
with insulin to induce 3T3-L1 differentiation from the fibroblastic phenotype to 
the adipogenic phenotype. To use the assay to investigate the effects of 
relevant channel blockers and MeG on cell differentiation. 
 
5.2. Materials and methods 
5.2.1. Materials 
7F2 (mouse osteoblast progenitor cell line) cells and 3T3-L1 (mouse 
embryonic fibroblast-adipose like cell-line) cells were donated from Dr 
Bronwen Evans, Department of Child Health, University Hospital of Wales, 
Heath Park Campus, Cardiff. All cell culture media ingredients, unless 
otherwise stated, were obtained from Gibco®, Invitrogen Ltd, Paisley, UK. D-
glucose, insulin, adipogenesis assay reagents as well as all the reagents used 
for RNA extraction, PCR and electrophoresis were purchased from Sigma-
Aldrich. 
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5.2.2. Cell culture 
The cells used for the determination of cell differentiation were 3T3-L1 (mouse 
embryonic fibroblast-adipose like cell line). This particular cell line was chosen 
because they have the ability to differentiate into adipocytes. For 3T3-L1 cell 
culture and cell husbandry see section 2.3.  
5.2.2.1. Adipogenesis assay cell culture medium 
The nature of the induction of adipogenesis depends on the specific cell 
culture model used because the responsiveness to inducing agents varies 
considerably between preadipose cell lines and primary preadipocytes. 
Overall, in serum-containing medium, the standard adipogenic cocktail for 
maximal differentiation contains, supraphysiological concentrations of insulin, 
dexamethasone (DEX) which is a synthetic glucocorticoid agonist traditionally 
used to stimulate the glucocorticoid receptor pathway and 
isobutylmethylxanthine (IBMX) which is a cAMP-phosphodiesterase inhibitor 
traditionally used to stimulate the cAMP-dependent protein kinase pathway 
(Gregoire, 2001, Gregoire et al., 1998, Ntambi and Young-Cheul, 2000). 
 
 Control cell 
culture medium 
(50 ml) 
Adipogenic cell 
culture medium  
(50 ml) 
Post-adipogenic cell 
culture medium (50 
ml) 
DMEM (ml) 44.988 43.488 43.488 
10 % FBS (ml) 5 5 5 
1 % pen/strep (ml) 0.5 0.5 0.5 
1 mg/ml insulin (ml) - 0.5 0.5 
1 mM dexamethasone (ml) - 0.0125 - 
50 mM IBMX (ml) - 0.5 - 
Ethanol (ml) 0.512 - 0.512 
 
Table 5.1. The volumes of reagents required to make 50 ml of control, 
adipogenic and post-adipogenic cell culture medium for 3T3-L1 cells. 
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5.2.3. Adipogenesis assays and adipocyte formation 
3T3-L1 cells, a cloned subline of 3T3-mouse embryo fibroblasts, undergo 
differentiation in culture, gaining both morphological and biochemical 
characteristics of adipocytes. Several days after reaching confluence, 3T3-L1 
cells lose their fibroblastic morphology, round up, and deposit large amounts 
of cytoplasmic triglyceride (Student et al., 1980). 
5.2.3.1. Adipogenesis assay 
Cells were seeded into 12-well plates at a density of 30,000/well. Figure 5.2 
shows the differentiation process that occurred once the cells reached 
confluency. Once confluent, the cells were left for a further 48 hours in 3T3-L1 
cell culture medium to begin spontaneous differentiation.  
To accelerate the differentiation process, the cell culture medium was 
aspirated from 2-day post-confluent cells and was replaced with the 
adipogenic cocktail containing 10 % FBS-DMEM, 1 μg/ml insulin, 0.25 μM 
dexamethasone and 0.5 mM IBMX. Forty-eight hours later, the adipogenic 
cocktail was aspirated and replaced with the post-adipogenic medium 
containing 10 % FBS-DMEM containing 1 μg/ml insulin. A further 48 hours 
later, the medium was aspirated and replaced with 10 % FBS-DMEM. 
Thereafter, the 10 % FBS-DMEM medium was changed every 2 days until 
completion of the assay at day 10 (Tafuri, 1996). 
 
 
 
Figure 5.2. Scheme showing the 3T3-L1 cell differentiation process 
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5.2.3.2. Oil red O staining for lipids 
Oil red O is a lysochrome (fat-soluble dye) diazo dye used for the staining of 
neutral triglycerides and lipids and was therefore used to distinguish between 
preadipocytes and adipocytes. 
A 0.5 % (w/v) stock solution of stain was prepared by dissolving oil red O 
(purchased from Sigma-Aldrich) in isopropanol and filtered to remove any grit. 
An oil red O working solution was prepared by mixing 6 ml of the 0.5 % (w/v) 
stock solution with 4 ml distilled water. The staining procedure was as follows: 
the 10 % FBS-DMEM medium was aspirated from the wells and the cell 
monolayer was washed with 1x D-PBS and the cells were then fixed with 
formal saline (10 % formaldehyde in PBS) for 15 minutes. Cells were then 
washed twice with distilled water. Stain was applied to each well and 
incubated for 15 minutes. The stain was aspirated and the cells were washed 
with 60 % isopropanol to remove any excess stain, followed by several 
washes with 1x D-PBS until all the background stain was removed. Cells were 
stored in 1x D-PBS and photographed under the microscope. Lipid droplets 
were stained red. 
5.2.3.3. Quantification of lipid formation 
The distilled water that was left for the photographing was aspirated and the 
cells were left to dry. Once dry, 100 % isopropanol was added to each well to 
break down the cell membrane and extract the dye. The 12-well plate was 
placed on a plate rocker for 15-30 minutes. Then 100 μl from each well was 
transferred into the wells of a 96-well plate and the absorbance was measured 
at 490 nm using an ELISA plate reader. 
5.2.4. Glucose uptake and GLUT4 expression 
The following techniques were studied and carried out to investigate the 
importance of insulin and to determine the effects of MeG on the biological 
actions of insulin.  
Glucose uptake by rat hemi-diaphragm and 7F2 can be determined using a 
glucose oxidase/peroxidase assay kit (Sigma). The assay kit contained 
glucose oxidase/peroxidase reagent, o-dianisidine reagent, assay reagent and 
a glucose standard.  
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The initial step in the determination of glucose uptake was to construct a 
standard curve. Into the first well of a 96-well plate, 40 μl of the blank was 
added, this was followed by the addition of 40 μl of each standard into their 
allocated wells. Each concentration was measured in duplicate. At time zero, 
the reaction was started with the addition of 80 μl of assay reagent into the two 
wells containing the blanks. Sixty second intervals were allowed between the 
additions of the assay reagent to the subsequent wells. The plate was 
wrapped in aluminium (Al) foil and placed in the incubator at 37 oC (5% CO2 
and 95% air) for 30 minutes. After the 30 minute incubation period, the 
reaction was stopped with the addition of 80 μl of 12 N H2SO4 again at 60 
second intervals. The absorbance of each well was measured against the 
reagent blank at 540 nm.  
5.2.4.1. Glucose uptake by the rat hemi-diaphragm in the presence and 
absence of insulin 
The diaphragm was removed from Sprague-Dawley rats by dissection and 
placed in Krebs-Ringer HEPES buffer. The diaphragm was cut into two equal 
pieces and blot dried to remove any excess buffer. Each half was weighed 
and the weight was recorded. Each half was placed in a universal tube 
containing 2 ml of testing solution. The universal tubes were placed on a 
rocker for 5 hours at 37 oC (5% CO2 and 95% air). Immediately after the tissue 
was added to the testing solution, a 40 μl sample was taken and transferred to 
a microtitre plate. Samples of the same volume were then taken every hour for 
the duration of the experiment. At each time point, triplicate readings were 
taken. At the end of the experiment, the tissue was removed from each of the 
universal tubes and blot dried, weighed and the weight was recorded. Once all 
the samples had been collected, glucose uptake could then be determined 
using the glucose oxidase/peroxidase assay.  
When all the samples were collected either from the rat hemi-diaphragm or 
7F2 cells the glucose oxidase/peroxidase assay was carried out. The assay 
was started by adding 80 μl of glucose oxidase/peroxidase assay reagent to 
the first three wells on the plate representing time zero. The assay reagent 
was the subsequently added to the remaining wells at 60 second intervals. 
The plate was wrapped in Al-foil and placed in the incubator at 37 oC (5% CO2 
and 95% air) for 30 minutes. After the 30 minute incubation period, the 
reaction was stopped by adding 80 μl of 12 N H2SO4 to each sample at 60 
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second intervals. The absorbance was measured against the blank at 540 nm 
using an ELISA plate reader. 
5.2.4.2. Glucose uptake by 7F2 cells in the presence and absence of 
insulin 
Cells were cultured in 75 cm2 flasks as a large number of cells were required 
for the determination of glucose uptake. The cells were cultured and 
maintained as previously described in section 2.3. Once the cells covered 
approximately 80% of the base of the flask, the cells were removed and 
counted. A cell suspension of 5 x 106 cells was placed into each Eppendorf. 
The Eppendorfs were centrifuged at 1000 rpm for 3 minutes. Pellets of cells 
had formed at the bottom of each tube. The supernatant was removed and 
discarded. The pellet of cells was resuspended in 1 ml testing solution. At time 
zero, 40 μl samples were taken from each tube and transferred into a 96-well 
plate and stored on dry ice. The microtitre plate was stored on dry ice so that 
the samples were frozen down immediately to prevent the cells from further 
utilising the glucose present. Samples were taken in triplicate every hour for 5-
6 hours. Once all the samples had been collected, glucose uptake could then 
be determined using glucose oxidase/peroxidase assay.  
When all the samples were collected either from the rat hemi-diaphragm or 
7F2 cells the glucose oxidase/peroxidase assay was carried out. The assay 
was started by adding 80 μl of glucose oxidase/peroxidase assay reagent to 
the first three wells on the plate representing time zero. The assay reagent 
was the subsequently added to the remaining wells at 60 second intervals. 
The plate was wrapped in Al-foil and placed in the incubator at 37 oC (5% CO2 
and 95% air) for 30 minutes. After the 30 minute incubation period, the 
reaction was stopped by adding 80 μl of 12 N H2SO4 to each sample at 60 
second intervals. The absorbance was measured against the blank at 540 nm 
using an ELISA plate reader. 
5.2.5. Molecular biology 
The aim of these experiments was to determine GLUT4 expression in mouse 
adipose tissue as well as undifferentiated and differentiated 3T3-L1 cells. 
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5.2.5.1. RNA extraction 
RNA extraction from mouse adipose tissue 
The RNA was kindly extracted from mouse adipose tissue and supplied by Dr 
Riffat Naseem.  
RNA extraction from 3T3-L1 cells 
The medium was aspirated from a confluent 25 cm2 flask of cells and the cell 
monolayer was washed with 1 ml PBS. Then 2.5 ml of Trizol (1 ml per 10 cm2) 
was added and spread over the base of the flask. The cell lysate was pipetted 
several times and transferred into two Eppendorfs. To the Eppendorfs, 0.2 ml 
of chloroform (CHCl3) was added. The tubes were shaken to mix. The tubes 
were left at room temperature for 2-3 minutes. The Eppendorfs were 
centrifuged at 12,000 rpm for 10 minutes. The supernatant was removed 
carefully to ensure that the colourless aqueous phase was not disturbed and 
discarded. The remaining colourless aqueous phase containing the RNA was 
transferred into Eppendorfs.  
5.2.5.2. Polymerase Chain Reaction 
Amplification of the cDNA took place in 12.5 μl reactions using primers 
purchased from Invitrogen, Ltd. Table 5.1 Contains primer information.  
 
Primer: Sequence: 
 
β-actin F: AGAGGGAAATCGTGCGTGACAT 
R: AGGAAGGCTGGAAAAGAGCC 
GLUT4 F: CCGCGGCCTCCTATGAGATACT 
R: AGCCACCCCGAAGATGAGT 
 
Table 5.2. Oligonucleotide primer details for the GLUT4 transporter 
 
Polymerase chain reaction (PCR) was carried out using the GoTaq® Flexi 
DNA Polymerase kit (purchased from Promega) and control reactions were 
carried out using either sterile nuclease-free water rather than cDNA. The 
standard composition of PCR reactions and the reaction conditions used are 
shown in Tables 5.2 and 5.3, respectively. The PCR amplification products 
were analysed by gel electrophoresis and stained with ethidium bromide, in 1x 
TAE buffer and visualised under UV light.  
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Components Final concentrations Volumes 
5x Green GoTaq
®
 Flexi buffer 1x 2.5 μl 
MgCl2, 25 mM 1.5 mM 0.75 μl 
PCR nucleotide (dNTP) mixture 200 μM each dNTP 1.25 μl 
Forward primer 0.4 μM 0.5 μl 
Reverse primer 0.4 μM 0.5 μl 
GoTaq
®
 DNA polymerase (5u μl
-1
) 0.3125 u 0.0625 μl 
cDNA (or nuclease-free H2O) - 0.5 μl 
Nuclease-free H2O - To 12.5 μl 
 
Table 5.3. The composition of 12.5 μl PCR reactions 
 
Step Temperature (
o
C) Time Number of cycles 
Initial denaturation 95 10 min 1 
Denaturation 95 30 s - 
Annealing 55 45 s 30 
Extension 72 1 min - 
Final extension 72 10 min 1 
soak 4 indefinate - 
 
Table 5.4. PCR reaction conditions 
 
5.2.5.3. Electrophoresis 
A 1 % agarose gel was made by adding 0.7 g of agarose to 70 ml TAE buffer. 
This was then placed in the microwave for three 10 second cycles to dissolve. 
The glass beaker holding the gel was placed in water and allowed to cool to a 
temperature of approximately 60 oC. Once cooled, 2.1 μl of ethidium bromide 
was added and mixed. The combs were placed in position and the gel was 
poured into the tank. If there were any bubbles present these were either 
carefully pushed to the side or removed from the gel. Once the gel had 
solidified it was covered with 1 % TAE buffer. The ladder (5 μl) and the sample 
(10 μl) were loaded on to the gel. The gel was then left to run for 50 minutes 
(100 mV and 200 mA). Once the gel had finished running, it was carefully 
removed from the tank and a picture of the gel was taken using a UV light.  
5.2.6. Statistical analysis 
One way analysis of variance (one-way ANOVA) was used to analyse the data 
produced. Results were considered to be significant if they were at the 95 % 
confidence level where p < 0.05. 
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5.3. Results 
3T3-L1 cells, a cloned subline of 3T3 mouse embryo fibroblasts, undergo 
differentiation in culture, acquiring both morphological and biochemical 
characteristics of adipocytes. Several days after reaching confluence, 3T3-L1 
cells lose their fibroblastic morphology, become spherical in shape and large 
amounts of cytoplasmic triglyceride are deposited within the cell (Student et 
al., 1980). Adipogenesis can be quantified using oil red O stain. Oil red O stain 
is a lysochrome (fat-soluble dye) diazo dye that stains neutral triglycerides and 
lipids.  
The results that follow show that 3T3-L1 cells can be converted from the 
fibroblastic form into adipocytes (fig. 5.3 and fig 5.4) and shows that certain 
agents can have an effect on cell differentiation (fig. 5.5 – fig. 5.8).  
5.3.1. The differentiation of 3T3-L1 cells induced by insulin 
In order to demonstrate the importance of insulin in 3T3-L1 cell differentiation 
it was first necessary to develop an adipogenesis assay that could be used to 
determine 3T3-L1 cell differentiation. Cell differentiation significantly increased 
when 3T3-L1 cells were treated with the adipogenic cocktail over a period of 
10 days (fig. 5.3 and fig. 5.4). The treatment of cells with the adipogenic 
cocktail resulted in a 2-fold (p < 0.05) and 8-fold (p < 0.01) increase in 
differentiation when compared to cells that were treated with cell maintenance 
media for the same duration.  
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Figure 5.3. The determination of 3T3-L1 cell differentiation on days 4, 7 and 10 in 
the presence and absence of adipogenic cocktail containing insulin, DEX and 
IBMX. Cells were seeded into a 12-well plate at a density of 30,000/well. Cells were 
left to reach confluency. Once confluent, cells were left for a further 48 hours in normal 
cell maintenance medium to begin spontaneous differentiation. The cell medium was 
aspirated from the 2-day post-confluent cells and was replaced with the adipogenic 
cocktail containing 10 % FBS-DMEM, 1 μg/ml insulin, 0.25 μM DEX and 0.5 mM IBMX 
to accelerate the differentiation process. 48 hours later, the adipogenic cocktail was 
replaced with the post-adipogenic medium containing 10 % FBS-DMEM and 1 μg/ml 
insulin. 2 days later, the post-adipogenic medium was replaced with 10 % FBS-
DMEM. This medium was changed every 2 days thereafter until completion of the 
assay at day 10. The cells were fixed with formal saline (10 % formaldehyde in PBS) 
and differentiation was quantified using oil red O stain. Error bars represent the mean 
+/- SE of three observations. Asterisks indicates significant difference where * 
represents p < 0.05 and ** represents p < 0.01 when compared with the 
corresponding bars for day 4. 
 
In order to distinguish between preadipocytes and adipocytes, oil red O 
staining was used as it stains neutral triglycerides and lipids red. The images 
that follow compare 3T3-L1 cells that were treated with cell maintenance 
medium (fig. 5.4 A-C) with those that were treated with the adipogenic cocktail 
(fig. 5.4 D-F) and these were then stained with oil red O to quantify cell 
differentiation. Cells that were treated with cell maintenance medium still 
appeared to have their fibroblastic morphology, did not appear round and 
staining did not show the presence of any triglycerides (fig. 5.4 A-C), therefore 
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suggesting that the cells were not differentiated into adipocytes. Cells that 
were treated with the adipogenic cocktail did appear round in shape and were 
stained red due to the presence of triglycerides (fig. 5.4 D-F). On day 4 only a 
few cells appeared to be round in shape and stained red (fig. 5.4D). 
Approximately 50 % of the cells stained on day 7 appeared round and are red 
due to the presence of triglycerides (fig. 5.4E) whereas nearly all the cells 
stained on day 10 appeared to have taken the adipocyte form (fig. 5.4F).  
 
 
 
Figure 5.4. Images showing adipocyte formation quantified using oil red O stain 
over a period of 10 days. Images A-C show 3T3-L1 cells treated with cell culture 
maintenance medium and stained with oil red O solution on: A) day 4; B) day 7 and C) 
day 10. Images D-F show 3T3-L1 cells treated with the adipogenic cocktail and 
stained with oil red O solution on: D) day 4; E) day 7 and F) day 10.  
 
5.3.2. The effect of insulin and other compounds on 3T3-L1 cell 
differentiation 
The results that follow show the effects of insulin and other compounds on 
3T3-L1 differentiation. Insulin is important for cell growth and differentiation. 
The initial aim was to demonstrate the importance of insulin in 3T3-L1 cell 
differentiation (fig. 5.5). Adipocytes were observed on all three days despite 
being treated with the general cell maintenance medium. 3T3-L1 cells were 
treated with the adipogenic cocktail with and without insulin to investigate the 
effect of the protein on differentiation. Cells that were treated with the 
adipogenic cocktail without insulin were still able to differentiate however the 
Chapter 5: The effect of methylglyoxal on insulin action 
 
158 
 
addition of insulin to the adipogenic cocktail did appear to significantly 
accelerate cell differentiation on day 10 (p < 0.05). 
 
 
 
Figure 5.5. The effect of insulin on 3T3-L1 cell differentiation over a period of 10 
days. Cells were seeded into a 12-well plate at a density of 30,000/well. Once 
confluent, cells were left for a further 48 hours in normal cell maintenance medium to 
begin spontaneous differentiation. The cell medium was aspirated from the 2-day 
post-confluent cells and was replaced with the adipogenic medium containing 10 % 
FBS-DMEM, 1 μg/ml insulin, 0.25 μM DEX and 0.5 mM IBMX or the adipogenic 
medium containing 10 % FBS-DMEM, 0.25 μM DEX and 0.5 mM IBMX. 48 hours 
later, the adipogenic medium +/- insulin was replaced with the post-adipogenic 
medium containing 10 % FBS-DMEM +/- 1 μg/ml insulin. 2 days later, the post-
adipogenic medium was replaced with 10 % FBS-DMEM. This medium was changed 
every 2 days thereafter until completion of the assay at day 10. The cells were fixed 
with formal saline (10 % formaldehyde in PBS) and differentiation was quantified using 
oil red O stain. Error bars represent the mean +/- SE of three observations. Asterisk 
indicates a significant difference where p < 0.05 when the differentiation observed in 
the presence of insulin was compared with that in the absence of insulin on the same 
day.  
 
Calcium channels play a role in cell proliferation and differentiation. In order to 
investigate if these channels were involved in 3T3-L1 cell proliferation and 
differentiation, the calcium channel blocker, tetrandrine was added to the 
adipogenic cocktail (fig. 5.6). Cells that were maintained in general cell culture 
medium showed reduced adipogenesis on days 7 and 10 however, this could 
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not be the case. Adipogenesis was enhanced in cells that were exposed to the 
adipogenic cocktail. Adipogenesis increased by approximately 15 and 50 % on 
days 7 and 10, respectively. The addition of 3 μM tetrandrine to both the 
general cell culture medium and the adipogenic cocktail had no significant 
effect on adipogenesis. 
 
 
 
Figure 5.6. The effect of tetrandrine on 3T3-L1 cell differentiation over a period 
of 10 days. Cells were seeded into a 12-well plate at a density of 30,000/well. Once 
confluent, cells were left for a further 48 hours in normal cell culture maintenance 
medium to begin spontaneous differentiation. The cell medium was aspirated from the 
2-day post-confluent cells and was replaced with the adipogenic cocktail containing 10 
% FBS-DMEM, 1 μg/ml insulin, 0.25 μM DEX and 0.5 mM IBMX or the adipogenic 
cocktail supplemented with 3 μM tetrandrine. 48 hours later, the adipogenic cocktail 
+/- 3 μM tetrandrine was replaced with the post adipogenic medium containing 10 % 
FBS-DMEM and 1 μg/ml insulin. 2 days later, the post-adipogenic medium was 
replaced with 10 % FBS-DMEM. This medium was changed every 2 days thereafter 
until completion of the assay at day 10. The cells were fixed with formal saline (10 % 
formaldehyde in PBS) and differentiation was quantified using oil red O stain. Error 
bars represent the mean +/- SE of three observations. 
 
Potassium channels are crucial for cell proliferation and differentiation. In 
order to investigate if these channels were involved in 3T3-L1 cell proliferation 
and differentiation, the BK potassium channel blocker, tetraethylammonium 
(TEA) was added to the adipogenic cocktail (fig. 5.7). Cells that were 
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maintained in cell maintenance medium for the duration of the experiment 
showed no significant increases in adipogenesis. Adipogenesis was enhanced 
in cells that were exposed to the adipogenic cocktail. In the presence of the 
adipogenic cocktail, adipogenesis increased by approximately 10 and 30 % on 
days 7 and 10, respectively. The addition of 10 mM TEA to the adipogenic 
cocktail, inhibited adipogenesis by approximately 30 and 50 % on days 7 and 
10, respectively. The inhibition of adipogenesis by TEA was only significant on 
day 10 (p < 0.05).  
 
 
 
Figure 5.7. The effect of tetraethylammonium (TEA) on 3T3-L1 cell differentiation 
over a period of 10 days. Cells were seeded into a 12-well plate at a density of 
30,000/well. Once confluent, cells were left for a further 48 hours in normal cell culture 
maintenance medium to begin spontaneous differentiation. The cell medium was 
aspirated from the 2-day post-confluent cells and was replaced with the adipogenic 
cocktail containing 10 % FBS-DMEM, 1 μg/ml insulin, 0.25 μM DEX and 0.5 mM IBMX 
or the adipogenic cocktail supplemented with 10 mM TEA. 48 hours later, the 
adipogenic medium +/- 10 mM TEA was replaced with the post adipogenic medium 
containing 10 % FBS-DMEM and 1 μg/ml insulin. 2 days later, the post-adipogenic 
medium was replaced with 10 % FBS-DMEM. This medium was changed every 2 
days thereafter until completion of the assay at day 10. The cells were fixed with 
formal saline (10 % formaldehyde in PBS) and differentiation was quantified using oil 
red O stain. Error bars represent the mean +/- SE of three observations. Asterisks 
indicates significant difference where p < 0.05 when the differentiation observed in the 
presence of 10 mM TEA was compared with that in the absence of 10 mM TEA on the 
same day. 
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MeG is known to directly inhibit insulin signalling in cultured adipocytes. In 
order to investigate the effect of MeG on 3T3-L1 cell proliferation and 
differentiation, MeG was added to the adipogenic cocktail containing insulin 
(fig. 5.8). Adipogenesis occurred in cells that were exposed to the general 
maintenance medium. Adipogenesis was enhanced in cells that were exposed 
to the adipogenic cocktail. In the presence of the adipogenic cocktail, 
adipogenesis increased by approximately 35, 60 and 100 % on days 4, 7 and 
10, respectively. The addition of 10 mM MeG to the adipogenic cocktail, had 
no significant effect on adipogenesis when compared with the adipogenesis in 
the absence of MeG observed on the same days.  
 
 
 
Figure 5.8. The effect of methylglyoxal (MeG) on 3T3-L1 cell differentiation over 
a period of 10 days. Cells were seeded into a 12-well plate at a density of 
30,000/well. Once confluent, cells were left for a further 48 hours in normal cell culture 
maintenance medium to begin spontaneous differentiation. The cell medium was 
aspirated from the 2-day post-confluent cells and was replaced with the adipogenic 
cocktail containing 10 % FBS-DMEM, 1 μg/ml insulin, 0.25 μM DEX and 0.5 mM IBMX 
or the adipogenic medium supplemented with 1 μM MeG. 48 hours later, the 
adipogenic cocktail +/- 1 μM MeG was replaced with the post adipogenic medium 
containing 10 % FBS-DMEM and 1 μg/ml insulin. 2 days later, the post-adipogenic 
medium was replaced with 10 % FBS-DMEM. This medium was changed every 2 
days thereafter until completion of the assay at day 10. The cells were fixed with 
formal saline (10 % formaldehyde in PBS) and differentiation was quantified using oil 
red O stain. Error bars represent the mean +/- SE of three observations.  
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5.3.3. Glucose uptake by rat hemi-diaphragm and 7F2 cells 
In order to investigate the effect of MeG (and other compounds) on insulin 
action an attempt was made to develop an assay whereby insulin stimulated 
glucose uptake by both insulin sensitive cells and tissue could be determined. 
Glucose uptake by the rat hemi-diaphragm and 7F2 cells proved 
unsuccessful. In experiments using the rat hemi-diaphragm there was no 
basal glucose uptake and insulin did not stimulate glucose uptake into the 
tissue (data not shown). In experiments using 7F2 cells no insulin stimulated 
glucose uptake was observed and in fact the data suggested that insulin 
actually inhibited glucose uptake (data not shown).  
 
5.4. Discussion and conclusions 
The results in this chapter have shown that 3T3-L1 cells are capable of 
differentiating from the fibroblastic form into adipocytes whether it occurs 
spontaneously or is accelerated via the addition of an adipogenic cocktail 
consisting of supraphysiological concentrations of insulin, DEX and IBMX (fig. 
5.3 and fig. 5.4). Insulin is important for 3T3-L1 cell differentiation as the 
exclusion of the hormone from the adipogenic cocktail significantly inhibited (p 
< 0.05) cell differentiation by approximately 5 and 30 % on days 7 and 10, 
respectively (fig. 5.5). The inclusion of tetrandrine (a calcium channel blocker) 
(fig. 5.6) to the adipogenic cocktail had no significant effect on 3T3-L1 cell 
adipogenesis. The addition of TEA (a BK potassium channel blocker) (fig. 5.7) 
to the adipogenic cocktail inhibited 3T3-L1 adipogenesis by approximately 30 
and 50 % on days 7 and 10, respectively. The inhibition of adipogenesis by 
TEA was only significant on day 10 (p < 0.05). The inhibition in adipogenesis 
produced by TEA suggested that potassium channels play an important role in 
the cell differentiation process. The addition of 10 mM MeG (fig. 5.8) to the 
adipogenic cocktail, had no significant effect on 3T3-L1 adipogenesis.  
Although 3T3-L1 differentiation was observed the amount of differentiation 
was not consistent in all experiments. For example, the initial experiment 
carried out to develop the adipogenesis assay showed that there was a 700 % 
increase in adipogenesis on day 10 whereas in other experiments there was 
only a 50 – 100 % increase in adipogenesis on day 10.  
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Reasons for the variation in the amount of differentiation might be due to the 
cells having different passage numbers (e.g. higher passage than others) 
and/or due to the degree of cell confluence (e.g. over confluent cells). Cells 
with a high passage number can experience changes in morphology and may 
not respond to stimuli as well as cells with a lower passage number and this 
may help explain why adipogenesis varied between individual experiments. 
Allowing the cells to become over confluent might have resulted in the 
inhibition of growth or prevented them from differentiating.  
The exclusion of insulin from the adipogenic cocktail caused 3T3-L1 cells to 
remain in the undifferentiated fibroblast-like preadipocyte form. However, 
when maintained in cell culture medium supplemented with FCS/FBS, the 
3T3-L1 fibroblast-like cells can spontaneously differentiate over a period of 
several weeks. These cells only express the adipocyte phenotype when the 
cells are confluent and cell division has stopped (Gregoire et al., 1998, Reed 
et al., 1977). The period of time needed for the confluent cell cultures to adopt 
the adipocyte phenotype can be altered by specific agents that are known to 
have an effect on lipogenesis and lipolysis (Reed et al., 1977). The standard 
adipogenic cocktail used for the accelerated induction of maximal 
differentiation at confluence contains supraphysiological concentrations of 
insulin, DEX and IBMX. DEX is a synthetic glucocorticoid agonist that is 
responsible for the activation of the glucocorticoid receptor pathway and IBMX 
is a cAMP-phosphodiesterase inhibitor which is used to activate the cAMP-
dependent protein kinase pathway (Gregoire, 2001, Reed et al., 1977, 
Gregoire et al., 1998, Ntambi and Young-Cheul, 2000, Schmidt et al., 1990). 
Both DEX and IBMX are used in conjunction with each other as IBMX can 
potentiate the effect of glucocorticoid agonists like DEX (Schmidt et al., 1990). 
The constant exposure of 3T3-L1 cells to these supraphysiological 
concentrations of insulin once confluent will result in > 75 % of the cells 
adopting the adipocyte form within 3-4 weeks. Therefore, supraphysiological 
concentrations of insulin are used to accelerate and maximise adipocyte 
formation, however, the removal of insulin from the differentiation cocktail will 
result in < 1 % of the cells adopting the adipocyte form (Reed et al., 1977). 
This confirms the importance of insulin and glucocorticoids such as DEX in the 
differentiation process.  
Hyperinsulinemia is a common feature in obesity and is associated with weight 
gain. Hyperinsulinemia can be due to the excessive production of exogenous 
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insulin or it can occur in those individuals who do not produce enough insulin 
or the insulin that is produced does not work efficiently and they require 
intense administration of exogenous insulin. It is possible that endogenous 
hyperinsulinemia as a result of excessive food consumption can stimulate 
adipogenesis as well as significantly increasing white adipose tissue (WAT) 
mass resulting in obesity with insulin resistance but this remains to be proved 
(Klemm et al., 2001). Insulin degrades rapidly in the 48 hours between 
medium changes in the adipogenesis process; this may explain why 
supraphysiological concentrations of insulin are required for cell differentiation. 
Differentiated cells have been shown to have higher rates of insulin 
degradation than undifferentiated cells (Reed et al., 1977). 
As the 3T3-L1 cells differentiate and become adipocytes the number of insulin 
receptors present are said to increase. It has been reported that the ability of 
human adipocytes to bind insulin is significantly greater than the ability of 
human fibroblasts to bind the hormone. However the mechanisms responsible 
for the increased number of insulin receptors seen in adipocytes remain 
unknown.  
Potassium channels are important for cell proliferation and cell differentiation. 
Ramirez-Ponce et al (1990) were the first to study the electrophysiological 
characteristics of white adipocytes using the whole-cell patch clamp method. 
They showed that rat white adipocytes contain voltage-dependent potassium 
(K+) channels of the delayed rectifier type (Hamida et al., 2011, Ramirez-
Ponce et al., 1996). Since then, a number of other authors have confirmed this 
finding in isolated white adipocytes. It is possible that insulin can modulate the 
K+-channel conductances in adipocytes. It has been predicted that insulin 
increases the number of voltage-dependent K+-channels in adipocytes and 
have implicated these channels in the adipogenesis process (Hamida et al., 
2011, Ramirez-Ponce et al., 1996).  
 
Potassium currents have been identified in all differentiated cells but only 
occasionally in preadipocytes. However, the number of K+-channels and thus 
K+ currents increased in adipocytes in the presence of insulin. Insulin alters 
the electrical properties of adipocytes and may therefore also modulate K+ 
conductance in these cells. K+-channels can be blocked by the K+-channel 
blocker, TEA. This chapter investigated whether K+-channels play a role in 
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adipogenesis by adding 10 mM TEA to the differentiation cocktail. It has been 
previously shown by (Henney et al., 2009) that a concentration of 0.3 mM TEA 
was sufficient enough to block the channel. Ramirez-Ponce et al (2002) also 
demonstrated that mature white adipocytes that were differentiated in culture 
can also be blocked by low concentrations of this K+-channel blocker. The 
data in this chapter suggested that the concentration of TEA used (10 mM) 
may not inhibit cell proliferation but may in fact inhibit cell differentiation, hence 
the decrease in adipogenesis observed when the cells were treated with the 
adipogenic cocktail supplemented with 10 mM TEA compared to the 
adipogenic cocktail in the absence of TEA. This data suggested that insulin 
was not the only important factor for adipocyte formation but that the 
expression of functional K+-channels are also important for adipocyte 
development in culture.  
Ramirez-Ponce et al (1991) also confirmed the presence of voltage-dependent 
calcium (Ca2+) channels in adipocytes. The Cav3.1 T-type channel is the 
dominant voltage-dependent Ca2+ channel in mouse preadipocytes and is 
thought to be involved in the regulation of preadipocyte proliferation which is 
an important step in the development of adipose tissue (Oguri et al., 2010). 
Intracellular calcium [Ca2+]i plays an important role in some of the metabolic 
disorders that are related to obesity. [Ca2+]i plays an important regulatory role 
in adipogenesis and is therefore an important contributor to increased adipose 
tissue mass. Increasing [Ca2+]i during the initial stages of the differentiation 
process will result in the inhibition of adipogenesis, however in contrast, 
increasing [Ca2+]i during the latter stages of adipogenesis will stimulate the 
differentiation process. Therefore, [Ca2+]i stimulates and accelerates 
adipogenesis whilst inducing the adipocyte phenotype during the latter stages 
of the differentiation process. For this to happen, increased [Ca2+]i levels result 
in a significant increase in the expression of PPARγ which is essential if the 
cells are to adopt the adipocyte phenotype (Cammisotto and Bukowiecki, 
2004, Shi et al., 2000). Therefore one would expect the addition of tetrandrine, 
a known Ca2+-channel blocker, to the adipogenic cocktail to inhibit [Ca2+]i 
resulting in reduced PPARγ expression and decreased adipogenesis, 
however, this was not the case.  
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Extensive research has been carried out to determine the role of MeG in the 
structural and functional changes in human insulin. Jia et al (2006) incubated 
insulin (1 μg/μl) with MeG (100 μM) for different periods of time. Using mass 
spectrometry they showed that after an incubation period of 2 hours there 
were no additional peaks noticed therefore suggesting that there were no 
changes in the structure or mass of insulin. After an incubation period of 3 
days, mass spectrometry identified two additional peaks at m/z 5880 and 
5934. The peak identified at m/z 5880 corresponded with the addition of one 
MeG molecule (72 Da) to insulin (5808 Da) whereas, the peak identified at m/z 
corresponded with the addition of two molecules of MeG to insulin along with 
the loss of one water molecule (54 Da) (Jia et al., 2006). This information 
suggested that the incubation with MeG caused the mass of insulin to 
increase. It is known that MeG can react readily with the free amino groups of 
arginine and lysine residues of proteins resulting in the formation of MeG-
adducts. Insulin contains one arginine and one lysine residue on the B-chain 
at positions 22 and 29, respectively. When MeG reacts with the lysine residue 
at position 29, CEL is formed and it is the formation of this that causes the 
mass of insulin to increase by 72 Da. However, when MeG reacts with the 
arginine residue at position 22, a condensation reaction occurs resulting in the 
formation of a hydroimidazolone. It is the formation of this hydroimidazolone 
that causes the mass of insulin to increase by 54 Da (Jia et al., 2006).  
The same authors have also shown that the formation of MeG-adducts will 
significantly inhibit glucose uptake by insulin-sensitive cells (e.g. 3T3-L1 cells). 
To determine the role of MeG in the development of insulin resistance, both 
insulin and MeG were added directly to the 3T3-L1 cells for a period of 30 
minutes prior to the determination of glucose uptake. The authors predicted 
that for the toxin to interfere with insulin-stimulated glucose uptake it would 
need to modify the insulin receptor therefore inhibiting the binding of insulin 
leading to impaired glucose uptake (Jia et al., 2006, Jia and Wu, 2007). Jia et 
al (2006) showed that the 30 minute exposure of cells to MeG did not 
significantly affect glucose uptake. They also showed that in the cells exposed 
to MeG there were no changes in the expression of the IR, IRS-1 and PI3K 
when compared with the expression observed in cells that were not exposed 
to the toxin. Although there were no changes in expression observed, they did 
report however, that there was reduced IRS-1 tyrosine phosphorylation and 
Chapter 5: The effect of methylglyoxal on insulin action 
 
167 
 
PI3K activity (Jia et al., 2006, Jia and Wu, 2007). The reduction in PI3K 
activity coincided with the inhibition of IRS-1 tyrosine phosphorylation.  
The addition of the MeG-scavenger N-acetyl-cysteine (NAC) reversed these 
reductions and therefore suggested that MeG was involved in the inhibition of 
insulin-stimulated glucose uptake. From this information, the authors 
concluded that MeG was not affecting the binding affinity or the expression of 
the insulin receptor but was in fact inhibiting insulin signalling in the insulin-
sensitive cells due to decreased IRS-1 tyrosine phosphorylation as well as 
impaired IRS-1/PI3K association (Riboulet-Chavey et al., 2006, Jia et al., 
2006, Jia and Wu, 2007).  
Jia et al (2006) also looked at the effect MeG-adduct formation had on the 
release of insulin from the pancreatic β-cells and on insulin clearance. The 
cleavage of proinsulin in the β-cells results in the production of insulin and C-
peptide. For every molecule of insulin that is released, one molecule of C-
peptide is also released. Therefore, it is possible to quantify insulin release 
from the β-cells by measuring the amount of C-peptide that is released (Jia et 
al., 2006). The authors showed that as a consequence of MeG-adduct 
formation, the amount of C-peptide, and therefore insulin, released from the 
cells decreased. Hyperinsulinemia may also occur due to reduced insulin 
clearance in the liver as a result of MeG-adduct formation (Jia et al., 2006). 
Insulin levels in the blood are maintained by a process known as endocytosis. 
During this process, the insulin receptor with bound insulin is internalised back 
into the cell where it is stored until it is required. In 3T3-L1 cells, endocytosis 
results in the breakdown of insulin and the recycling of the receptors back to 
the plasma membrane. These authors compared insulin levels in the media of 
cells that were treated with either insulin or MeG-modified insulin. They found 
that the media of cells treated with insulin contained lower concentrations of 
insulin than the media of cells treated with MeG-modified insulin. This 
information suggested that modified insulin was unable to undergo 
endocytosis but the mechanism involved in this process requires further 
investigation (Jia et al., 2006). 
As MeG was added to the differentiation cocktail containing insulin, it was 
possible that the insulin was covalent modified and as a result caused 
changes in insulin signalling and therefore insulin action. It has been shown in 
this chapter that insulin is important for adipogenesis and if there is impaired 
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insulin signalling due to MeG-adduct formation this would explain the 
decreases in adipogenesis observed.  
The addition of MeG to the differentiation cocktail may also decrease 
adipogenesis via the inhibition of both PPARγ and C/EBPα (CCAAT/enhancer 
binding protein-α) as both of these are known to be crucial for cell 
differentiation to occur.  
An attempt to investigate the effect of MeG on insulin action using a glucose 
uptake assay proved unsuccessful. The 7F2 cells were in their osteoblastic 
form rather than their differentiated adipocytic form. This may partly explain 
insulin did not stimulate glucose uptake by these cells. Also whilst still in the 
osteoblastic form, these cells would not express the GLUT4 transporter that is 
crucial for insulin-stimulated glucose uptake. However, if they had been 
differentiated into adipocytes the cells should then express the GLUT4 
transporter and insulin-stimulated glucose uptake would be expected. Both the 
rat hemi-diaphragm tissue and 7F2 cells may also be lacking insulin receptors. 
Insulin receptors are vital so that insulin can bind. Once insulin binds to its 
receptor, it stimulates GLUT4 translocation from the intracellular storage sites 
to the plasma ready for glucose uptake. Therefore, reductions in insulin 
receptors means less insulin can bind resulting in decreased glucose uptake.  
Interestingly, it was found that the undifferentiated 3T3-L1 cells expressed 
high levels of GLUT4. As 3T3-L1 cells can spontaneously differentiate over a 
period of time one would therefore expect to see GLUT4 expression. These 
cells can also express high quantities of the GLUT1 transporter isoform (Olson 
and Knight, 2003), this may help explain why there might also be reduced 
GLUT4 expression.  
Insulin can rapidly decrease GLUT4 expression in 3T3-L1 adipocytes (Flores-
Riveros et al., 1993, Olson and Knight, 2003). If 3T3-L1 cells are continuously 
exposed to insulin, GLUT4 expression varies in vivo and in vitro. Animals that 
have been exposed to intense concentrations of insulin have demonstrated 
increased GLUT4 expression in their adipose tissue, whereas the intense 
exposure of 3T3-L1 cells in vitro resulted in either no change or a significant 
decrease in GLUT4 expression. This suggests that the GLUT4 is no longer 
responding to insulin directly (Olson and Knight, 2003). The incubation of 3T3-
L1 adipocytes in media not supplemented with glucose results in reduced 
GLUT4 expression. GLUT4 expression in such cases reduced 10-fold and 
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leads to increases in GLUT1 expression (Olson and Knight, 2003). Therefore, 
further work needs to be carried out to optimise conditions for molecular 
biology and then to determine both GLUT4 and GLUT1 expression in 3T3-L1 
cells.  
This chapter has shown that 3T3-L1 cells can differentiate from their 
fibroblastic form to the adipogenic form whether it occurs spontaneously or is 
accelerated via the addition of a differentiation cocktail. The importance of 
insulin in the differentiation process has been shown as well as highlighting 
the role of K+ and Ca2+ channels in this process. In view of the lack of effect of 
insulin on glucose uptake, it is now necessary to look at the antilipolytic effects 
by determining glycerol release from differentiated cells. Another approach to 
determine the effect of MeG on insulin action would be to carry out receptor 
binding assays.  
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6.1. General discussion and conclusions 
The overall aim of this thesis was to investigate the potential role of the 
bacterial metabolic toxin hypothesis in the development of diabetes. In order 
to do this, the strategy was to identify a property of the two major proteins in 
the blood (HSA and insulin) that could be measured in order to determine 
covalent modification. The property chosen was coelenterazine 
chemiluminescence. The results in this thesis showed that: 
 Both albumin and insulin have a mono-oxygenase activity 
demonstrated by coelenterazine chemiluminescence 
 That coelenterazine binds to Sudlow’s site I (warfarin site) on HSA 
 That the production of the bacterial metabolic toxin, MeG, leads to the 
covalent modification of both albumin and insulin, thus reducing the 
biological activities of these proteins. 
The data in this thesis demonstrated that both HSA and BSA were able to 
catalyse coelenterazine chemiluminescence (fig. 3.6). However, BSA was 
significantly better (p < 0.001) than HSA at catalysing coelenterazine 
chemiluminescence despite having a 78 % sequence similarity. Using this 
same method, the abilities of three other proteins – insulin, gelatin and 
haemoglobin at catalysing coelenterazine chemiluminescence were also 
investigated (fig. 3.7). Insulin was also shown to catalyse coelenterazine 
chemiluminescence. Interestingly, gelatin and the well known oxygen carrier, 
haemoglobin, were poor at catalysing the coelenterazine chemiluminescence 
reaction. It was then necessary to demonstrate if the ability of these proteins 
at catalysing coelenterazine chemiluminescence was consistent with them 
having enzymatic activity. To demonstrate this, 4 criteria were used to 
determine if HSA catalysed coelenterazine chemiluminescence was 
enzymatic: (1) heat denaturable; (2) exhibits saturable substrate 
characteristics; (3) inhibition or activation by specific cations that are known to 
bind to the protein and (4) inhibition by drugs that are known to bind to the 
protein.  
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It was shown that HSA catalysed coelenterazine chemiluminescence was heat 
denaturable (fig. 3.8). Denaturation is defined as the loss of enough structure 
to make the enzyme inactive. Increasing temperature is factor known to 
denature proteins. When HSA was exposed to a temperature of 95 oC for 15 
minutes, it was irreversibly denatured thus preventing it from refolding when 
cooled, resulting in reduced enzymatic activity and the inhibition of HSA 
catalysed coelenterazine chemiluminescence. It has since been shown that by 
increasing the heating period from 15 minutes to 30 minutes, HSA catalysed 
coelenterazine chemiluminescence was inhibited by > 90 % (Vassel et al., 
2012). Under the same conditions, insulin was not denatured (fig. 3.9). Human 
insulin is a much smaller protein than HSA, thus making it more difficult to 
denature. It has been shown that insulin can be denatured in Tris-HCl buffer, 
pH 7.4, containing 0.2 mM cysteine for 6 hours at a temperature of 22 oC 
(Jiang and Chang, 2005). 
To determine the maximum velocity of the HSA catalysed coelenterazine 
chemiluminescence reaction (fig. 3.10), the coelenterazine concentration was 
increased until a constant rate of product formation was seen. From this, the 
substrate concentration (Km) at which the rate is half of the Vmax was 
determined. It was shown that at a coelenterazine concentration of 40 μM, the 
protein was saturated. Saturation occurs because as the substrate 
concentration increased, more of the free-HSA was converted to the 
coelenterazine-HSA form. The Km was shown to be approximately 20 μM.  
The effect of increasing pH on the ability of HSA and insulin to catalyse 
coelenterazine chemiluminescence was also investigated. It was shown that 
HSA (fig. 3.11) and insulin (fig. 3.12) were pH sensitive. As the pH became 
increasingly alkaline, the coelenterazine chemiluminescence catalysed by 
both proteins increased. The half maximum for HSA and insulin were at 
approximately pH 8.2 and pH 7.8, respectively. The large increase in 
chemiluminescence observed at alkaline pH suggests that there must be at 
least one basic amino acid residue in the binding region that is important for 
the catalysis. Therefore, the pH at the half maximum represents the pKa of the 
amino group in the protein that is important for catalysis.  
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The entrance to the pocket to which coelenterazine is predicted to bind on 
HSA consists of two lysine residues (Ly195 and Lys199) and three arginine 
residues (Arg218, Arg222 and Arg257) (Otagiri, 2005, Sugio et al., 1999). 
Under acidic conditions, the amino groups of these residues are protonated, 
therefore making the entrance to the pocket positively charged. This positive 
charge under these conditions prevents coelenterazine from binding to the 
protein, hence why no chemiluminescence was observed. As the pH becomes 
more alkaline, the residues at the entrance lose protons through deprotonation 
making the entrance uncharged, resulting in chemiluminescence. 
Albumin has a negative charge but several cations can bind weakly and 
reversible to the protein (Varshney et al., 2010). Of the cations tested, Fe2+, 
Fe3+ and Zn2+ (p < 0.001; fig. 3.13 – fig. 3.15 and fig. 3.17) significantly 
inhibited coelenterazine chemiluminescence catalysed by HSA, however, this 
was dependent on the concentration and had a potency of Fe2+/Fe3+ > Zn2+. 
The addition of Ca2+ (fig. 3.16) did not significantly affect the coelenterazine 
chemiluminescence catalysed by HSA. The presence of the cation and 
coelenterazine at the same concentration will result in them both competing 
for the binding site. Which of these will bind depends on their binding affinities 
for the protein. If the cation had the highest affinity for the protein then it would 
bind resulting in the inhibition of HSA catalysed coelenterazine 
chemiluminescence and vice versa. When the concentration of the cation 
increases above the coelenterazine concentration (> 10-5 M) the cation will 
bind to the protein. The cation binds due to its ability to saturate the protein, 
therefore inhibiting light emission. However, when the concentration of the 
substrate is higher than that of the cation, coelenterazine will bind to the 
protein, resulting in enhanced light emission. The cation binding site is 
unknown and it is possible that the effect produced by these cations may be 
due to an allosteric effect. 
Interestingly, Zn2+ produced opposite effects on HSA and human insulin. The 
addition of Zn2+ significantly inhibited HSA catalysed coelenterazine 
chemiluminescence (p < 0.001; fig. 3.17), but significantly enhanced human 
insulin catalysed coelenterazine chemiluminescence (p < 0.0001; fig. 3.18). 
Zn2+ is known to be important for the biosynthesis and storage of insulin and is 
known to interact with insulin. Enhanced human insulin catalysed 
coelenterazine chemiluminescence may be due to Zn2+ causing the protein to 
undergo a conformational change, and it is this change that allows 
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coelenterazine to bind more effectively resulting in increased 
chemiluminescence.  
An advantage of knowing that certain drugs can bind to either Sudlow’s site I 
(e.g. warfarin) or Sudlow’s site II (e.g. diazepam) made it possible to predict 
the coelenterazine binding site on the protein. All of the drugs that are known 
to bind to Sudlow’s site I tested significantly inhibited HSA catalysed 
coelenterazine chemiluminescence (p < 0.001; fig. 4.6 – fig. 4.9). At this site, 
competition can exist between coelenterazine and the drug when they are 
present at the same concentration however; the compound with the highest 
binding affinity for the site will displace the other (Rahman et al., 2005). The 
concentration of each of the compounds will determine which will become 
bound to HSA. If the concentration of the drug is lower than the coelenterazine 
concentration (< 10-5 M) there is more of the substrate present and therefore it 
is the coelenterazine that will bind to HSA, hence why no significant change in 
HSA catalysed coelenterazine chemiluminescence was observed. As the 
concentration of the drug rises above the coelenterazine concentration (> 10-5 
M), there is more drug present and available to bind to HSA, therefore 
preventing coelenterazine from binding thus inhibiting HSA catalysed 
coelenterazine chemiluminescence. The addition of the site II drug – 
diazepam, also significantly inhibited HSA catalysed coelenterazine 
chemiluminescence (p < 0.001; fig. 4.10) but not to the same extent as that 
observed with the addition of the site I drugs. However, the other site II drugs 
tested (phenytoin and ibuprofen) did not significantly affect HSA catalysed 
coelenterazine chemiluminescence (fig. 4.11 and fig. 4.12). From this data, 
Sudlow’s site I was predicted to be the coelenterazine binding site.  
Competitive binding experiments can be used to investigate the high affinity 
binding of drugs to proteins (Kragh-Hansen, 1991). Binding may occur to one 
site (Brodersen et al., 1977) and it was therefore necessary to investigate the 
competitive binding properties of warfarin and coelenterazine on HSA 
catalysed coelenterazine chemiluminescence. Warfarin is known to have a 
weak fluorescence, but this fluorescence is enhanced when it binds to HSA. 
The fluorescence observed when warfarin binds to HSA decreases if a second 
ligand such as coelenterazine competes for the site already occupied by 
warfarin (Sahoo et al., 2008). However, the inhibition of HSA catalysed 
coelenterazine chemiluminescence by the addition of warfarin demonstrated 
characteristics of both competitive and uncompetitive inhibition. As both 
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competitive and uncompetitive inhibition was observed, this suggests that 
warfarin is capable of binding with different affinities to either the free enzyme 
(HSA only) or to the HSA-coelenterazine complex. Therefore, it is possible 
that warfarin could interfere with substrate binding (increase Km) and reduce 
catalysis in the HSA-coelenterazine complex (decrease Vmax) (fig. 4.13). From 
this, it can be concluded that the inhibition observed in the presence of 
warfarin exhibited mixed inhibition enzyme kinetics. Mixed inhibition is usually 
the result of an allosteric effect where the inhibitor binds to a different site on 
the enzyme to that of the substrate. The binding of warfarin to the allosteric 
site causes the enzyme to undergo a conformational change and causes the 
substrate to have a decreased affinity for the binding site. In such cases, the 
binding of the inhibitor will affect the binding of the substrate and the binding of 
the substrate will affect the binding of the inhibitor.  
In the experiment used to determine the type of enzyme inhibition in the 
presence of warfarin, the concentration of HSA was similar to or higher than 
the coelenterazine concentration, thus a key condition for the Michaelis-
Menten equation is that the enzyme does not significantly reduce the 
substrate concentration, therefore to a first approximation the equation may 
not hold. That is why the results state that the approximate Km was 20 μM as it 
was not possible to a precise Lineweaver-Burk plot. 
Molecular 3D modelling was used to identify the coelenterazine binding site. 
This method demonstrated the importance of Sudlow’s site I as the major 
catalytic site on HSA (fig. 4.14A), therefore confirming this site as the 
coelenterazine binding site. It was shown that coelenterazine fit “snugly” into 
site I, where warfarin is also capable of binding. However, when 
coelenterazine was placed in the pocket containing site II, it did not fit 
comfortably and resulted in a number of interactions with the surface of the 
protein (fig. 4.14B). As well as confirming the coelenterazine binding site, 
molecular 3D modelling also highlighted five basic amino acid residues – 
Tyr150, Lys195, Arg222, His242 and Arg257 within the binding site (fig. 
4.14A). These residues fit with and support the pH profile of HSA shown in 
Chapter 3 (fig. 3.11) where an increase in HSA catalysed coelenterazine 
chemiluminescence at alkaline pH was consistent with at least one basic 
amino acid being involved in coelenterazine binding and/or catalysis. 
Interestingly, similar basic amino acid residues have been found in the 
coelenterazine binding sites of aequorin and obelin. This data suggests that 
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only a few fundamental amino acid residues at the coelenterazine binding site 
are enough to catalyse coelenterazine chemiluminescence.  
From this, the genetic engineering of Sudlow’s site I could significantly 
enhance HSA catalysed coelenterazine chemiluminescence and can 
potentially bring it close to or better than the naturally occurring coelenterazine 
luciferases and photoproteins (Vassel et al., 2012). 
The incubation of both albumin and insulin with MeG for a period of one week 
resulted in the covalent modification of the proteins (fig. 4.15). MeG is known 
to target arginine and lysine residues of such proteins, but of these, MeG 
favours arginine residues (Gao and Wang, 2006). MeG can cause the 
irreversible modification of arginine residues resulting in the formation of 
hydroimidazolones (Lo et al., 1994, Thornalley, 2008). Hydroimidazolones are 
the most common adducts found in the plasma. It is the modification of these 
residues that alters the biological activity of the proteins. The modification of 
these residues on the insulin molecule can result in changes in biological 
function. Changes in insulin function that are associated with modification by 
MeG suggests that the toxin may be involved in the development of insulin 
resistance and may potentially lead to the progression of diabetes (Jia et al., 
2006). Interestingly, the modification of albumin and insulin by H2O2 
significantly enhanced protein catalysed coelenterazine chemiluminescence (p 
< 0.01; fig. 4.16).  
In order to investigate the effect of MeG on insulin action an attempt was 
made to develop an assay whereby insulin stimulated glucose uptake by both 
insulin sensitive cells (7F2) and tissue (rat hemi-diaphragm) could be 
determined. Glucose uptake by these proved unsuccessful. The rat hemi-
diaphragm demonstrated no basal glucose uptake and the addition of insulin 
did not stimulate glucose uptake. In experiments using 7F2 cells, no insulin 
stimulated glucose uptake was observed and in some cases the data 
suggested that insulin was actually inhibiting glucose uptake.  
It was demonstrated that 3T3-L1 cells could be differentiated from the 
fibroblastic to the adipogenic form by treatment with an adipogenic cocktail 
containing supraphysiological concentration of insulin as well as IBMX and 
DEX (fig. 5.3 and fig. 5.4). The importance of insulin in this process was 
demonstrated as the removal of insulin from the adipogenic cocktail 
significantly inhibited cell differentiation (fig. 5.5).  
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The decreases in cell differentiation observed in cells treated with the 
adipogenic cocktail supplemented with TEA (fig. 5.7) demonstrated the 
importance of voltage-dependent K+ channels in the cell differentiation 
process.  
To conclude, the results demonstrate for the first time the ability of HSA and 
BSA to catalyse coelenterazine chemiluminescence. This was consistent with 
HSA having a mono-oxygenase activity. Insulin was also able to catalyse 
coelenterazine chemiluminescence. The coelenterazine chemiluminescence 
catalysed by insulin increased with the addition of Zn2+. HSA catalysed 
coelenterazine chemiluminescence was heat denaturable, saturable by the 
substrate, inhibited by cations that can bind to the protein and inhibited by 
drugs that are known to bind to Sudlow’s site I on the protein. Molecular 3D 
modelling confirmed the coelenterazine binding and also identified five basic 
amino acid residues that may play a crucial role in the binding of 
coelenterazine and the catalysis of the reaction. These results support the 
bacterial metabolic toxin hypothesis and have important consequences in 
diseases such as diabetes, where a mono-oxygenase has the potential of 
affecting a number of cell surface proteins. The coelenterazine 
chemiluminescence model used has the potential to be developed into a 
clinical test where the concentrations of these toxins in the blood of subjects 
can be measured. It can also be used in the pharmaceutical industry to 
investigate the pharmacokinetics of new drugs prior to their release on to the 
market. 
6.2. Future work 
The results in this thesis have demonstrated how the modification of proteins, 
such as insulin by bacterial metabolic toxins, like MeG, may play an important 
role in the development of diabetes. However, there is still a considerable 
amount of work that can be carried out to further investigate this topic as well 
as a number of experiments that generated negative data requiring further 
investigation. Further work can be carried out to determine the enzymatic 
activity of proteins: 
 To determine if insulin is a mono-oxygenase as molecular 3D 
modelling did not identify the binding site. Also, the ability of insulin to 
oxidise its receptor needs to be investigated 
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 To investigate the effect of superoxide on protein catalysed 
coelenterazine chemiluminescence. The addition of superoxide 
dismutase should convert superoxide to H2O2 thus reducing the activity 
of the protein (Lucas and Solano, 1992) 
 The conditions used to denature HSA were not sufficient enough to 
denature human insulin. Therefore it is now necessary establish 
another technique such as that described by Jiang and Chang (2005) 
to denature insulin. Then once insulin has been successfully denatured 
to investigate the effect of denaturation on insulin catalysed 
coelenterazine chemiluminescence 
 It was not possible to determine the approximate Km of coelenterazine 
on insulin as an experiment to demonstrate the chemiluminescence in 
the presence of increasing substrate concentrations was not 
investigated. It is now necessary to demonstrate whether the effect of 
insulin on coelenterazine chemiluminescence is saturable in order to 
determine if it is binding or is it actually generating superoxide which is 
an established oxidant for coelenterazine (Lucas and Solano, 1992) 
 More attention needs to be focused on Zn2+ to further determine its role 
as it may have a significant clinical relevance (e.g. to investigate what 
is the mechanism of action of Zn2+) 
 In order to determine the kcat of HSA and insulin, it is necessary to 
determine the fluorescence of the product, coelenteramide, to quantify 
the turnover (Shimomura and Teranishi, 2000) 
 To construct a Dixon plot to determine the Ki for the HSA-
coelenterazine complex 
 The genetic engineering of Sudlow’s site I could significantly enhance 
HSA catalysed coelenterazine chemiluminescence thereby bringing it 
close to or even better than the other naturally occurring 
coelenterazine luciferases and photoproteins 
 To determine if other drugs that are known to bind to albumin (e.g. 
furosemide) exhibit competitive/mixed enzyme kinetics 
 It has been shown that the bacterial metabolic toxin, MeG, can 
covalently modify both albumin and insulin, therefore further work 
needs to be carried out to investigate the effect of other metabolites, 
such as alcohols, diols, aldehydes, ketones and acids on such proteins 
(Campbell et al., 2010) 
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 The covalent modification of insulin resulted in reduced mono-
oxygenase activity, the consequences of this on diabetes will need to 
be investigated 
 To determine if MeG-adduct formation can be detected in clinical 
samples and if so, could this be used as a clinical test to predict the 
development of pathological conditions, such as the complications 
associated with diabetes (microvascular or macrovascular conditions) 
in the future 
 To determine if protein catalysed coelenterazine chemiluminescence 
can be developed into a clinical test whereby this method is used to 
investigate the pharmacokinetics of new drugs to their release on the 
market 
Investigations to determine the effect of MeG on the biological activity were 
unsuccessful. Therefore, future work to determine the effect of the toxin on the 
biological activity of insulin will include: 
 Now that it has been shown that these proteins can be covalently 
modified by these putative toxins, the next step would be to investigate 
the biological activity of the modified proteins in processes such as 
glucose uptake and cell differentiation. For example, as insulin is 
known to increase glucose uptake by insulin-sensitive tissues as well 
as playing an important role in cell differentiation, work can be carried 
out to compare glucose uptake and cell differentiation in the presence 
of normal and covalently modified insulin 
 To quantify the expression of GLUT1 and GLUT4 in insulin-sensitive 
tissues (e.g. 3T3-L1 cells and rat hemi-diaphragm) 
 PPARγ and C/EBPα are known to be crucial for cell differentiation, 
therefore it is also necessary to investigate the expression of both of 
these in undifferentiated and differentiated 3T3-L1 cells 
 Lipolysis is a process where triglycerides are hydrolysed into glycerol 
and free fatty acids. Increased lipolysis has been observed in obese 
and diabetic subjects. Therefore, lipolysis assays can be carried out on 
differentiated 3T3-L1 to quantify glycerol release (Green et al., 2004). 
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Chaichi, J., Holland, I. B., Green, J. & Wann, K. T. (2010) Bacterial 
metabolic ‘toxins’: a new mechanism for lactose and food intolerance, 
and irritable bowel syndrome. Toxicology, 278, 268-76.  
 
2. Vassel, N., Cox, C. D., Naseem, R., Morse, V., Evans, R. T., Power, 
R. L., Brancale, A., Wann, K. T. & Campbell, A. K. (2012) Enzymatic 
activity of albumin shown by coelenterazine chemiluminescence. 
Luminescence, 27, 234-41. 
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7.2. Cell culture media formulae 
 
MINIMAL ESSENTIAL MEDIUM (MEM) ALPHA 
 
Components       MW    Concentration 
       (mg/L) 
Amino acids 
Glycine      75  50 
L-Alanine      89  25 
L-Arginine      211  105 
L-Asparagine-H2O     150  25 
L-Aspartic acid     133  30 
L-Cysteine hydrochloride-H2O   176  100 
L-Cysteine      313  31 
L-Glutamic acid     147  75 
L-Glutamine      146  292 
L-Histidine      155  31 
L-Isoleucine      131  52.4 
L-Leucine      131  52 
L-Lysine      183  73 
L-Methionine      149  15 
L-Phenylalanine     165  32 
L-Proline      115  40 
L-Serine      105  25 
L-Threonine      119  48 
L-Tryptophan      204  10 
L-Tyrosine      181  36 
L-Valine      117  46 
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Vitamins 
Ascorbic acid      176  50 
Biotin       244  0.1 
Choline chloride     140  1 
D-Calcium pantothenate    477  1 
Folic acid      441  1 
Niacinamide      122  1 
Pyridoxal hydrochloride    204  1 
Riboflavin      376  0.1 
Thiamine hydrochloride    337  1 
Vitamin B12      1355  1.36 
i-Inositol      180  2 
 
Inorganic salts 
Calcium chloride (CaCl2-2H2O)   147  264 
Magnesium sulphate (MgSO4) (anhyd.)  120  97.67 
Potassium chloride (KCl)    75  400 
Sodium bicarbonate (NaHCO3)   84  2200 
Sodium Chloride (NaCl)    58  6800 
Sodium phosphate monobasic (NaH2PO4-2H2O) 156  158 
 
Other components 
D-Glucose (Dextrose)     180  1000 
Lipoic acid      206  0.2 
Phenol red      376.4  10 
Sodium pyruvate     110  110 
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DULBECCO’S MODIFIED EAGLE MEDIUM (D-MEM) 
 
Components       MW    Concentration 
       (mg/L) 
Amino acids 
Glycine      75  30 
L-Arginine hydrochloride    211  84 
L-Cysteine 2HCl     313  63 
L-Glutamine      146  580 
L-Histidine hydrochloride-H2O   210  42 
L-Isoleucine      131  105 
L-Leucine      131  105 
L-Lysine hydrochloride    183  146 
L-Methionine      149  30 
L-Phenylalanine     165  66 
L-Serine      105  42 
L-Threonine      119  95 
L-Tryptophan      204  16 
L-Tyrosine      181  72 
L-Valine      117  94 
 
Vitamins 
Choline chloride     140  4 
D-Calcium pantothenate    477  4 
Folic acid      441  4 
Niacinamide      122  4 
Pyridoxine hydrochloride    204  4 
Riboflavin      376  0.4 
Thiamine hydrochloride    337  4 
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i-Inositol      180  7.2 
 
Inorganic salts 
Calcium chloride (CaCl2-2H2O)   147  264 
Ferric nitrate (Fe(NO3)3-9H2O)   404  0.1 
Magnesium sulphate (MgSO4-7H2O)   246  200 
Potassium chloride (KCl)    75  400 
Sodium bicarbonate (NaHCO3)   84  3700 
Sodium chloride (NaCl)    58  6400 
Sodium phosphate monobasic (NaH2PO4-2H2O) 154  141 
 
Other components 
D-Glucose (Dextrose)     180  4500 
Phenol red      376.4  15 
Sodium pyruvate     110  110 
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